

**(19) AUSTRALIAN PATENT OFFICE**

(54) Title  
Spliceosome mediated RNA trans-splicing

(51)<sup>6</sup> International Patent Classification(s)  
**C12N** 15/09 (2006.01) 31/04  
**A61K** 35/76 (2006.01) 20060101ALI2005122  
**A61K** 38/43 (2006.01) OBMJP **A61P**  
**A61K** 48/00 (2006.01) 35/00  
**A61P** 31/00 (2006.01) 20060101ALI2005122  
**A61P** 31/04 (2006.01) OBMJP **A61P**  
**A61P** 35/00 (2006.01) 37/02  
**A61P** 37/02 (2006.01) 20060101ALI2005122  
**A61P** 37/06 (2006.01) OBMJP **A61P**  
**C12N** 1/15 (2006.01) 37/06  
**C12N** 1/19 (2006.01) 20060101ALI2005122  
**C12N** 1/21 (2006.01) OBMJP **C12N**  
**C12N** 5/10 (2006.01) 1/15  
**C12N** 15/10 (2006.01) 20060101ALI2005122  
**C12N** 15/85 (2006.01) OBMJP **C12N**  
**C12N** 15/09 (2006.01) 1/19  
**C12N** 15/09 (2006.01) 20060101ALI2005122  
20060101AFI2005122 OBMJP **C12N**  
OBMJP **A61K** 1/21  
35/76 (2006.01) 20060101ALI2005122  
20060101ALI2005122 OBMJP **C12N**  
OBMJP **A61K** 5/10  
38/43 (2006.01) 20060101ALI2005122  
20060101ALI2005122 OBMJP **C12N**  
OBMJP **A61K** 15/10  
48/00 (2006.01) 20060101ALI2007072  
20060101ALI2005122 1BMFP **C12N**  
OBMJP **A61P** 15/85  
31/00 (2006.01) 20060101ALI2005100  
20060101ALI2005122 8BMFP  
OBMJP **A61P** PCT/US02/00416

(21) Application No: 2002246959

(22) Application Date: 2002 .01 .08

(87) WIPO No: W002/053581

(30) Priority Data

(31) Number	(32) Date	(33) Country
09/838,858	2001 .04 .20	US
09/756,095	2001 .01 .08	US
09/756,097	2001 .01 .08	US
09/941,492	2001 .08 .29	US
09/756,096	2001 .01 .08	US

(43) Publication Date : 2002 .07 .16

(43) Publication Journal Date : 2003 .01 .23

(71) Applicant(s)  
VIRxSYS Corporation

(72) Inventor(s)  
Mitchell, Lloyd, G.; Puttaraju, Madaiah; Mansfield, Gary, S.; Garcia-Blanco, Mariano, A.

(74) Agent/Attorney  
Davies Collison Cave, 1 Nicholson Street, Melbourne, VIC, 3000

(56) Related Art  
WO 00/009734 A

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number  
WO 02/053581 A3

- (51) International Patent Classification: C07H 21/02, C12N 5/10, 15/09, C12P 19/34
- (74) Agents: SEIDE, Rochelle, K. et al.; Baker Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112-0228 (US).
- (21) International Application Number: PCT/US02/00416
- (22) International Filing Date: 8 January 2002 (08.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- |            |                             |    |
|------------|-----------------------------|----|
| 09/756,095 | 8 January 2001 (08.01.2001) | US |
| 09/756,096 | 8 January 2001 (08.01.2001) | US |
| 09/756,097 | 8 January 2001 (08.01.2001) | US |
| 09/838,858 | 20 April 2001 (20.04.2001)  | US |
| 09/941,492 | 29 August 2001 (29.08.2001) | US |
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: INTRONN, INC. [US/US]; 840 Main Campus Drive, Suite 3500, Raleigh, NC 027606 (US).
- (72) Inventors: MITCHELL, Lloyd, G.; 4500 Highgate Drive, Durham, NC 27713 (US). GARCIA-BLANCO, Mariano, A.; 12 Sanderling Court, Durham, NC 27713 (US). BAKER, Carl, C.; 10606 Crossing Creek Road, Potomac, MD 20854 (US). PUTTARAJU, Madaiah; 416 Tall Oaks Drive, Durham, NC 27713 (US). MANSFIELD, Gary, S.; 1005 Prologue Road, Durham, NC 27712 (US). CHAO, Hengjun, 1000 Smith Level Road, D8, Carboro, NC 27510 (US).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
26 September 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/053581 A3

(54) Title: SPLICEOSOME MEDIATED RNA TRANS-SPLICING

(57) Abstract: The molecules and methods of the present invention provide a means for *in vivo* production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a *trans*-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The *in vivo trans*-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism: a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

2002246959 18 Feb 2008

1

**SPLICEOSOME MEDIATED RNA TRANS-SPLICING****SPECIFICATION**

5 The present application is a continuation-in-part of a pending application  
 09/838,858 filed on April 20, 2001 which is a continuation-in-part of pending application  
 serial number 09/756096 filed January 8, 2001 which is a continuation-in-part of pending  
 application serial number 09/158,863 filed September 23, 1998 which is a continuation-in-  
 part of serial number 09/133,717 filed on August 13, 1998 which is a continuation-in-part  
 10 of serial number 09/087,233 filed on May 28, 1998, which is a continuation-in-part of  
 pending application serial number 08/766,354 filed on December 13, 1996, which claims  
 benefit to provisional application number 60/008,317 filed on December 15, 1995.

The present invention was made with government support under Grant Nos. SBIR  
 R43DK56526-01 and SBIR R44DK56526-02. The government has certain rights in the  
 15 invention.

Throughout this specification and the claims which follow, unless the context  
 requires otherwise, the word "comprise", and variations such as "comprises" and  
 "comprising", will be understood to imply the inclusion of a stated integer or step or group  
 of integers or steps but not the exclusion of any other integer or step or group of integers or  
 20 steps.

The reference in this specification to any prior publication (or information derived  
 from it), or to any matter which is known, is not, and should not be taken as an  
 acknowledgment or admission or any form of suggestion that that prior publication (or  
 information derived from it) or known matter forms part of the common general  
 25 knowledge in the field of endeavour to which this specification relates.

2002246959 18 Feb 2008

2

## 1. INTRODUCTION

The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). The PTMs of the invention are genetically engineered so as to result in the production of a novel chimeric RNA which may itself perform a function, such as inhibiting the translation of the RNA, or that encodes a protein that complements a defective or, inactive protein in a cell, or encodes a toxin which kills specific cells. Generally, the target pre-mRNA is chosen as a target because it is expressed within a specific cell type thus providing a means for targeting expression of the novel chimeric RNA to a selected cell type. The invention further relates to PTMs that have been genetically engineered for the

2002246959 18 Feb 2008

3

- identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. In addition, PTMs can be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type. The methods of the invention encompass contacting the PTMs of the invention with a target pre-mRNA under conditions in which a portion of the PTM is *trans*-spliced to a portion of the target pre-mRNA to form a novel chimeric RNA molecule. The methods and compositions of the invention can be used in cellular gene regulation, gene repair and suicide gene therapy for treatment of proliferative disorders such as cancer or treatment of genetic, autoimmune or infectious diseases. In addition, the methods and compositions of the invention can be used to generate novel nucleic acid molecules in plants through targeted splicesomal *trans*-splicing. For example, targeted *trans*-splicing may be used to regulate gene expression in plants for treatment of plants diseases, engineering of disease resistant plants or expression of desirable genes in plants. The methods and compositions of the invention can also be used to map intron-exon boundaries and to identify novel proteins expressed in any given cell.

## 2. BACKGROUND OF THE INVENTION

- DNA sequences in the chromosome are transcribed into pre-mRNAs which contain coding regions (exons) and generally also contain intervening non-coding regions (introns). Introns are removed from pre-mRNAs in a precise process called splicing (Chow *et al.*, 1977, Cell 12:1-8; and Berget, S.M. *et al.*, 1977, Proc. Natl. Acad. Sci. USA 74:3171-3175). Splicing takes place as a coordinated interaction of several small nuclear ribonucleoprotein particles (snRNP's) and many protein factors that assemble to form an enzymatic complex known as the spliceosome (Moore *et al.*, 1993, in The RNA World, R.F. Gestland and J.F. Atkins eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Kramer, 1996, Annu. Rev. Biochem., 65:367-404; Staley and Guthrie, 1998, Cell 92:315-326).

2002246959 18 Feb 2008

Pre-mRNA splicing proceeds by a two-step mechanism. In the first step, the 5' splice site is cleaved, resulting in a "free" 5' exon and a lariat intermediate (Moore, M.J. and P.A. Sharp, 1993, *Nature* 365:364-368). In the second step, the 5' exon is ligated to the 3' exon with release of the intron as the lariat product. These steps are catalyzed in a complex of small nuclear ribonucleoproteins and proteins called the spliceosome. The splicing reaction sites are defined by consensus sequences around the 5' and 3' splice sites. The 5' splice site consensus sequence is AG/GURAGU (where A=adenosine, U=uracil, G=guanine, C=cytosine, R=purine and / = the splice site). The 3' splice region consists of three separate sequence elements: the branch point or branch site, a polypyrimidine tract and the 3' splice consensus sequence (YAG). These elements loosely define a 3' splice region, which may encompass 100 nucleotides of the intron upstream of the 3' splice site. The branch point consensus sequence in mammals is YNYURAC (where N = any nucleotide, Y=pyrimidine). The underlined A is the site of branch formation (the BPA = branch point adenosine). The 3' splice consensus sequence is YAG/G. Between the branch point and the splice site there is usually found a polypyrimidine tract, which is important in mammalian systems for efficient branch point utilization and 3' splice site recognition (Roscianno, R., F. *et al.*, 1993, *J. Biol. Chem.* 268:11222-11229). The first YAG trinucleotide downstream from the branch point and polypyrimidine tract is the most commonly used 3' splice site (Smith, C.W. *et al.*, 1989, *Nature* 342:243-247).

In most cases, the splicing reaction occurs within the same pre-mRNA molecule, which is termed *cis*-splicing. Splicing between two independently transcribed pre-mRNAs is termed *trans*-splicing. *Trans*-splicing was first discovered in trypanosomes (Sutton & Boothroyd, 1986, *Cell* 47:527; Murphy *et al.*, 1986, *Cell* 47:517) and subsequently in nematodes (Krause & Hirsh, 1987, *Cell* 49:753); flatworms (Rajkovic *et al.*, 1990, *Proc. Nat'l. Acad. Sci. USA*, 87:8879; Davis *et al.*, 1995, *J. Biol. Chem.* 270:21813) and in plant mitochondria (Malcek *et al.*, 1997, *Proc. Nat'l. Acad. Sci. USA* 94:553). In the parasite *Trypanosoma brucei*, all mRNAs acquire a splice leader (SL) RNA at their 5' termini by *trans*-splicing. A 5' leader sequence is also *trans*-spliced onto some genes in *Caenorhabditis elegans*. This

2002246959 18 Feb 2008

mechanism is appropriate for adding a single common sequence to many different transcripts.

5 The mechanism of *trans*-splicing, which is nearly identical to that of conventional *cis*-splicing, proceeds via two phosphoryl transfer reactions. The first causes the formation of a 2'-5' phosphodiester bond producing a 'Y' shaped branched intermediate, equivalent to the lariat intermediate in *cis*-splicing. The second reaction, exon ligation, proceeds as in conventional *cis*-splicing. In addition, sequences at the 3' splice site and some of the snRNPs which catalyze the *trans*-splicing reaction, closely resemble their counterparts involved in *cis*-splicing.

10 *Trans*-splicing may also refer to a different process, where an intron of one pre-mRNA interacts with an intron of a second pre-mRNA, enhancing the recombination of splice sites between two conventional pre-mRNAs. This type of *trans*-splicing was postulated to account for transcripts encoding a human immunoglobulin variable region sequence linked to the endogenous constant region in a transgenic mouse (Shimizu *et al.*, 1989, Proc. Nat'l. Acad. Sci. USA 86:8020). In addition, *trans*-splicing of c-myc pre-mRNA has been demonstrated (Vellard, M. *et al.* Proc. Nat'l. Acad. Sci., 1992 89:2511-2515) and more recently, RNA transcripts from cloned SV40 *trans*-spliced to each other were detected in cultured cells and nuclear extracts (Eul *et al.*, 1995, EMBO. J. 14:3226). However, naturally occurring *trans*-splicing of mammalian pre-mRNAs is thought to be an exceedingly rare event.

20 *In vitro trans*-splicing has been used as a model system to examine the mechanism of splicing by several groups (Konarska & Sharp, 1985, Cell 46:165-171 Solnick, 1985, Cell 42:157; Chiara & Reed, 1995, Nature 375:510; Pasman and Garcia-Blanco, 1996, Nucleic Acids Res. 24:1638). Reasonably efficient *trans*-splicing (30% of *cis*-spliced analog) was achieved between RNAs capable of base pairing to each other, splicing of RNAs not tethered by base pairing was further diminished by a factor of 10. Other *in vitro trans*-splicing reactions not requiring obvious RNA-RNA interactions among the substrates were observed by Chiara & Reed (1995, Nature 375:510), Bruzik J.P. & Maniatis, T. (1992, Nature 360:692) and Bruzik J.P. and Maniatis, T., (1995, Proc. Nat'l. Acad. Sci. USA 92:7056-7059).

2002246959 18 Feb 2008

These reactions occur at relatively low frequencies and require specialized elements, such as a downstream 5' splice site or exonic splicing enhancers.

In addition to splicing mechanisms involving the binding of multiple proteins to the precursor mRNA which then act to correctly cut and join RNA, a third mechanism involves cutting and joining of the RNA by the intron itself, by what are termed catalytic RNA molecules or ribozymes. The cleavage activity of ribozymes has been targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. Upon hybridization to the target RNA, the catalytic region of the ribozyme cleaves the target. It has been suggested that such ribozyme activity would be useful for the inactivation or cleavage of target RNA *in vivo*, such as for the treatment of human diseases characterized by production of foreign or aberrant RNA. The use of antisense RNA has also been proposed as an alternative mechanism for targeting and destruction of specific RNAs. In such instances small RNA molecules are designed to hybridize to the target RNA and by binding to the target RNA prevent translation of the target RNA or cause destruction of the RNA through activation of nucleases.

Until recently, the practical application of targeted *trans*-splicing to modify specific target genes has been limited to group I ribozyme-based mechanisms. Using the *Tetrahymena* group I ribozyme, targeted *trans*-splicing was demonstrated in *E. coli* (Sullenger B.A. and Cech. T.R., 1994, Nature 341:619-622), in mouse fibroblasts (Jones, J.T. et al., 1996, Nature Medicine 2:643-648), human fibroblasts (Phylacton, L.A. et al. Nature Genetics 18:378-381) and human erythroid precursors (Lan et al., 1998, Science 280:1593-1596). While many applications of targeted RNA *trans*-splicing driven by modified group I ribozymes have been explored, targeted *trans*-splicing mediated by native mammalian splicing machinery, *i.e.*, spliceosomes, has not been previously reported.

### 3. SUMMARY OF THE INVENTION

The present invention relates to compositions and methods for generating novel nucleic acid molecules through spliceosome-mediated targeted *trans*-splicing. The compositions of the invention include pre-*trans*-splicing



2002246959 18 Feb 2008

- molecules (hereinafter referred to as "PTMs") designed to interact with a natural target pre-mRNA molecule (hereinafter referred to as "pre-mRNA") and mediate a spliceosomal *trans*-splicing reaction resulting in the generation of a novel chimeric RNA molecule (hereinafter referred to as "chimeric RNA"). The methods of the
- 5 invention encompass contacting the PTMs of the invention with a natural target pre-mRNA under conditions in which a portion of the PTM is spliced to the natural pre-mRNA to form a novel chimeric RNA. The PTMs of the invention are genetically engineered so that the novel chimeric RNA resulting from the *trans*-splicing reaction may itself perform a function such as inhibiting the translation of RNA, or
- 10 alternatively, the chimeric RNA may encode a protein that complements a defective or inactive protein in the cell, or encodes a toxin which kills the specific cells. Generally, the target pre-mRNA is chosen because it is expressed within a specific cell type thereby providing a means for targeting expression of the novel chimeric RNA to a selected cell type. The target cells may include, but are not limited to those
- 15 infected with viral or other infectious agents, benign or malignant neoplasms, or components of the immune system which are involved in autoimmune disease or tissue rejection. The PTMs of the invention may also be used to correct genetic mutations found to be associated with genetic diseases. In particular, double-*trans*-splicing reactions can be used to replace internal exons. The PTMs of the invention
- 20 can also be genetically engineered to tag exon sequences in a mRNA molecule as a method for identifying intron/exon boundaries in target pre-mRNA. The invention further relates to the use of PTM molecules that are genetically engineered to encode a peptide affinity purification tag for use in the purification and identification of proteins expressed in a specific cell type. The methods and compositions of the
- 25 invention can be used in gene regulation, gene repair and targeted cell death. Such methods and compositions can be used for the treatment of various diseases including, but not limited to, genetic, infectious or autoimmune diseases and proliferative disorders such as cancer and to regulate gene expression in plants.

2002246959 18 Feb 2008

#### 4. BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A. Model of Pre-*Trans*-splicing RNA.

Figure 1B. Model PTM constructs and targeted *trans*-splicing strategy. Schematic representation of the first generation PTMs (PTM+Sp and PTM-Sp). BD, binding domain; NBD, non-binding domain; BP, branch point; PPT, pyrimidine tract; ss, splice site and DT-A, diphtheria toxin subunit A. Unique restriction sites within the PTMs are indicated by single letters: E; EcoRI; X, XhoI; K, KpnI; P, PstI; A, AclI; B, BamHI and H; HindIII.

Figure 1C. Schematic drawing showing the binding of PTM+Sp via conventional Watson Crick base pairing to the  $\beta$ HCG6 target pre-mRNA and the proposed *cis*- and *trans*-splicing mechanism.

Figure 2A. *In vitro trans*-splicing efficiency of various PTM constructs into  $\beta$ HCG6 target. A targeted binding domain and active splice sites correlate with PTM *trans*-splicing activity. Full length targeted (pePTM+Sp), non-targeted (PTM-Sp) and the splice mutants [Py(-)AG(-) and BP(-)Py(-)AG(-)] PTM RNAs were added to splicing reactions containing  $\beta$ HCG6 target pre-mRNA. The products were RT-PCR amplified using primers  $\beta$ HCG-F (specific for target  $\beta$ HCG6 exon 1) and DT-5R (complementary to DT-A) and analyzed by electrophoresis in a 1.5% agarose gel.

Figure 2B. *In vitro trans*-splicing efficiency of various PTM constructs. Full length PTM with a spacer between the binding domain and splice site (PTM+Sp), PTM without the spacer region (PTM+) and short PTMs that contain a target binding domain (short PTM+) or a non-target binding region (PTM-) were added to splicing reactions containing  $\beta$ HCG target pre-mRNA. The products were RT-PCR amplified using primers  $\beta$ HCG-F and DT-3. For reactions containing the short PTMs, the reverse PCR primer was DT-4, since the binding site for DT-3 was removed from the PTM.

Figure 3. Nucleotide sequence demonstrating the *in vitro trans*-spliced product between a PTM and target pre-mRNA. The 466 bp *trans*-spliced RT-PCR product from Figure 2 (lane 2) was re-amplified using a 5' biotin labeled forward primer ( $\beta$ HCG-F) and a nested unlabeled reverse primer (DT-3R). Single stranded

2002246959 18 Feb 2008

DNA was purified and sequenced directly using toxin specific DT-3R primer. The arrow indicates the splice junction between the last nucleotide of target  $\beta$ HCG6 exon I and the first nucleotide encoding DT-A.

- 5 Figure 4A. Schematic diagram of the "safety" PTM and variations, demonstrating the PTM intramolecular base-paired stem, intended to mask the BP and PPT from splicing factors. Underlined sequences represent the  $\beta$ HCG6 intron 1 complementary target-binding domain, sequence in italics indicate target mismatches that are homologous to the BP.

- 10 Figure 4B. Schematic of a safety PTM in open configuration upon binding to the target.

Figure 4C. *In vitro trans*-splicing reactions were carried out by incubating either safety PTM or safety PTM variants with the  $\beta$ HCG6 target. Splicing reactions were amplified by RT-PCR using  $\beta$ HCG-F and DT-3R primers; products were analyzed in a 2.0% agarose gel.

- 15 Figure 5. Specificity of targeted *trans*-splicing is enhanced by the inclusion of a safety into the PTM.  $\beta$ HCG6 pre-mRNA (250 ng) and  $\beta$ -globin pre-mRNA (250 ng) were annealed together with either PTM+SF (safety) or pcPTM+Sp (linear) RNA (500 ng). *In vitro trans*-splicing reactions and RT-PCR analysis were performed as described under experimental procedures and the products were separated on a 2.0% agarose gel. Primers used for RT-PCR are as indicated.

- 20 Figure 6. In the presence of increasing PTM concentration, *cis*-splicing is inhibited and replaced by *trans*-splicing. *In vitro* splicing reactions were performed in the presence of a constant amount of  $\beta$ HCG6 target pre-mRNA (100 ng) with increasing concentrations of PTM (pcPTM+Sp) RNA (52-300 ng). RT-PCR for *cis*-spliced and un-spliced products utilized primers  $\beta$ HCG-F (exon 1 specific) and  $\beta$ HCG-R2 (exon 2 specific - Panel A); primers  $\beta$ HCG-F and DT-3R were used to RT-PCR *trans*-spliced products (Panel B). Reaction products were analyzed on 1.5% and 2.0% agarose gels, respectively. In panel A, lane 9 represents the 60 min time point in the presence of 300 ng of PTM, which is equivalent to lane 10 in panel B.

- 25 Figure 7A. PTMs are capable of *trans*-splicing in cultured human cancer cells. Total RNA was isolated from each of 4 expanded neomycin resistant

H1299 lung carcinoma colonies transfected with pcSp+CRM (expressing non-toxic mutant DT-A) RT-PCR was performed using 1 µg of total RNA and 5' biotinylated βHCG-F and non-biotinylated DT-3R primers. Single stranded DNA was purified and sequenced.

5 Figure 7B. Nucleotide sequence (sense strand) of the *trans*-spliced product between endogenous βHCG6 target and CRM197 mutant toxin is shown. Two arrows indicate the position of the splice junction.

Figure 8A. Schematic diagram of a double splicing pre-therapeutic mRNA.

10 Figure 8B. Selective *trans*-splicing of a double splicing PTM. By varying the PTM concentration the PTM can be *trans*-spliced into either the 5' or the 3' splice site of the target.

Figure 9. Schematic diagram of the use of PTM molecules for exon tagging. Two examples of PTMs are shown. The PTM on the left is capable of non-specifically *trans*-splicing into a target pre-mRNA 3' splice site. The other PTM on the right is designed to non-specifically *trans*-splice into a target pre-mRNA 5' splice site. A PTM mediated *trans*-splicing reaction will result in the production of a chimeric RNA comprising a specific tag to either the 5' or 3' side of an authentic exon.

15 Figure 10A. Schematic diagram of constructs for use in the lacZ knock-out model. The target lacZ pre-mRNA contains the 5' fragment of lacZ followed by βHCG6 intron 1 and the 3' fragment of lacZ (target 1). The PTM molecule for use in the model system was created by digesting pPTM +SP with PstI and HindIII and replacing the DT-A toxin with βHCG6 exon 2 (pc3.1PTM2).

20 Figure 10B. Schematic diagram of restoration of β-Gal activity by Spliceosome Mediated RNA Trans-splicing. Schematic diagram of constructs for use in the lacZ knock-in model (pc.3.1 lacZ T2). The lacZ target pre-mRNA is identical to that target pre-mRNA used for the knock-out experiments except that it contains two stop codons (TAA TAA) in frame four codons after the 3' splice site. The PTM molecule for use in the model system was created by digesting pPTM +SP with PstI and HindIII and replacing the DT-A toxin with functional 3' fragment of lacZ.

2002246959 18 Feb 2008

Figure 11A. Demonstration of *cis*- and *trans*-splicing when utilizing the lacZ knock-out model. The LacZ splice target 1 pre-mRNA and PTM2 were co-transfected into 293T cells. Total RNA was then isolated and analyzed by PCR for *cis*-spliced and *trans*-spliced products using the appropriate specific primers. The amplified PCR products were separated on a 2% agarose gel.

Figure 11B-C. Assays for  $\beta$ -galactosidase activity. 293 cells were transfected with lacZ target 2 DNA alone (panel B) or lacZ target 2 DNA and PTM1 (panel C).

Figure 12A. Nucleotide sequence of *trans*-spliced molecule demonstrating accurate *trans*-splicing.

Figure 12B. Nucleotide sequences of the *cis*-spliced product and the *trans*-spliced product. The nucleotide sequences were those sequences expected for each of the different splicing reactions.

Figure 13. Gene repair model for repair of the cystic fibrosis transmembrane regulator (CFTR) gene.

Figure 14. RT-PCR demonstration of *trans*-splicing between an exogenously supplied CFTR mini-gene target and PTM. Plasmids were co-transfected into 293 embryonic kidney cells. The primers pairs used for RT-PCR reactions are listed above each lane. The lower band (471 bp) in each lane represents a *trans*-spliced product. The lower band in lane 1 (471bp) was purified from a 2% Seakem agarose gel and the DNA sequence of the band was determined.

Figure 15. DNA sequence of the *trans*-spliced product (lane 1, lower band shown in Figure 14). The DNA sequence indicates the presence of the F508 codon (CCT), exon 9 sequence is contiguous with exon 10 sequence, and the His tag sequence.

Figure 16. Schematic representation of repair of an exogenously supplied CFTR target molecule carrying an F508 deletion in exon 10.

Figure 17. Repair of endogenous CFTR transcripts by exon 10 replacement using a double splicing PTM. The use of a double splicing PTM permits repair of the  $\Delta$ 508 mutation with a very short PTM molecule.

2002246959 18 Feb 2008

Figure 18. Model lacZ target consisting of lacZ 5' exon - CFTR mini-intron 9 - CFTR exon 10 (delta 508) - CFTR mini-intron 10 followed by the lacZ 3' exon. Binding domains for PTMs are bracketed.

Figure 19. Schematic representation of double-*trans*-splicing PTMs designed to restore  $\beta$ -gal function.

Figure 20. Schematic representation of a double-*trans*-splicing reaction showing the binding of DSPTM7 with DSCFT1.6 target pre-mRNA.

Figure 21. Important structural elements of DSPTM7: The double splicing PTM has both 3' and 5' functional splice sites as well as binding domains.

Figure 22. Schematic diagram of mutant double splicing PTMs.

Figure 23. Accuracy of double-*trans*-splicing reaction.

Figure 24. Double-*trans*-splicing between the target pre-mRNA and the DSPTM7 produces full-length protein. Western blot analysis of total cell lysates using polyclonal anti- $\beta$ -galactosidase antiserum.

Figure 25. Precise internal exon substitution between the DSCFT1.6 target pre-mRNA and DSPTM7 RNA by double-*trans*-splicing produces functionally active  $\beta$ -gal protein. Total cell extracts were prepared and assayed for  $\beta$ -gal activity using an ONPG assay.

Figure 26. 3' and 5' splice sites are essential for the restoration of  $\beta$ -gal function by double-*trans*-splicing reaction.

Figure 27. Double-*trans*-splicing: titration of target and PTM. Different concentrations of the target and PTM were co-transfected and analyzed for  $\beta$ -gal activity restoration.

Figure 28. Constructs designed to test the specificity of double-*trans*-splicing reaction.

Figure 29. Specificity of a double-*trans*-splicing reaction.

Figure 30. *Trans*-splicing repair of the cystic fibrosis gene using a PTM that mediates a double-*trans*-splicing event.

Figure 31. PTM with a long binding domain masking two splice sites and part of exon 10 in a mini-gene target.

2002246959 18 Feb 2008

Figure 32. Sequence of a single PCR product showing target exon 9 correctly spliced to PTM exon 10 (with modified codons) (upper panel), codon 508 in exon 10 of the PTM (middle panel) and PTM exon 10 correctly spliced to target exon 11 (lower panel). The sequence of a repaired target was generated by RT-PCR

5 followed by PCR.

Figure 33. *Trans*-splicing repair of the cystic fibrosis gene using a PTM that can perform 5' exon replacement.

Figure 34. Schematic diagram of three different PTM molecules with different binding domains.

10 Figure 35. Schematic diagram of PTM exon 10 with modified codon usage to reduce antisense effects with its own binding domain.

Figure 36. Sequence of *cis*- and *trans*-spliced products.

Figure 37. Model system for repair of messenger RNAs by *trans*-splicing. (A) Schematic illustration of a defective *lacZCF9m* splice target used in  
15 the present study (see Materials and Methods for details). BP, branch point; PPT, polypyrimidine tracts; ss, splice sites and pA, polyadenylation signal. (B) A prototype PTM showing the key components of the *trans*-splicing domain, and the diagrams of various PTMs showing the binding domain length and approximate positions at which they bind to the target pre-mRNA. Unique restriction sites within  
20 the *trans*-splicing domain are N, *Nhe* I; S, *Sac* II; K, *Kpn* I and E, *EcoR* V. (C) Schematic diagram showing the binding of a PTM through antisense binding and repair of defective *lacZ* pre-mRNA through targeted RNA *trans*-splicing. Expected *cis* and *trans*-spliced products and the primer binding sites for Lac-9F, Lac-3R and Lac-5R are indicated.

25 Figure 38. Efficient repair of *lacZ* messenger RNA. Target specific primers, Lac-9F (5' exon) and Lac-3R (3' exon) were used to amplify *cis*-spliced products (lanes 1-6), while; target and PTM specific primers, Lac-9F (5' exon) and Lac-5R (3' exon) were used to amplify *trans*-spliced products (lanes 7-15). 25-50 ng of total RNA was used to measure target *cis*-splicing (lanes 1-6) and 50-200 ng of  
30 total RNA was used to measure PTM induced RNA *trans*-splicing (lanes 7-12). Lanes 13-15, 25-50 ng of total RNA from cells transfected with *lacZCF9* a control for

2002246959 18 Feb 2008

*trans*-splicing. (B) Endogenous mRNA repair by *trans*-splicing. Lanes 1-3, RNA from cells transfected with PTM-CF14; lanes 4-6, PTM-CF22 and lanes 7-9, PTM-CF24. Lane 10, RNA from mock-transfected cells and lane 11 is a control in which reverse-transcription reaction was omitted.

5 Figure 39. Messenger RNA repair leads to synthesis of full-length  $\beta$ -galactosidase. Lane 1, lacZCF9 (positive control, 5  $\mu$ g); lane 2, lacZCF9m target alone (25  $\mu$ g); lane 3, PTM-CF24 alone (25  $\mu$ g) and lane 4, lacZCF9m target + PTM-CF24 (25  $\mu$ g).

10 Figure 40. Messenger RNA repair by SMART produces functional  $\beta$ -galactosidase. (A) In situ detection of functional  $\beta$ -galactosidase produced by *trans*-splicing. 293T cells were either transfected (transient assay) with lacZCF9m target alone (panel A) or co-transfected with lacZCF9m target + PTM-CF24 (panel B) expression plasmids as described above. 48-hr post-transfection, cells were rinsed with PBS and stained *in situ* for  $\beta$ -gal activity. (B) Repair of a defective lacZ mRNA  
15 produces functional  $\beta$ -galactosidase. Target and PTM, extracts from cells transfected with either lacZCF9m target or PTM-CF24 plasmid alone, and the rest were from cells co-transfected with lacZCF9m target and one of the PTMs as indicated. (C) Endogenous mRNA repair by *trans*-splicing produces functional  $\beta$ -galactosidase. Stable cells expressing an endogenous lacZCF9m pre-mRNA target was transfected  
20 with "linear" PTMs (PTM-CF14, PTM-CF22 or PTM-CF24) as described above. Following transfection, total cell lysate was prepared and assayed for  $\beta$ -gal activity. The results presented are the average of two independent transfections.

Figure 41. Messenger RNA repair is specific. (A) Experimental  
25 strategy to measure non-specific *trans*-splicing between lacZHCG1m pre-mRNA and "linear" PTMs. (B) Extended binding domains enhance the specificity of *trans*-splicing. Lanes 1-3, PTM-CF14; 4-6, PTM-CF22; 7-9, PTM-CF24; 10-12, PTM-CF26 and 13-15, PTM-CF27. (C) PTMs with very long binding domains are capable of increasing specificity. Total cell extract (5  $\mu$ l) was assayed in solution for  $\beta$ -gal activity and the specific activity was calculated.  $\beta$ -gal activity was normalized to  
30 mock and the results presented are the average of two independent transfections.



2002246959 18 Feb 2008

Control, extract from cells transfected with lacZHCg1m target alone and the rest were co-transfected with lacZHCg1m target and one of the linear PTMs.

Figure 42. Complete sequence of CFTR PTM 30 (5' exon replacement PTM) showing the *trans*-splicing domain (underlined) and the coding sequence for exons 1-10 of the CFTR gene. Modified codons in exon 10 are underlined and bold.

Figure 43A. 153 base-pair PTM 24 Binding Domain.

Figure 43B. Complete sequence of CFTR PTM 24 (3' exon replacement PTM) showing the *trans*-splicing domain (underlined) and the coding sequence for exons 10-24 of the CFTR cDNA. At the end of the coding is a histidine tag and the translation stop codon.

Figure 44A. Detailed structure of the mouse factor VIII PTM containing normal mouse sequences for exons 16-26. BGH=bovine growth hormone 3' UTR (untranslated sequence); Binding Domain=125bp; base changes to eliminate cryptic sites are circled: F5, F6, F7, F8=primer sites.

Figure 44B. Schematic diagram showing the extent of the binding domain in the mouse factor VIII gene.

Figure 44C. Changes to the promoter in AAV vectors pDLZ20 and pDLZ20-M2 to eliminate cryptic donor sites in sequence upstream of the PTM binding domain.

Figure 44D. Factor VIII repair model. Schematic diagram of a PTM binding to the 3' splice site of intron 15 of the mouse factor VIII gene.

Figure 45. Schematic diagram of a F8 PTM with the *trans*-splicing domain eliminated. This represents a control PTM to test whether repair is a result of *trans*-splicing.

Figure 46. Data indicating repair of factor VIII in Factor VIII knock out mice. Blood was assayed for factor VIII activity using a contest assay.

Figure 47A. Detailed structure of a mouse factor VIII PTM containing normal sequences for exons 16-26 and a C-terminal FLAG tag. BGH=bovine growth hormone 3'UTR; Binding domain=125 bp.

Figure 47B. Detailed structure of a human or canine factor VIII PTM containing normal sequences for exons 23-26.

2002246959 18 Feb 2008

Figure 48. Transcription Map of HPV-16.

Figure 49. Disruption of Human Papillomavirus Type 16 Expression by PTM. Schematic diagram of HPV-PTM 2 binding to the 3' splice site of the HPV type 16 target pre-mRNA.

5 Figure 50. E7 Targeting Strategy in which Multiple PTMs are targeted to HPV E7.

Figure 51. PTM Design indicating the binding domain, branch point and polypyrimidine tract.

10 Figure 52A. HPV-PTM 1 with 80 bp binding domain targeted to 3' ss at 409.

Figure 52B. HPV-PTM 2 with 149 bp binding domain targeted to 3' ss at 409.

Figure 53. Binding Domains of HPV-PTM 3 and 4.

15 Figure 54. Binding Domains of HPV-PTM 5 and 6. Nucleotides in bold are modified to prevent cryptic splicing of PTMs.

Figure 55. Positions of HPV-PTM targeting domains.

Figure 56. *Trans*-splicing Efficiency of HPV-PTMs in 293 T Cells. 293T cells were con-transfected with 2 µg of p1059 target and 1.5 µg of PTM expression plasmids. 48 hr post-transfection, total RNA was isolated and analyzed by  
20 RT-PCR. Target specific primers, oJMD15 and JMD16 were used to amplify *cis*-spliced products (lanes 1-11, upper panel), while; target and PTM specific primers, oJMD15 and Lac-6R were used to amplify *trans*-spliced products (lanes 1-12, lower panel). Lanes 13-14 (upper panel), RNA isolated from cells that are transfected with lacZCF9 and HPV-PTM1 and 2 respectively, hence, serve as controls for evaluating  
25 the specificity of HPV-PTMs.

Figure 57. Nucleotide sequence showing the *trans*-splice junctions between the HPV target pre-mRNA and the PTM. The RT-PCR product was purified and sequenced directly using primer Lac5R (binds to 3' exon of the PTM). The arrow indicate trans-splice junction between E6 of HPV pre-mRNA target and lacZ 3' exon  
30 of the PTM..

2002246959 18 Feb 2008

Figure 58. *Trans*-splicing in 293 cells (Co-transfections)

Quantification of *trans*-splicing efficiency was determined using real-time QRT-PCR.

- 5 Figure 59. *Trans*-splicing efficiency of HPV-PTMs into an endogenous pre-mRNA target. SiHa and CaSki cells were transfected with 1.5 µg of either HPV-PTM1, 2 or CPTR targets PTM14 or 27 expression plasmids. 48 hr post-transfected, total RNA was isolated and analyzed by RT-PCR. *Trans*-splicing between the endogenous HPV target and the PTM was detected using target and PTM specific primers oJMD15 and Lac-16R. The expected *trans*-spliced product (418 bp) is clearly visible in cells that are transfected with HPV-PTMs (lanes 2-3 and 5-7) but not in control (lanes 1 and 4). In addition, *trans*-splicing is also detected in lane 8 due to non-specific *trans*-splicing.
- 10

Figure 60. Accurate *Trans*-splicing of HPV-PTM1 in SiHa Cells.

Target pre-mRNA was endogenous mRNA. Sequence analysis of *trans*-spliced chimeric RNA indicates that *trans*-splicing is accurate.

- 15 Figure 61. Quantification of *trans*-splicing efficiency in SiHa cells using real-time QRT-PCR.

Figure 62. *Trans*-splicing efficiency of HPV-PTM 1, HPV-PTM 5, & HPV-PTM 6 in SiHa cells. Analysis of total RNA was performed using RT-PCR.

- 20 Figure 63. Deletion of polypyrimidine tract abolishes *trans*-splicing. Lanes 1 and 2 represent RNA from cells transfected with mutant HPV-PPT. Lanes 3 and 4 represent RNA from cells transfected with HPV-PTM5 plasmid. 269 bp product resulting from *trans*-splicing is detected.

Figure 64. Schematic Diagram of a PTM binding to the 5' splice site of the HPV mini-gene target and the resulting *trans*-spliced chimera RNA.

- 25 Figure 65. Double *Trans*-splicing. Schematic diagram of a double *trans*-splicing PTM binding to the 3' and 5' splice sites of the HPV mini-gene target. The resultant *trans*-spliced mRNA is shown.

Figure 66A. *Trans*-splicing by 3' exon replacement. Schematic diagram of a PTM binding to the 3' splice site of the HPV mini-gene target.

- 30 Figure 66B. *Trans*-splicing by 5' exon replacement. Schematic diagram of a PTM binding to the 5' splice site of the HPV mini-gene target.

Figure 67. Schematic of a double splicing HPV-PTM designed for internal exon replacement.

#### 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compositions comprising pre-trans-splicing molecules (PTMs) and the use of such molecules for generating novel nucleic acid molecules. The PTMs of the invention comprise one or more target binding domains that are designed to specifically bind to pre-mRNA, a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site and/or a 5' splice donor site; and one or more spacer regions that separate the RNA splice site from the target binding domain. In addition, the PTMs of the invention can be engineered to contain any nucleotide sequences such as those encoding a translatable protein product.

The methods of the invention encompass contacting the PTMs of the invention with a natural pre-mRNA under conditions in which a portion of the PTM is trans-spliced to a portion of the natural pre-mRNA to form a novel chimeric RNA. The target pre-mRNA is chosen as a target due to its expression within a specific cell type thus providing a mechanism for targeting expression of a novel RNA to a selected cell type. The resulting chimeric RNA may provide a desired function, or may produce a gene product in the specific cell type. The specific cells may include, but are not limited to those infected with viral or other infectious agents, benign or malignant neoplasms, or components of the immune system which are involved in autoimmune disease or tissue rejection. Specificity is achieved by modification of the binding domain of the PTM to bind to the target endogenous pre-mRNA. The gene products encoded by the chimeric RNA can be any gene, including genes having clinical usefulness, for example, therapeutic or marker genes, and genes encoding toxins.

##### 5.1. STRUCTURE OF THE PRE-TRANS-SPLICING MOLECULES

The present invention provides compositions for use in generating novel chimeric nucleic acid molecules through targeted trans-splicing. The PTMs of the invention comprise (i) one or more target binding domains that targets binding of

2002246959 18 Feb 2008

19

the PTM to a pre-mRNA (ii) a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site and/or 5' splice donor site; and (iii) one or more spacer regions to separate the RNA splice site from the target binding domain. Additionally, the PTMs can be engineered to contain any nucleotide sequence encoding a translatable protein product. In yet another embodiment of the invention, the PTMs can be engineered to contain nucleotide sequences that inhibit the translation of the chimeric RNA molecule. For example, the nucleotide sequences may contain translational stop codons or nucleotide sequences that form secondary structures and thereby inhibit translation. Alternatively, the chimeric RNA may function as an antisense molecule thereby inhibiting translation of the RNA to which it binds.

The target binding domain of the PTM may contain multiple binding domains which are complementary to and in anti-sense orientation to the targeted region of the selected pre-mRNA. As used herein, a target binding domain is defined as any sequence that confers specificity of binding and anchors the pre-mRNA closely in space so that the spliceosome processing machinery of the nucleus can *trans-splice* a portion of the PTM to a portion of the pre-mRNA. The target binding domains may comprise up to several thousand nucleotides. In preferred embodiments of the invention the binding domains may comprise at least 10 to 30 and up to several hundred nucleotides. As demonstrated herein, the specificity of the PTM can be increased significantly by increasing the length of the target binding domain. For example, the target binding domain may comprise several hundred nucleotides or more. In addition, although the target binding domain may be "linear" it is understood that the RNA may fold to form secondary structures that may stabilize the complex thereby increasing the efficiency of splicing. A second target binding region may be placed at the 3' end of the molecule and can be incorporated into the PTM of the invention. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex. The ability to hybridize will depend on both the degree of complementarity and the length of the nucleic acid (See, for example, Sambrook et

2002246959 18 Feb 2008

al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex. One skilled in the art can ascertain a tolerable degree of mismatch or length of duplex by use of standard procedures to determine the stability of the hybridized complex.

Where the PTMs are designed for use in intron-exon tagging or for peptide affinity tagging, a library of PTMs is genetically engineered to contain random nucleotide sequences in the target binding domain. Alternatively, for intron-exon tagging the PTMs may be genetically engineered so as to lack target binding domains. The goal of generating such a library of PTM molecules is that the library will contain a population of PTM molecules capable of binding to each RNA molecule expressed in the cell. A recombinant expression vector can be genetically engineered to contain a coding region for a PTM including a restriction endonuclease site that can be used for insertion of random DNA fragments into the PTM to form random target binding domains. The random nucleotide sequences to be included in the PTM as target binding domains can be generated using a variety of different methods well known to those of skill in the art, including but not limited to, partial digestion of DNA with restriction enzymes or mechanical shearing of DNA to generate random fragments of DNA. Random binding domain regions may also be generated by degenerate oligonucleotide synthesis. The degenerate oligonucleotides can be engineered to have restriction endonuclease recognition sites on each end to facilitate cloning into a PTM molecule for production of a library of PTM molecules having degenerate binding domains.

Binding may also be achieved through other mechanisms, for example, through triple helix formation or protein/nucleic acid interactions such as those in which the PTM is engineered to recognize a specific RNA binding protein, *i.e.*, a protein bound to a specific target pre-mRNA. Alternatively, the PTMs of the invention may be designed to recognize secondary structures, such as for example, hairpin structures resulting from intramolecular base pairing between nucleotides within an RNA molecule.

2002246959 18 Feb 2008

The PTM molecule also contains a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor AG site and/or a 5' splice donor site. Consensus sequences for the 5' splice donor site and the 3' splice region used in RNA splicing are well known in the art (See, Moore, *et al.*, 1993, *The RNA World*, Cold Spring Harbor Laboratory Press, p. 303-358). In addition, modified consensus sequences that maintain the ability to function as 5' donor splice sites and 3' splice regions may be used in the practice of the invention. Briefly, the 5' splice site consensus sequence is AG/GURAGU (where A=adenosine, U=uracil, G=guanine, C=cytosine, R=purine and /=the splice site). The 3' splice site consists of three separate sequence elements: the branch point or branch site, a polypyrimidine tract and the 3' consensus sequence (YAG). The branch point consensus sequence in mammals is YNYURAC (Y=pyrimidine). The underlined A is the site of branch formation. A polypyrimidine tract is located between the branch point and the splice site acceptor and is important for different branch point utilization and 3' splice site recognition.

Further, PTMs comprising a 3' acceptor site (AG) may be genetically engineered. Such PTMs may further comprise a pyrimidine tract and/or branch point sequence.

Recently, pre-messenger RNA introns beginning with the dinucleotide AU and ending with the dinucleotide AC have been identified and referred to as U12 introns. U12 intron sequences as well as any sequences that function as splice acceptor/donor sequences may also be used in PTMs.

A spacer region to separate the RNA splice site from the target binding domain is also included in the PTM. The spacer region can have features such as stop codons which would block any translation of an unspliced PTM and/or sequences that enhance *trans*-splicing to the target pre-mRNA.

In a preferred embodiment of the invention, a "safety" is also incorporated into the spacer, binding domain, or elsewhere in the PTM to prevent non-specific *trans*-splicing. This is a region of the PTM that covers elements of the 3' and/or 5' splice site of the PTM by relatively weak complementarity, preventing non-specific *trans*-splicing. The PTM is designed in such a way that upon hybridization

2002246959 18 Feb 2008

of the binding /targeting portion(s) of the PTM, the 3' and/or 5' splice site is uncovered and becomes fully active.

The "safety" consists of one or more complementary stretches of *cis*-sequence (or could be a second, separate, strand of nucleic acid) which weakly binds to one or both sides of the PTM branch point, pyrimidine tract, 3' splice site and/or 5' splice site (splicing elements), or could bind to parts of the splicing elements themselves. This "safety" binding prevents the splicing elements from being active (i.e. block U2 snRNP or other splicing factors from attaching to the PTM splice site recognition elements). The binding of the "safety" may be disrupted by the binding of the target binding region of the PTM to the target pre-mRNA, thus exposing and activating the PTM splicing elements (making them available to *trans*-splice into the target pre-mRNA).

A nucleotide sequence encoding a translatable protein capable of producing an effect, such as cell death, or alternatively, one that restores a missing function or acts as a marker, is included in the PTM of the invention. For example, the nucleotide sequence can include those sequences encoding gene products missing or altered in known genetic diseases. Alternatively, the nucleotide sequences can encode marker proteins or peptides which may be used to identify or image cells. In yet another embodiment of the invention nucleotide sequences encoding affinity tags such as, HIS tags (6 consecutive histidine residues) (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976), the C-terminus of glutathione-S-transferase (GST) (Smith and Johnson, 1986, Proc. Natl. Acad. Sci. USA 83:8703-8707) (Pharmacia) or FLAG (Asp-Tyr-Lys-Asp-Asp-Lys) (Eastman Kodak/IBI, Rochester, NY) can be included in PTM molecules for use in affinity purification. The use of PTMs containing such nucleotide sequences results in the production of a chimeric RNA encoding a fusion protein containing peptide sequences normally expressed in a cell linked to the peptide affinity tag. The affinity tag provides a method for the rapid purification and identification of peptide sequences expressed in the cell. In a preferred embodiment the nucleotide sequences may encode toxins or other proteins which provide some function which enhances the susceptibility of the cells to subsequent treatments, such as radiation or chemotherapy.



2002246959 18 Feb 2008

In a highly preferred embodiment of the invention a PTM molecule is designed to contain nucleotide sequences encoding the Diphtheria toxin subunit A (Greenfield, L., et al., 1983, Proc. Nat'l. Acad. Sci. USA 80: 6853-6857). Diphtheria toxin subunit A contains enzymatic toxin activity and will function if expressed or delivered into human cells resulting in cell death. Furthermore, various other known peptide toxins may be used in the present invention, including but not limited to, ricin, *Pseudomonas* toxin, *Shiga* toxin and exotoxin A.

Additional features can be added to the PTM molecule either after, or before, the nucleotide sequence encoding a translatable protein, such as polyadenylation signals or 5' splice sequences to enhance splicing, additional binding regions, "safety"-self complementary regions, additional splice sites, or protective groups to modulate the stability of the molecule and prevent degradation.

Additional features that may be incorporated into the PTMs of the invention include stop codons or other elements in the region between the binding domain and the splice site to prevent unspliced pre-mRNA expression. In another embodiment of the invention, PTMs can be generated with a second anti-sense binding domain downstream from the nucleotide sequences encoding a translatable protein to promote binding to the 3' target intron or exon and to block the fixed authentic *cis*-5' splice site (U5 and/or U1 binding sites).

PTMs may also be generated that require a double-*trans*-splicing reaction for generation of a chimeric *trans*-spliced product. Such PTMs could be used to replace an internal exon which could be used for RNA repair. PTMs designed to promote two *trans*-splicing reactions are engineered as described above, however, they contain both 5' donor sites and 3' splice acceptor sites. In addition, the PTMs may comprise two or more binding domains and splicer regions. The splicer regions may be placed between the multiple binding domains and splice sites or alternatively between the multiple binding domains.

Further elements such as a 3' hairpin structure, circularized RNA, nucleotide base modification, or a synthetic analog can be incorporated into PTMs to promote or facilitate nuclear localization and spliceosomal incorporation, and intracellular stability.

2002246959 18 Feb 2008

Additionally, when engineering PTMs for use in plant cells it may not be necessary to include conserved branch point sequences or polypyrimidine tracts as these sequences may not be essential for intron processing in plants. However, a 3' splice acceptor site and/or 5' splice donor site, such as those required for splicing in vertebrates and yeast, will be included. Further, the efficiency of splicing in plants may be increased by also including UA-rich intronic sequences. The skilled artisan will recognize that any sequences that are capable of mediating a *trans*-splicing reaction in plants may be used.

The PTMs of the invention can be used in methods designed to produce a novel chimeric RNA in a target cell. The methods of the present invention comprise delivering to the target cell a PTM which may be in any form used by one skilled in the art, for example, an RNA molecule, or a DNA vector which is transcribed into a RNA molecule, wherein said PTM binds to a pre-mRNA and mediates a *trans*-splicing reaction resulting in formation of a chimeric RNA comprising a portion of the PTM molecule spliced to a portion of the pre-mRNA.

## 5.2. SYNTHESIS OF THE *TRANS*-SPLICING MOLECULES

The nucleic acid molecules of the invention can be RNA or DNA or derivatives or modified versions thereof, single-stranded or double-stranded. By nucleic acid is meant a PTM molecule or a nucleic acid molecule encoding a PTM molecule, whether composed of deoxyribonucleotides or ribonucleosides, and whether composed of phosphodiester linkages or modified linkages. The term nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).

The RNA and DNA molecules of the invention can be prepared by any method known in the art for the synthesis of DNA and RNA molecules. For example, the nucleic acids may be chemically synthesized using commercially available reagents and synthesizers by methods that are well known in the art (see, e.g., Gait, 1985, *Oligonucleotide Synthesis: A Practical Approach*, IRL Press, Oxford, England). Alternatively, RNA molecules can be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be

2002246959 18 Feb 2008

- incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. RNAs may be produced in high yield via *in vitro* transcription using plasmids such as SPS65 (Promega Corporation, Madison, WI). In addition, RNA amplification methods such as Q- $\beta$  amplification can be utilized to produce RNAs.
- The nucleic acid molecules can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, transport into the cell, etc. For example, modification of a PTM to reduce the overall charge can enhance the cellular uptake of the molecule. In addition modifications can be made to reduce susceptibility to nuclease degradation. The nucleic acid molecules may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.*, 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre *et al.*, 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. W088/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol *et al.*, 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the nucleic acid molecules may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc. Various other well-known modifications to the nucleic acid molecules can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3' ends of the molecule. In some circumstances where increased stability is desired, nucleic acids having modified internucleoside linkages such as 2'-O-methylation may be preferred. Nucleic acids containing modified internucleoside linkages may be synthesized using reagents and methods that are well known in the art (see, Uhlmann *et al.*, 1990, Chem. Rev. 90:543-584; Schneider *et al.*, 1990, Tetrahedron Lett. 31:335 and references cited therein).

2002246959 18 Feb 2008

The nucleic acids may be purified by any suitable means, as are well known in the art. For example, the nucleic acids can be purified by reverse phase chromatography or gel electrophoresis. Of course, the skilled artisan will recognize that the method of purification will depend in part on the size of the nucleic acid to be purified.

In instances where a nucleic acid molecule encoding a PTM is utilized, cloning techniques known in the art may be used for cloning of the nucleic acid molecule into an expression vector. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et al.* (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY.

The DNA encoding the PTM of interest may be recombinantly engineered into a variety of host vector systems that also provide for replication of the DNA in large scale and contain the necessary elements for directing the transcription of the PTM. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of PTMs that will form complementary base pairs with the endogenously expressed pre-mRNA targets and thereby facilitate a *trans*-splicing reaction between the complexed nucleic acid molecules. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of the PTM molecule. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art.

Vectors encoding the PTM of interest can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the PTM can be regulated by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Benoist, C. and Chambon, P. 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*,

2002246959 18 Feb 2008

1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, 1982, Nature 296:39-42), the viral CMV promoter, the human chorionic gonadotropin- $\beta$  promoter (Hollenberg *et al.*, 1994, Mol. Cell. Endocrinology 106:111-119), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired target cell.

For use of PTMs encoding peptide affinity purification tags, it is desirable to insert nucleotide sequences containing random target binding sites into the PTMs and clone them into a selectable mammalian expression vector system. A number of selection systems can be used, including but not limited to selection for expression of the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyl transferase protein in tk-, hprt- or aprt- deficient cells, respectively. Also, anti-metabolic resistance can be used as the basis of selection for dihydrofolate transferase (*dhfr*), which confers resistance to methotrexate; xanthine-guanine phosphoribosyl transferase (*gpt*), which confers resistance to mycophenolic acid; neomycin (*neo*), which confers resistance to aminoglycoside G-418; and hygromycin B phosphotransferase (*hygro*) which confers resistance to hygromycin. In a preferred embodiment of the invention, the cell culture is transformed at a low ratio of vector to cell such that there will be only a single vector, or a limited number of vectors, present in any one cell. Vectors for use in the practice of the invention include any eukaryotic expression vectors, including but not limited to viral expression vectors such as those derived from the class of retroviruses or adeno-associated viruses.

### 5.3. USES AND ADMINISTRATION OF TRANS-SPlicing MOLECULES

#### 5.3.1. USE OF PTM MOLECULES FOR GENE REGULATION, GENE REPAIR AND TARGETED CELL DEATH

The compositions and methods of the present invention will have a variety of different applications including gene regulation, gene repair and targeted

2002246959 18 Feb 2008

cell death. For example, *trans*-splicing can be used to introduce a protein with toxic properties into a cell. In addition, PTMs can be engineered to bind to viral mRNA and destroy the function of the viral mRNA, or alternatively, to destroy any cell expressing the viral mRNA. In yet another embodiment of the invention, PTMs can  
 5 be engineered to place a stop codon in a deleterious mRNA transcript thereby decreasing the expression of that transcript.

In an embodiment of the invention PTM molecules were designed to bind to papilloma virus RNA and inhibit the function of the viral RNA. Specifically anti-HPV PTMs were designed to specifically target HPV pre-mRNAs and result in  
 10 the expression of a disruptive or toxic protein only in the HPV-infected cancer cells. Thus, the invention provides PTM molecules designed to inhibit the function of papilloma virus RNA. Such papilloma viruses, include but are not limited to mammalian papillomaviruses including human papillomaviruses.

The papilloma viruses are a group of small DNA viruses which induce  
 15 papillomas (warts) in a variety of vertebrates, including human. In addition, human papilloma virus is one of the most common causes of sexually transmitted diseases in the country and the vast majority of cervical cancers are associated with oncogenic human papillomaviruses and express viral mRNAs encoding the E6 and E7 oncoproteins. Thus, the PTM molecules of the invention may be used to inhibit the  
 20 proliferation of papillomaviruses within an infected host.

Targeted *trans*-splicing, including double-*trans*-splicing reactions, 3' exon replacement and/or 5' exon replacement can be used to repair or correct transcripts that are either truncated or contain point mutations. The PTMs of the invention are designed to cleave a targeted transcript upstream or downstream of a  
 25 specific mutation or upstream of a premature 3' and correct the mutant transcript via a *trans*-splicing reaction which replaces the portion of the transcript containing the mutation with a functional sequence.

In addition, double *trans*-splicing reactions may be used for the selective expression of a toxin in tumor cells. For example, PTMs can be designed to  
 30 replace the second exon of the human  $\beta$ -chronic gonadotropin-6 (hCG6) gene transcripts and to deliver an exon encoding the subunit A of diphtheria toxin (DT-A).

2002246959 18 Feb 2008

Expression of DT-A in the absence of subunit B should lead to toxicity only in the cells expressing the gene.  $\beta$ hCG6 is a prototypical target for genetic modification by trans-splicing. The sequence and the structure of the  $\beta$ hCG6 gene are completely known and the pattern of splicing has been determined. The  $\beta$ hCG6 gene is highly expressed in many types of solid tumors, including many non-germ line tumors, but the  $\beta$ hCG6 gene is silent in the majority cells in a normal adult. Therefore, the  $\beta$ hCG6 pre-mRNA represents a desirable target for a trans-splicing reaction designed to produce tumor-specific toxicity.

The first exon of  $\beta$ hCG6 pre-mRNA is ideal in that it encodes only five amino acids, including the initiator AUG, which should result in minimal interference with the proper folding of the DT-A toxin while providing the required signals for effective translation of the trans-spliced mRNA. The DT-A exon, which is designed to include a stop codon to prevent chimeric protein formation, will be engineered to trans-splice into the last exon of the  $\beta$ hCG6 gene. The last exon of the  $\beta$ hCG6 gene provides the construct with the appropriate signals to polyadenylate the mRNA and ensure translation.

Cystic fibrosis (CF) is one of the most common fatal genetic disease in humans. Based on both genetic and molecular analyses, the gene associated with cystic fibrosis has been isolated and its protein product deduced (Kerem, B.S. et al., 1989, Science 245:1073-1080; Riordan et al., 1989, Science 245:1066-1073; Rommans, et al., 1989, Science 245:1059-1065). The protein product of the CF associated gene is called the cystic fibrosis transmembrane conductance regulator (CFTR). In a specific embodiment of the invention, a *trans*-splicing reaction will be used to correct a genetic defect in the DNA sequence encoding the cystic fibrosis transmembrane regulator (CFTR) whereby the DNA sequence encoding the cystic fibrosis trans-membrane regulator protein is expressed and a functional chloride ion channel is produced in the airway epithelial cells of a patient.

Population studies have indicated that the most common cystic fibrosis mutation is a deletion of the three nucleotides in exon 10 that encode phenylalanine at position 508 of the CFTR amino acid sequence. As indicated in Figure 15, a *trans*-splicing reaction was capable of correcting the deletion at position 508 in the CFTR.

2002246959 18 Feb 2008

amino acid sequence. The PTM used for correction of the genetic defect contained a CFTR BD intron 9 sequence, a spacer sequence, a branch point, a polypyrimidine tract, a 3' splice site and a wild type CFTR BD exon 10 sequence (Figure 13). The successful correction of the mutated DNA encoding CFTR utilizing a *trans*-splicing reaction supports the general application of PTMs for correction of genetic defects.

Hemophilia A is an X-linked bleeding disorder characterized by a deficiency in the activity of factor VIII, an important component of the coagulation cascade. The incidence of hemophilia A is approximately 1 in 5,000 to 10,000 males. Affected individuals suffer joint and muscle hemorrhage, easy bruising, and prolonged bleeding from wounds. Hemophilia A arises from a variety of mutations within the factor VIII gene. The gene comprises 26 exons and spans 186 kb. About 95 percent of those patients with hemophilia A in whom mutations have been characterized, have point mutations in the gene. In a specific embodiment of the invention, a *trans*-splicing reaction will be used to correct a genetic defect in the DNA sequence encoding factor VIII whereby the DNA sequence encoding the factor VIII protein is expressed and a functional clotting factor is produced in the plasma of a patient. The PTMs of the invention can be genetically engineered to repair any exon of interest, or combination of exons for the purpose of correcting a defect in the coding region of the factor VIII gene.

Genetic studies have indicated that the most common factor VIII mutation(s) are be generated. As indicated in Figure 46, a *trans*-splicing reaction was capable of correcting the mutation in the factor VIII amino acid sequence. The mutation was created by an insertion of the neomycin gene into exon 16 and intron 16 of the mouse gene, interrupting the open reading frame of exon 16 and eliminating intron 16's 3' splice donor site. The PTM used for correction of the genetic defect contained factor VIII exons 16-24 coding sequences, a spacer sequence, a branch point, a polypyrimidine tract, and a 3' acceptor splice (Figure 44A). The successful correction of the mutated DNA encoding factor VIII utilizing a *trans*-splicing reaction further supports the general application of PTMs for correction of genetic defects.

The methods and compositions of the invention may also be used to regulate gene expression in plants. For example, *trans*-splicing may be used to place



2002246959 18 Feb 2008

the expression of any engineered gene under the natural regulation of a chosen target plant gene, thereby regulating the expression of the engineered gene. *Trans*-splicing may also be used to prevent the expression of engineered genes in non-host plants or to convert an endogenous gene product into a more desirable product.

5 In a specific embodiment of the invention *trans*-splicing may be used to regulate the expression of the insecticidal gene that produces Bt toxin (*Bacillus thuringiensis*). For example, the PTM may be designed to *trans*-splice into an injury response gene (pre-mRNA) that is expressed only after an insect bites the plant. Thus, all cells of the plant would carry the gene for Bt in the PTM, but the cells would  
10 only produce Bt when and where an insect injures the plant. The rest of the plant will make little or no Bt. A PTM could *trans*-splice the Bt gene into any chosen gene with a desired pattern of expression. Further, it should be possible to target a PTM so that no Bt is produced in the edible portion of the plant.

One advantage associated with the use of PTMs is that the PTM  
15 acquires the native gene control elements of the target gene, thus, reducing the time and effort that might otherwise be spent attempting to identify and reconstitute appropriate regulatory sequences upstream of an engineered gene. Thus, expression of the PTM regulated gene should occur only in those plant cells containing the target pre-mRNA. By targeting a gene not expressed in the edible portion of the plant or in  
20 the pollen, *trans*-splicing can alleviate opposition to genetically modified plants, as consumers would not be eating the proteins made from modified genes. The edible portion of such crops should test negative for genetically modified proteins.

In addition, PTM can be targeted to a unique sequence of the host gene that is not present in other plants. Therefore, even if the gene (DNA) which encodes  
25 the PTM jumps to another species of plant, the PTM gene will not have an appropriate target for *trans*-splicing. Thus, *trans*-splicing offers a "fail-safe" mode for prevention of gene "jumping" to other plant species: the PTM gene will be expressed only in the engineered host plant, which contains the appropriate target pre-mRNA. Expression in non-engineered plants would not be possible.

30 *Trans*-splicing also provides a more efficient way to convert one gene product into another. For example, *trans*-splicing ribozymes and chimeric oligos can

2002246959 18 Feb 2008

be incorporated into corn genomes to modify the ratio of saturated to unsaturated oils. *Trans*-splicing can also be used to convert one gene product into another.

Various delivery systems are known and can be used to transfer the compositions of the invention into cells, *e.g.* encapsulation in liposomes,

- 5 microparticles, microcapsules, recombinant cells capable of expressing the composition, receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, injection of DNA, electroporation, calcium phosphate mediated transfection, etc.

- 10 The compositions and methods can be used to treat cancer and other serious viral infections, autoimmune disorders, and other pathological conditions in which the alteration or elimination of a specific cell type would be beneficial. Additionally, the compositions and methods may also be used to provide a gene encoding a functional biologically active molecule to cells of an individual with an  
15 inherited genetic disorder where expression of the missing or mutant gene product produces a normal phenotype.

- In a preferred embodiment, nucleic acids comprising a sequence encoding a PTM are administered to promote PTM function, by way of gene delivery and expression into a host cell. In this embodiment of the invention, the nucleic acid  
20 mediates an effect by promoting PTM production. Any of the methods for gene delivery into a host cell available in the art can be used according to the present invention. For general reviews of the methods of gene delivery see Strauss, M. and Barranger, J.A., 1997, *Concepts in Gene Therapy*, by Walter de Gruyter & Co., Berlin; Goldspiel *et al.*, 1993, *Clinical Pharmacy* 12:488-505; Wu and Wu, 1991, *Biotherapy* 3:87-95; Tolstoshev, 1993, *Ann. Rev. Pharmacol. Toxicol.* 33:573-596;  
25 Mulligan, 1993, *Science* 260:926-932; and Morgan and Anderson, 1993, *Ann. Rev. Biochem.* 62:191-217; 1993, *TIBTECH* 11(5):155-215. Exemplary methods are described below.

- 30 Delivery of the nucleic acid into a host cell may be either direct, in which case the host is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, host cells are first transformed with the nucleic acid

2002246959 18 Feb 2008

*in vitro*, then transplanted into the host. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene delivery.

In a specific embodiment, the nucleic acid is directly administered *in vivo*, where it is expressed to produce the PTM. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.* by infection using a defective or attenuated retroviral or other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432).

In a specific embodiment, a viral vector that contains the PTM can be used. For example, a retroviral vector can be utilized that has been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA (see Miller *et al.*, 1993, Meth. Enzymol. 217:581-599). Alternatively, adenoviral or adeno-associated viral vectors can be used for gene delivery to cells or tissues. (See, Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503 for a review of adenovirus-based gene delivery).

Another approach to gene delivery into a cell involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. The resulting recombinant cells can be delivered to a host by various methods known in the art. In a preferred embodiment, the cell used for gene delivery is autologous to the host cell.

2002246959 18 Feb 2008

The present invention also provides for pharmaceutical compositions comprising an effective amount of a PTM or a nucleic acid encoding a PTM, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical sciences" by E.W. Martin.

In specific embodiments, pharmaceutical compositions are administered: (1) in diseases or disorders involving an absence or decreased (relative to normal or desired) level of an endogenous protein or function, for example, in hosts where the protein is lacking, genetically defective, biologically inactive or underactive, or under expressed; or (2) in diseases or disorders wherein, *in vitro* or *in vivo*, assays indicate the utility of PTMs that inhibit the function of a particular protein. The activity of the protein encoded for by the chimeric mRNA resulting from the PTM mediated *trans*-splicing reaction can be readily detected, e.g., by obtaining a host tissue sample (e.g., from biopsy tissue) and assaying it *in vitro* for mRNA or protein levels, structure and/or activity of the expressed chimeric mRNA. Many methods standard in the art can be thus employed, including but not limited to immunoassays to detect and/or visualize the protein encoded for by the chimeric mRNA (e.g., Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect formation of chimeric mRNA expression by detecting and/or visualizing the presence of chimeric mRNA (e.g., Northern assays, dot blots, *in situ* hybridization, and Reverse-Transcription PCR, etc.), etc.

The present invention also provides for pharmaceutical compositions comprising an effective amount of a PTM or a nucleic acid encoding a PTM, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized

2002246959 18 Feb 2008

pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical sciences" by E.W. Martin. In a specific embodiment, it

5 may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment. This may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of  
10 a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Other control release drug delivery systems, such as nanoparticles, matrices such as controlled-release polymers, hydrogels.

The PTM will be administered in amounts which are effective to produce the desired effect in the targeted cell. Effective dosages of the PTMs can be  
15 determined through procedures well known to those in the art which address such parameters as biological half-life, bioavailability and toxicity. The amount of the composition of the invention which will be effective will depend on the nature of the disease or disorder being treated, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify  
20 optimal dosage ranges.

The present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency  
25 regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

### 5.3.2. USE OF PTM MOLECULES FOR EXON TAGGING

In view of current efforts to sequence and characterize the genomes of  
30 humans and other organisms, there is a need for methods that facilitate such

2002246959 18 Feb 2008

characterization. A majority of the information currently obtained by genomic mapping and sequencing is derived from complementary DNA (cDNA) libraries, which are made by reverse transcription of mRNA into cDNA. Unfortunately, this process causes the loss of information concerning intron sequences and the location of exon/intron boundaries.

The present invention encompasses a method for mapping exon-intron boundaries in pre-mRNA molecules comprising (i) contacting a pre-trans-splicing molecule with a pre-mRNA molecule under conditions in which a portion of the pre-trans-splicing molecule is trans-spliced to a portion of the target pre-mRNA to form a chimeric mRNA; (ii) amplifying the chimeric mRNA molecule; (iii) selectively purifying the amplified molecule; and (iv) determining the nucleotide sequence of the amplified molecule thereby identifying the intron-exon boundaries.

In an embodiment of the present invention, PTMs can be used in trans-splicing reactions to locate exon-intron boundaries in pre-mRNAs molecules. PTMs for use in mapping of intron-exon boundaries have structures similar to those described above in Section 5.1. Specifically, the PTMs contain (i) a target binding domain that is designed to bind to many pre-mRNAs; (ii) a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site, or a 5' splice donor site; (iii) a spacer region that separates the mRNA splice site from the target binding domain; and (iv) a tag region that will be trans-spliced onto a pre-mRNA. Alternatively, the PTMs to be used to locate exon-intron boundaries may be engineered to contain no target binding domain.

For purposes of intron-exon mapping, the PTMs are genetically engineered to contain target binding domains comprising random nucleotide sequences. The random nucleotide sequences contain at least 15-30 and up to several hundred nucleotide sequences capable of binding and anchoring a pre-mRNA so that the spliceosome processing machinery of the nucleus can trans-splice a portion (tag or marker region) of the PTM to a portion of the pre-mRNA. PTMs containing short target binding domains, or containing inosines bind under less stringent conditions to the pre-mRNA molecules. In addition, strong branch point sequences and pyrimidine tracts serve to increase the non-specificity of PTM trans-splicing.

2002246959 18 Feb 2008

The random nucleotide sequences used as target binding domains in the PTM molecules can be generated using a variety of different methods, including, but not limited to, partial digestion of DNA with restriction endonucleases or mechanical shearing of the DNA. The use of such random nucleotide sequences is designed to generate a vast array of PTM molecules with different binding activities for each target pre-mRNA expressed in a cell. Randomized libraries of oligonucleotides can be synthesized with appropriate restriction endonucleases recognition sites on each end for cloning into PTM molecules genetically engineered into plasmid vectors. When the randomized oligonucleotides are ligated and expressed, a randomized binding library of PTMs is generated.

In a specific embodiment of the invention, an expression library encoding PTM molecules containing target binding domains comprising random nucleotide sequences can be generated using a variety of methods which are well known to those of skill in the art. Ideally, the library is complex enough to contain PTM molecules capable of interacting with each target pre-mRNA expressed in a cell.

By way of example, Figure 9 is a schematic representation of two forms of PTMs which can be utilized to map intron-exon boundaries. The PTM on the left is capable of non-specifically trans-splicing into a pre-mRNA 3' splice site, while the PTM on the right is capable of trans-splicing into a pre-mRNA 5' splice site. Trans-splicing between the PTM and the target pre-mRNA results in the production of a chimeric mRNA molecule having a specific nucleotide sequence "tag" on either the 3' or 5' end of an authentic exon.

Following selective purification, a DNA sequencing reaction is then performed using a primer which begins in the tag nucleotide sequence of the PTM and proceeds into the sequence of the tagged exon. The sequence immediately following the last nucleotide of the tag nucleotide sequence represents an exon boundary. For identification of intron-exon tags, the trans-splicing reactions of the invention can be performed either *in vitro* or *in vivo* using methods well known to those of skill in the art.

2002246959 18 Feb 2008

### 5.3.3. USE OF PTM MOLECULES FOR IDENTIFICATION OF PROTEINS EXPRESSED IN A CELL

In yet another embodiment of the invention, PTM mediated trans-splicing reactions can be used to identify previously undetected and unknown proteins expressed in a cell. This method is especially useful for identification of proteins that cannot be detected by a two-dimensional electrophoresis, or by other methods, due to *inter alia* the small size of the protein, low concentration of the protein, or failure to detect the protein due to similar migration patterns with other proteins in two-dimensional electrophoresis.

The present invention relates to a method for identifying proteins expressed in a cell comprising (i) contacting a pre-trans-splicing molecule containing a random target binding domain and a nucleotide sequence encoding a peptide tag with a pre-mRNA molecule under conditions in which a portion of the pre-trans-splicing molecule is trans-spliced to a portion of the target pre-mRNA to form a chimeric mRNA encoding a fusion polypeptide or separating it by gel electrophoresis (ii) affinity purifying the fusion polypeptide; and (iii) determining the amino acid sequence of the fusion protein.

To identify proteins expressed in a cell, the PTMs of the invention are genetically engineered to contain: (i) a target binding domain comprising randomized nucleotide sequences; (ii) a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site and/or a 5' splice donor site; (iii) a spacer region that separates the PTM splice site from the target binding domain; and (iv) nucleotide sequences encoding a marker or peptide affinity purification tag. Such peptide tags include, but are not limited to, HIS tags (6 histidine consecutive residues) (Janknecht, et al., 1991 Proc. Natl. Acad. Sci. USA 88:8972-8976), glutathione-S-transferase (GST) (Smith, D.B. and Johnson K.S., 1988, Gene 67:31) (Pharmacia) or FLAG (Kodak/IBI) tags (Nisson, J. et al. J. Mol. Recognit., 1996, 5:585-594).

Trans-splicing reactions using such PTMs results in the generation of chimeric mRNA molecules encoding fusion proteins comprising protein sequences normally expressed in a cell linked to a marker or peptide affinity purification tag. The desired goal of such a method is that every protein synthesized in a cell receives a



2002246959 18 Feb 2008

marker or peptide affinity tag thereby providing a method for identifying each protein expressed in a cell.

In a specific embodiment of the invention, PTM expression libraries encoding PTMs having different target binding domains comprising random

5 nucleotide sequences are generated. The desired goal is to create a PTM expression library that is complex enough to produce a PTM capable of binding to each pre-mRNA expressed in a cell. In a preferred embodiment, the library is cloned into a mammalian expression vector that results in one, or at most, a few vectors being present in any one cell.

10 To identify the expression of chimeric proteins, host cells are transformed with the PTM library and plated so that individual colonies containing one PTM vector can be grown and purified. Single colonies are selected, isolated, and propagated in the appropriate media and the labeled chimeric protein exon(s) fragments are separated away from other cellular proteins using, for example, an  
15 affinity purification tag. For example, affinity chromatography can involve the use of antibodies that specifically bind to a peptide tag such as the FLAG tag. Alternatively, when utilizing HIS tags, the fusion proteins are purified using a  $\text{Ni}^{2+}$  nitriloacetic acid agarose columns, which allows selective elution of bound peptide eluted with imidazole containing buffers. When using GST tags, the fusion proteins are purified  
20 using glutathione-S-transferase agarose beads. The fusion proteins can then be eluted in the presence of free glutathione.

Following purification of the chimeric protein, an analysis is carried out to determine the amino acid sequence of the fusion protein. The amino acid sequence of the fusion protein is determined using techniques well known to those of  
25 skill in the art, such as Edman Degradation followed by amino acid analysis using HPLC, mass spectrometry or an amino acid analyzation. Once identified, the peptide sequence is compared to those sequences available in protein databases, such as GenBank. If the partial peptide sequence is already known, no further analysis is done. If the partial protein sequence is unknown, then a more complete sequence of  
30 that protein can be carried out to determine the full protein sequence. Since the fusion protein will contain only a portion of the full length protein, a nucleic acid

2002246959 18 Feb 2008

encoding the full length protein can be isolated using conventional methods. For example, based on the partial protein sequence oligonucleotide primers can be generated for use as probes or PCR primers to screen a cDNA library.

## 6. EXAMPLE: PRODUCTION OF TRANS-SPLICING MOLECULES

5 The following section describes the production of PTMs and the demonstration that such molecules are capable of mediating *trans*-splicing reactions resulting in the production of chimeric mRNA molecules.

### 6.1. MATERIALS AND METHODS

#### 6.1.1. CONSTRUCTION OF PRE-mRNA MOLECULES

10 Plasmids containing the wild type diphtheria toxin subunit A (DT-A, wild-type accession #K01722) and a DT-A mutant (CRM 197, no enzymatic activity) were obtained from Dr. Virginia Johnson, Food and Drug Administration, Bethesda, Maryland (Uchida *et al.*, 1973 J. Biol. Chem 248:3838). For *in vitro* experiments, DT-A was amplified using primers: DT-1F (5'-  
15 GGGCGTGCAGGGCGCTGATGATGTTGTTG); and DT-2R (5'-GGCGAAG CTTGGATCCGACACGATTTCCTGCACAGG), out with PstI and HindIII, and cloned into PstI and HindIII digested pBS(-) vector (Stratagene, La Jolla, CA). The resulting clone, pDTA was used to construct the individual PTMs. (1) pPTM+: Targeted construct. Created by inserting IN3-1 (5'AATTCTCTAGATGCTT  
20 CACCCGGGCCCTGACTCGAGTACTAACTGGTACCTCTCTTTTTCCTGCA ) and IN2-4 (5'-GGAAAAAAGAAGAGGTACCAGTTAGTACTCGAGTCAGG CCGGGTGAAGCATCTAGAG) primers into EcoRI and PstI digested pDTA. (2) pPTM+Sp: As pPTM+ but with a 30 bp spacer sequence between the BD and BP. Created by digesting pPTM+ with XhoI and ligating in the oligonucleotides, spacer S  
25 (5'-TCGAGCAACGTTATAATAATGTTTC) and spacer AS (5'-TCGAGAACATTATTATAACGTTGC). For *in vivo* studies, an EcoRI and HindIII fragment of pCPTM+Sp was cloned into mammalian expression vector pcDNA3.1 (Invitrogen), under the control of a CMV promoter. Also, the methionine at codon 14 was changed into isoleucine to prevent initiation of translation. The resulting

2002246959 18 Feb 2008

plasmid was designated as pcPTM+Sp. (3) pPTM+CRM: As pPTM+Sp but the wild type DT-A was substituted with CRM mutant DT-A (T. Uchida, et al., 1973, J. Biol. Chem. 248:3838). This was created by PCR amplification of a DT-A mutant (mutation at G52E) using primers DT-1F and DT-2R. For *in vivo* studies, an EcoRI

- 5 HindIII fragment of PTM+CRM was cloned into pc3.IDNA that resulted in pcPTM+ARM. (4) PTM-: Non-targeted construct. Created by digestion of PTM+ with EcoRI and Pst I, gel purified to remove the binding domain followed by ligation of the oligonucleotides, IN-5 (5'-ATCTCTAGATCAGGCCCGGTGAAGCC CGAG) and IN-6 (5'-TGCTTCACCC GGCCTGATCTAGAG). (5) PTM-Sp, is an identical version of the PTM-, except it has a 30 bp spacer sequence at the PstI site. Similarly, the splice mutants [Py(-)AG(-) and BP(-)Py(-)AG(-)] and safety variants [PTM+SF-Py1, PTM+SF-Py2, PTM+SFBP3 and PTM+SFBP3-Py1] were constructed either by insertion or deletion of specific sequences (see 1).

Table 1. Binding/non-binding domain, BP, PPT and 3' as sequences of different PTMs.

PTM construct	BD/NBD	BP	PPT	3'as
PTM+Sp (targeted)	:TGCITCACC CGG CCTGA	TACTA <u>A</u> C	CTCTCTTTTTTTTCC	CAG
PTM-Sp (non-targeted)	:CAACGTTATAATAATGTT	TACTA <u>A</u> C	CTCTCTTTTTTTTCC	CAG
PTM+Py(-)AG(-)BP(-)	:TGCITCACC CGG CCTGA	GGCTG <u>A</u> T	CTGTGATTAATAGCGG	ACG
PTM+Py(-)AG(-)	:TGCITCACC CGG CCTGA	TACTA <u>A</u> C	CCTGGACGCGGAAGTT	ACG
PTM+SF	:CTGGGACAAGGACACTGCTT CACC CGTTAGTAGAACCACA GCCCTGAAGCC	TACTA <u>A</u> C	CTCTGTTTTTTCTC	CAG
PTM+SF-Py	:As in PTM+SF	TACTA <u>A</u> C	CTCTGTATTATTCTC	CAG
PTM+SF-Py	:As in PTM+SF	TACTA <u>A</u> C	GTCTGTCTTGTCTC	CAG
PTM+SF-BP3	:As in PTM+SF	TGCTG <u>A</u> C	CTCTGTTTTTTCTC	CAG
PTM+SFBP3-Py	:As in PTM+SF	TGCTG <u>A</u> C	CTCTGTATTATTCTC	CAG

15

Nucleotides in bold indicate the mutations compared to normal BP, PPT and 3' splice site.

20

Branch site A is underlined. The nucleotides in italics indicates the mismatch introduced into safety BD to mask the BP sequence in the PTM.

A double-trans-splicing PTM construct (DS-PTM) was also made adding a 5' splice site and a second target binding domain complementary to the second intron of  $\beta$ HCG pre-mRNA to the 3' end of the toxin coding sequence of PTM+SF (Figure A).

#### 5 6.1.2. $\beta$ HCG6 TARGET PRE-mRNA

To produce the *in vitro* target pre-mRNA, a *SacI* fragment of  $\beta$ HCG gene 6 (accession #X00266) was cloned into pBS(-). This produced an 805 bp insert from nucleotide 460 to 1265, which includes the 5' untranslated region, initiation codon, exon 1, intron 1, exon 2, and most of intron 2. For *in vivo* studies, an *EcoRI* and *BamHI* fragment was cloned into mammalian expression vector (pc3.1DNA), producing  $\beta$ HCG6.

#### 6.1.3. mRNA PREPARATION

For *in vitro* splicing experiments,  $\beta$ HCG6,  $\beta$ -globin pre-mRNA and different PTM mRNAs were synthesized by *in vitro* transcription of *BamHI* and *HindIII* digested plasmid DNAs respectively, using T7 mRNA polymerase (Pasman & Garcia-Blanco, 1996, Nucleic Acids Res. 24:1638). Synthesized mRNAs were purified by electrophoresis on a denaturing polyacrylamide gel, and the products were excised and eluted.

#### 6.1.4. *IN VITRO* SPLICING

PTMs and target pre-mRNA were annealed by heating at 98°C followed by slow cooling to 30-34°C. Each reaction contained 4  $\mu$ l of annealed mRNA complex (100 ng of target and 200 ng of PTM), 1X splice buffer (2 mM  $MgCl_2$ , 1 mM ATP, 5 mM creatinine phosphate, and 40 mM KCl) and 4  $\mu$ l of HeLa splice nuclear extract (Promega) in a 12.5  $\mu$ l final volume. Reactions were incubated at 30°C for the indicated times and stopped by the addition of an equal volume of high salt buffer (7 M urea, 5% SDS, 100 mM LiCl, 10 mM EDTA and 10 mM TrisHCl, pH 7.5). Nucleic acids were purified by extraction with phenol:chloroform:isoamyl alcohol (50:49:1) followed by ethanol precipitation.

2002246959 18 Feb 2008

#### 6.1.5. REVERSE TRANSCRIPTION-PCR REACTIONS

RT-PCR analysis was performed using EZ-RT PCR kit (Perkin-Elmer, Foster City, CA). Each reaction contained 10 ng of *cis*- or *trans*-spliced mRNA, or 1-2 µg of total mRNA, 0.1 µl of each 3' and 5' specific primer, 0.3 mM of each dNTP, 5 1X EZ buffer (50 mM bicine, 115 mM potassium acetate, 4% glycerol, pH 8.2), 2.5 mM magnesium acetate and 5 U of *rTth* DNA polymerase in a 50 µl reaction volume. Reverse transcription was performed at 60°C for 45 min followed by PCR amplification of the resulting cDNA as follows: one cycle of initial denaturation at 94°C for 30 sec, and 25 cycles of denaturation at 94°C for 18 sec and annealing and 10 extension at 60°C for 40 sec, followed by a 7 min final extension at 70°C. Reaction products were separated by electrophoresis in agarose gels.

Primers used in the study were as follows:

DT-1F: GGCCTGTCAGGGCGCTGATGATGTTGTTG  
 DT-2R: GCGAAGCTTGGATCCGACACGATTTCTGACACAGG  
 15 DT-3R: CATCGTCATAATTCCTTGTG  
 DT-4R: ATGGAATCTACATAACCAGG  
 DT-5R: GAAGGCTGAGCACTACACGC  
 HCG-R2: CGGCACCGTGGCCGAAGTGG,  
 Bio-HCG-F: ACCGGAATTCATGAAGCCAGGTACACCAGG  
 20 β-globulin-F: GGGCAAGGTGAACGTGGATG  
 β-globulin-R: ATCAGGAGTGGACAGATCC

#### 6.1.6. CELL GROWTH TRANSFECTION AND mRNA ISOLATION

Human lung cancer cell line H1299 (ATCC accession # CRL-5803) 25 was grown in RPMI medium supplemented with 10% fetal bovine serum at 37°C in a 5% CO<sub>2</sub> environment. Cells were transfected with pcSp+CRM (CRM is a non-functional toxin), a vector expressing a PTM, or vector alone (pcDNA3.1) using lipofectamine reagent (Life Technologies, Gaithersburg, MD). The assay was scored for neomycin resistance (*neo*<sup>r</sup>) colony formation two weeks after transfection. Four 30 *neo*<sup>r</sup> colonies were selected and expanded under continued *neo* selection. Total

cellular mRNA was isolated using RNA exol (BioChain Institute, Inc., San Leandro, CA) and used for RT-PCR.

#### 6.1.7. TRANS-SPLICING IN TUMORS IN NUDE MICE

Eleven nude mice were bilaterally injected (except B10, B11 and B12 had 1 tumor) into the dorsal flank subcutaneous space with  $1 \times 10^7$  H1299 human lung tumor cells (day 1). On day 14, the mice were given an appropriate dose of anesthesia and injected with, or without electroporation (T820, BTX Inc., San Diego, CA) in several orientations with a total volume of 100  $\mu$ l of saline containing 100  $\mu$ g pcSp+CRM with or without pc $\beta$ HCG6 or pcPTM+Sp. Solutions injected into the right side tumors also contained India ink to mark needle tracks. The animals were sacrificed 48 hours later and the tumor excised and immediately frozen at -80°C. For analysis, 10 mg of each tumor was homogenized and mRNA was isolated using a Dynabeads mRNA direct kit (Dyna) following the manufacturers directions. Purified mRNA (2  $\mu$ l of 10  $\mu$ l total volume) was subjected to RT-PCR using  $\beta$ HCG-F and DT-5R primers as described earlier. All samples were re-amplified using DT-3R, a nested DT-A primer and biotinylated  $\beta$ HCG-F and the products were analyzed by electrophoresis on a 2% agarose gel. Samples that produced a band were processed into single stranded DNA using M280 Streptavidin Dynabeads and sequenced using a toxin specific primer (DT-3R).

### 6.2. RESULTS

#### 6.2.1. SYNTHESIS OF PTM

A prototypical *trans*-splicing mRNA molecule, pcPTM+Sp (Figure 1A) was constructed that included: an 18 nt target binding domain (complementary to  $\beta$ HCG6 intron 1), a 30 nucleotide spacer region, branch point (BP) sequence, a polypyrimidine tract (PPT) and an AG dinucleotide at the 3' splice site immediately upstream of an exon encoding diphtheria toxin subunit A (DT-A) (Uchida *et al.*, 1973, J. Biol. Chem. 248:3838). Later DT-A exons were modified to eliminate translation initiation sites at codon 14. The PTM constructs were designed for maximal activity

2002246959 18 Feb 2008

in order to demonstrate *trans*-splicing; therefore, they included potent 3' splice elements (yeast BP and a mammalian PPT) (Moore *et al.*, 1993, In The mRNA World, R.F. Gesteland and J.F. Atkins, eds. (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press).  $\beta$ HCG6 pre-mRNA (Talmadge *et al.*, 1984, Nucleic Acids Res. 12:8415) was chosen as a model target as this gene is expressed in most tumor cells. It is not expressed in normal adult cells, with the exception of some in the pituitary gland and gonads. (Acevedo *et al.*, 1992, Cancer 76:1467; Hoon *et al.*, 1996, Int J. Cancer 69:369; Bellet *et al.*, 1997, Cancer Res. 57:516). As shown in Figure 1C, pcPTM+Sp forms conventional Watson-Crick base pairs by its binding domain with the 3' end of  $\beta$ HCG6 intron 1, masking the intronic 3' splice signals of the target. This feature is designed to facilitate *trans*-splicing between the target and the PTM.

HeLa nuclear extracts were used in conjunction with established splicing procedures (Pasman & Garcia-Blanco, 1996, Nucleic Acids Res. 24:1638) to test if a PTM construct could invade the  $\beta$ HCG6 pre-mRNA target. The products of *in vitro trans*-splicing were detected by RT-PCR, using primers specific for chimeric mRNA molecules. The predicted product of a successful *trans*-splicing reaction is a chimeric mRNA comprising the first exon of  $\beta$ HCG6, followed immediately by the exon contributed from pcPTM+Sp encoding DT-A (Figure 1C). Such chimeric mRNAs were readily detected by RT-PCR using primers  $\beta$ HCG-F (specific to  $\beta$ HCG6 exon 1) and DT-3R (specific to DT-A, Figure 2A, lanes 1-2). At time zero or in the absence of ATP, no 466 bp product was observed, indicating that this reaction was both ATP and time dependent.

The target binding domain of pcPTM+Sp contained 18 nucleotides complementary to  $\beta$ HCG6 intron 1 pre-mRNA and demonstrated efficient *trans*-splicing (Figure 2A, lanes 1-2). *Trans*-splicing efficiency decreased at least 8 fold (Figure 2, lanes 3-4) using non-targeted PTM-Sp, which contains a non-complementary 18 nucleotide "non-binding domain". *Trans*-splicing efficiencies of PTM mRNAs with or without a spacer between the binding domain and BP were also compared. This experiment demonstrated a significant increase in the efficiency of *trans*-splicing by the addition of a spacer (Figure 2B, lanes 2 + 5). To facilitate the

2002246959 18 Feb 2008

recruitment of splicing factors required for efficient *trans*-splicing, some space may be needed between the 3' splice site and the double-stranded secondary structure produced by the binding domain/target interaction.

- To investigate the effect of PTM length on *trans*-splicing specificity, shorter PTMs were synthesized from *AccI* cut PTM plasmid (see Figure 1). This eliminated 479 nt from the 3' end of the DT-A coding sequence. Figure 2B shows the *trans*-splicing ability of a targeted short PTM(+) (lanes 10-12), compared to a non-targeted short PTM(-) (lanes 14-17). Short PTM+ produced substantially more *trans*-spliced product (Figure 2B, lane 12) than its counterpart, non-targeted short PTM (Figure 2B, lane 17). These experiments indicate that longer PTMs may have increased potential to mediate *trans*-splicing non-specifically.

#### 6.2.2. ACCURACY OF PTM SPLICEOSOME MEDIATED *TRANS*-SPLICING

- To confirm that *trans*-splicing between the pcPTM+Sp and  $\beta$ HCG6 target is precise, RT-PCR amplified product was produced using 5' biotinylated  $\beta$ HCG-F and nonbiotinylated DT-3R primers. This product was converted into single stranded DNA and sequenced directly with primer DT-3R (DT-A specific reverse primer) using the method of Mitchell and Merrill (1989, Anal. Biochem. 178:239). *Trans*-splicing occurred exactly between the predicted splice sites (Figure 3), confirming that a conventional pre-mRNA can be invaded by an engineered PTM construct during splicing; moreover, this reaction is precise.

- In addition selective *trans*-splicing of a double splicing PTM (DS-PTM) was observed (Figure 8B). The DS-PTM can produce *trans*-splicing by contributing either a 3' or 5' splice site. Further, DS-PTMs can be constructed which will be capable of simultaneously double-*trans*-splicing, at both a 3' and 5' site, thereby permitting exon replacement. Figure 8B demonstrates that in this construct the 5' splice site is most active at a 1:1 concentration of target  $\beta$ HCG pre-mRNA:DS-PTM. At a 1:6 ratio the 3' splice site is more active.



2002246959 18 Feb 2008

### 6.2.3. 3' SPLICE SITES ARE ESSENTIAL FOR PTM *TRANS*-SPLICING

In general, the 3' splice site contains three elements: 1) a BP sequence located 5' of the acceptor site, 2) a PPT consisting of a short run of pyrimidine residues, and 3) a YAG trinucleotide splice site acceptor at the intron-exon border (Senapathy *et al.*, 1990, Cell 91:875; Moore *et al.*, 1993). Deletion or alteration of one of these sequence elements are known to either decrease or abolish splicing (Aebi *et al.*, 1986; Reed & Maniatis 1988, Genes Dev. 2:1268; Reed, 1989, Genes Dev. 3:2113; Roscigno *et al.*, 1993, J. Biol. Chem. 268:11222; Coolidge *et al.*, 1997, Nucleic Acids Res. 25:888). The role of these conserved elements in targeted *trans*-splicing was addressed experimentally. In one case [(BP(-)Py(-)AG(-))], all three *cis*-elements (BP, PPT and AG dinucleotide) were replaced by random sequences. A second splicing mutant [(Py(-)AG(-))] was constructed in which the PPT and the 3' splice site acceptor were mutated and substituted by random sequences. Neither construct was able to support *trans*-splicing *in vitro* (Figure 2A, lanes 5-8), suggesting that, as in the case of conventional *cis*-splicing, the PTM *trans*-splicing process also requires a functional BP, PPT and AG acceptor at the 3' splice site.

### 6.2.4. DEVELOPMENT OF A "SAFETY" SPLICE SITE TO INCREASE SPECIFICITY

To improve the levels of target specificity achieved by the inclusion of a binding domain or by shortening the PTM, the target-binding domain of several PTM constructs was modified to create an intra-molecular stem to mask the 3' splice site (termed a "safety PTM"). The safety stem is formed by portions of the binding domain that partially base pair with regions of the PTM 3' splice site or sequences adjacent to them, thereby blocking the access of spliceosomal components to the PTM 3' splice site prior to target acquisition (Figure 4A, PTM+SF). Base pairing between free portions of the PTM binding domain and  $\beta$ HCG6 target region unwinds the safety stem, allowing splicing factors such as U2AF to bind to the PTM 3' splice site and initiate *trans*-splicing (Figure 4B).

This concept was tested in splicing reactions containing either PTM+SF (safety) or pcPTM+Sp (linear), and both target ( $\beta$ HCG6) and non-target ( $\beta$ -

2002246959 18 Feb 2008

globin) pre-mRNA. The spliced products were subsequently analyzed by RT-PCR and gel electrophoresis. Using  $\beta$ HCG-F and DT-3R primers, the specific 196 bp *trans*-spliced band was demonstrated in reactions containing  $\beta$ HCG target and either linear PTM (pcPTM+Sp, Figure 5, lane 2) or safety PTM (PTM+SF, Figure 5, lane 8).

- 5 Comparison of the targeted *trans*-splicing between linear PTM (Figure 5, lane 2) and safety PTM (Figure 5, lane 8) demonstrated that the safety PTM *trans*-spliced less efficiently than the linear PTM.

- 10 Non-targeted reactions were amplified using  $\beta$ -globin-F (specific to exon 1 of  $\beta$ -globin) and DT-3R primers. The predicted product generated by non-specific PTM *trans*-splicing with  $\beta$ -globin pre-mRNA is 189 bp. Non-specific *trans*-splicing was evident between linear PTM and  $\beta$ -globin pre-mRNA (Figure 5, lane 5). In contrast, non-specific *trans*-splicing was virtually eliminated by the use of safety PTM (Figure 5, lane 11). This was not unexpected, since the linear PTM was
- 15 splicing. The open structure of the linear PTM combined with its potent 3' splice sites strongly promotes the binding of splicing factors. Once bound, these splicing factors can potentially initiate *trans*-splicing with any 5' splice site, in a process similar to *trans*-splicing in trypanosomes. The safety stem was designed to prevent splicing factors, such as U2AF from binding to the PTM prior to target acquisition. This result
- 20 is consistent with a model that base-pairing between the free portion of the binding domain and the  $\beta$ HCG6 target unwinds the safety stem (by mRNA-mRNA interaction), uncovering the 3' splice site, permitting the recruitment of splicing factors and initiation of *trans*-splicing. No *trans*-splicing was detected between  $\beta$ -globin and  $\beta$ HCG6 pre-mRNAs (Figure 5, lanes 3, 6, 9 and 12).

#### 25 6.2.5. IN VITRO TRANS-SPICING OF SAFETY PTM AND VARIANTS

- To better understand the role of *cis*-elements at the 3' splice site in *trans*-splicing a series of safety PTM variants were constructed in which either the PPT was weakened by substitution with purines and/or the BP was modified by base substitution (see Table I). *In vitro trans*-splicing efficiency of the safety (PTM+SF)
- 30 was compared to three safety variants, which demonstrated a decreased ability to

2002246959 18 Feb 2008

*trans*-splice. The greatest effect was observed with variant 2 (PTM+SFPy2), which was *trans*-splicing incompetent (Figure 4C, lanes 5-6). This inhibition of *trans*-splicing may be attributed to a weakened PPT and/or the higher  $T_m$  of the safety stem. In contrast, variations in the BP sequence (PTM+SFBP3) did not markedly effect

5 *trans*-splicing (Figure 4C, lanes 7-8). This was not surprising since the modifications introduced were within the mammalian branch point consensus range YNYURAC (where Y = pyrimidine, R = purine and N = any nucleotide) (Moore *et al.*, 1993). This finding indicates that the branch point sequence can be removed without affecting splicing efficiency. Alterations in the PPT (PTM+SF-Pyl) decreased the

10 level of *trans*-splicing (lanes 3-4). Similarly, when both BP and PPT were altered PTM+SFBP3-Pyl, they caused a further reduction in *trans*-splicing (Figure 4C, lanes 9-10). The order of *trans*-splicing efficiency of these safety variants is PTM+SF>PTM+SFBP3> PTM+SFPyl>PTM+SFBP3-Pyl>PTM+SFPy2. These results confirm that both the PPT and BP are important for efficient *in vitro trans*-

15 splicing (Roscigno *et al.*, 1993, J. Biol. Chem. 268:11222).

#### 6.2.6. COMPETITION BETWEEN *CIS*- AND *TRANS*-SPLICING

To determine if it was possible to block pre-mRNA *cis*-splicing by increasing concentrations of PTM, experiments were performed to drive the reaction towards *trans*-splicing. Splicing reactions were conducted with a constant amount of

20  $\beta$ HCG6 pre-mRNA target and various concentrations of *trans*-splicing PTM. *Cis*-splicing was monitored by RT-PCR using primers to  $\beta$ HCG-F (exon 1) and  $\beta$ HCG-R2 (exon 2). This amplified the expected 125 bp *cis*-spliced and 478 bp unspliced products (Figure 6A). The primers  $\beta$ HCG-F and DT-3R were used to detect *trans*-spliced products (Figure 6B). At lower concentrations of PTM, *cis*-splicing (Fig. 6A,

25 lanes 1-4) predominated over *trans*-splicing (Figure 6B, lanes 1-4). *Cis*-splicing was reduced approximately by 50% at a PTM concentration 1.5 fold greater than target. Increasing the PTM mRNA concentration to 3 fold that of target inhibited *cis*-splicing by more than 90% (Figure 6A, lanes 7-9), with a concomitant increase in the *trans*-spliced product (Figure 6B, lanes 6-10). A competitive RT-PCR was performed to

30 simultaneously amplify both *cis* and *trans*-spliced products by including all three

2002246959 18 Feb 2008

primers (βHCG-F, HCG-R2 and DT-3R) in a single reaction. This experiment had similar results to those seen in Figure 6, demonstrating that under *in vitro* conditions, a PTM can effectively block target pre-mRNA *cis*-splicing and replace it with the production of an engineered *trans*-spliced chimeric mRNA.

#### 5 6.2.7. TRANS-SPLICING IN TISSUE CULTURE

To demonstrate the mechanism of *trans*-splicing in a cell culture model, the human lung cancer line H1299 (βHCG6 positive) was transfected with a vector expressing SP+CRM (a non-functional diphtheria toxin) or vector alone (pcDNA3.1) and grown in the presence of neomycin. Four neomycin resistant colonies were individually collected after 14 days and expanded in the continued presence of neomycin. Total mRNA was isolated from each clone and analyzed by RT-PCR using primers βHCG-F and DT-3R. This yielded the predicted 196 bp *trans*-spliced product in three out of the four selected clones (Figure 7A, lanes 2, 3 and 4). The amplified product from clone #2 was directly sequenced, confirming that PTM driven *trans*-splicing occurred in human cells exactly at the predicted splice sites of endogenously expressed βHCG6 target exon 1 and the first nucleotide of DT-A (Figure 7B).

#### 6.2.8. TRANS-SPLICING IN AN *IN VIVO* MODEL

To demonstrate the mechanism of *trans*-splicing *in vivo*, the following experiment was conducted in athymic (nude) mice. Tumors were established by injecting 10<sup>7</sup> H1299 cells into the dorsal flank subcutaneous space. On day 14, PTM expression plasmids were injected into tumors. Most tumors were then subjected to electroporation to facilitate plasmid delivery (see Table 2, below). After 48 hrs, tumors were removed, poly-A mRNA was isolated and amplified by RT-PCR. *Trans*-splicing was detected in 8 out of 19 PTM treated tumors. Two samples produced the predicted *trans*-spliced product (466 bp) from mRNA after one round of RT-PCR. Six additional tumors were subsequently positive for *trans*-splicing by a second PCR amplification using a nested set of primers that produced the predicted 196 bp product (Table 2). Each positive sample was sequenced, demonstrating that βHCG6 exon 1

2002246959 18 Feb 2008

was precisely *trans*-spliced to the coding sequence of DT-A (wild type or CRM mutant) at the predicted splice sites. Six of the positive samples were from treatment groups that received cotransfected plasmids, pcPTM+CRM and pcHCG6, which increased the concentration of target pre-mRNA. This was done to enhance the probability of detecting *trans*-spliced events. The other two positive tumors were from a group that received only pcPTM+Sp (wild type DT-A). These tumors were not transfected with  $\beta$ HCG6 expression plasmid, demonstrating once again, as in the tissue culture model described in Section 6.2.7, that *trans*-splicing occurred between the PTM and endogenous  $\beta$ HCG6 pre-mRNA produced by tumor cells.

2002246959 18 Feb 2008

Table 2. <i>Trans</i> -splicing in tumors in nude mice.							
Mouse	Plasmid	Left	Right	Electroporation	RT-PCR Left Right	Nested PCR	Nucleotide Sequence
B1	PCMV-Sport	B1-1	B1-2	-	- -	- -	- -
B2	PCMV-Sport	B1-3	B1-4	<sup>a</sup> 1000V/cm	- -	- -	- -
B3	pcSp+CRM	B3-1	B3-2	<sup>a</sup> 1000V/cm	- -	- -	- -
		B3-3	B3-4	<sup>a</sup> 1000V/cm	- -	- -	- -
B4	pcSp+CRM	B4-1	B4-2	<sup>b</sup> 50V/cm	- -	- -	- -
		B4-3	B4-4	<sup>c</sup> 25V/cm	- -	- -	- -
B5	PcSp+CRM/ pcHCG6	B5-1	B5-2	<sup>a</sup> 1000V/cm	+ -	+ +	ATGTTCCAGTGGCGTGATGA (SEQ ID NO:53)
		B5-3	B5-4	<sup>a</sup> 1000V/cm	+ -	- +	ATGTTCCAGTGGCGTGATGA (SEQ ID NO:53)
B6	PcSp+CRM/ pcHCG6	B6-1	B6-2	<sup>b</sup> 50V/cm	- -	- -	- -
		B6-3	B6-4	<sup>c</sup> 25V/cm	- -	+ +	ATGTTCCAGTGGCGTGATGA (SEQ ID NO:53)
B7	pcPTM+Sp	B7-1		<sup>a</sup> 1000V/cm	- -	- -	- -
B8	PcPTM+Sp	B8-1		<sup>b</sup> 50V/cm	- -	+ -	ATGTTCCAGTGGCGTGATGA (SEQ ID NO:53)
B9	PcPTM+Sp	B9-1		-	- -	+ -	ATGTTCCAGTGGCGTGATGA (SEQ ID NO:53)

<sup>a</sup>: 6 pulses of 99 $\mu$ s sets of 3 pulses administered orthogonally<sup>b</sup>: 8 pulses of 10ms sets of 4 pulses administered orthogonally<sup>c</sup>: 8 pulses of 50ms sets of 4 pulses administered orthogonally

+: positive for RT-PCR trans-spliced product

-: did not receive electroporation

#### 7. EXAMPLE: *lacZ* TRANS-SPICING MODEL

In order to demonstrate and evaluate the generality of the mechanism of spliceosome mediated targeted *trans*-splicing between a specific pre-mRNA target and a PTM, a simple model system based on expression of enzyme  $\beta$ -galactosidase was developed. The following section describes results demonstrating successful spliceosome mediated targeted *trans*-splicing between a specific target and a PTM.

2002246959 18 Feb 2008

7.1. MATERIALS AND METHODS7.1.1. PRIMER SEQUENCES

The following primers were used for testing the *lacZ* model system:

5' Lac-1F  
5 GCATGAATTCGGTACCATGGGGGGTCTCATCATCATC  
5' Lac-1R  
CTGAGGATCCTTTACCTGTAAACGCCCATACTGAC  
3' Lac-1F  
GCATGGTAACCTGCAGGGCGGCTTCGTCTGGGACTGG  
10 3' Lac-1R  
CTGAAAGCTTGTTAACTTATTATTTTGACACCAGACC  
3' Lac-Stop  
GCATGGTAACCTGCAGGGCGGCTTCGTCTAATAATGGGACTGGGT  
G  
15 HCG-In1F  
GCATGGATCCTCCGGAGGGCCCTGGGCACCTTCCAC  
HCG-In1R  
CTGACTGCAGGGTAACCGGACAAGGACACTGCTTCACC  
HCG-Ex2F  
20 GCATGGTAACCTGCAGGGGCTGCTGCTGTTGCTG  
HCG-Ex2R  
CTGAAAGCTTGTTAACCAGCTCACCATGGTGGGGCAG  
Lac-TR1 (Biotin): 7-GGCTTTGCTACCTGGAGAGAC  
Lac-TR2 GCTGGATGCGGCGTGCGGTCG  
25 HCG-R2: CGGCACCGTGCCGAAGTGG

7.1.2. CONSTRUCTION OF THE *lacZ* PRE-mRNA TARGET MOLECULE

The *lacZ* target 1 pre-mRNA (pc3.1 lacT1) was constructed by cloning of the following three PCR products: (i) the 5' fragment of *lacZ*; followed by (ii)

30 βHCG6 intron 1; (iii) and the 3' fragment of *lacZ*. The 5' and 3' fragment of the *lacZ*

2002246959 18 Feb 2008

gene were PCR amplified from template pcDNA3.1/His/lacZ (Invitrogen, San Diego, CA) using the following primers: 5' Lac-1F and 5' Lac-1R (for 5' fragment), and 3' Lac-1F and 3' Lac-1R (for 3' fragment). The amplified lacZ 5' fragment is 1788 bp long which includes the initiation codon, and the amplified 3' fragment is 1385 bp long and has the natural 5' and 3' splice sites in addition to a branch point, polypyrimidine tract and  $\beta$ HCG6 intron 1. The  $\beta$ HCG6 intron 1 was PCR amplified using the following primers: HCG-In1F and HCG-In1R.

The lacZ target 2 is an identical version of lacZ target 1 except it contains two stop codons (TAA TAA) in frame four codons after the 3' splice site.

10 This was created by PCR amplification of the 3' fragment (lacZ) using the following primers: 3' Lac-Stop and 3' Lac 1R and replacing the functional 3' fragment in lacZ target 1.

#### 7.1.3. CONSTRUCTION OF pc3.1 PTM1 and pc3.1 PTM2

The pre-trans-splicing molecule, pc3.1 PTM1 was created by digesting

15 pPTM +Sp with PstI and HindIII and replacing the DNA fragment encoding the DT-A toxin with the a DNA fragment encoding the functional 3' end of lacZ. This fragment was generated by PCR amplification using the following primers: 3' Lac-1F and 3' Lac-1R. For cell culture experiments, an EcoRI and HindIII fragment of pc3.1 PTM2 which contains the binding domain to HCG intron 1, a 30 bp spacer, a yeast

20 branch point (TACTAAC), and strong polypyrimidine tract followed by the lacZ cloned was cloned into pcDNA3.1.

The pre-trans-splicing molecule, pc3.1 PTM2 was created by digesting pPTM +Sp with PstI and HindIII and replacing the DNA fragment encoding the DT-A toxin with the  $\beta$ HCG6 exon 2.  $\beta$ HCG6 exon 2 was generated by PCR

25 amplification using the following primers: HCG-Ex2F and HCG-Ex2R. For cell culture experiments, an EcoRI and HindIII fragment of pc3.1 PTM2 which contains the binding domain to HCG intron 1, a 30 bp spacer, a yeast branch point (TACTAAC), and strong polypyrimidine tract followed by the  $\beta$ HCG6 exon 2 cloned was used.



55

2002246959 18 Feb 2008

#### 7.1.4. CO-TRANSFECTION OF THE *lacZ* SPLICE TARGET PRE-mRNA AND PTMS INTO 293T CELLS

Human embryonic kidney cells (293T) were grown in DMEM medium supplemented with 10% FBS at 37°C in a 5% CO<sub>2</sub>. Cells were co-transfected with pc3.1 *lacT1* and pc3.1 PTM2, or pc3.1 *lacT2* and pc3.1 PTM1, using Lipofectamine Plus (Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. 24 hours post-transfection, the cells were harvested; total RNA was isolated and RT-PCR was performed using specific primers for the target and PTM molecules.  $\beta$ -galactosidase activity was also monitored by staining the cells using a  $\beta$ -gal staining kit (Invitrogen, San Diego, CA).

### 7.2. RESULTS

#### 7.2.1. THE *lacZ* SPLICE TARGET *CIS*-SPLICES EFFICIENTLY TO PRODUCE FUNCTIONAL $\beta$ -GALACTOSIDASE

To test the ability of the splice target pre-mRNA to *cis*-splice efficiently, pc3.1 *lacT1* was transfected into 293 T cells using Lipofectamine Plus reagent (Life Technologies, Gaithersburg, MD) followed by RT-PCR analysis of total RNA. Sequence analysis of the *cis*-spliced RT-PCR product indicated that splicing was accurate and occurred exactly at the predicted splice sites (Fig. 12B). In addition, accurate *cis*-splicing of the target pre-mRNA molecule results in formation of a mRNA capable of encoding active  $\beta$ -galactosidase which catalyzes the hydrolysis of  $\beta$ -galactosidase, *i.e.*, X-gal, producing a blue color that can be visualized under a microscope. Accurate *cis*-splicing of the target pre-mRNA was further confirmed by successfully detecting  $\beta$ -galactosidase enzyme activity.

Repair of defective *lacZ* target 2 pre-mRNA by trans-splicing of the functional 3' *lacZ* fragment (PTM1) was measured by staining for  $\beta$ -galactosidase enzyme activity. For this purpose, 293T cells were co-transfected with *lacZ* target 2 pre-mRNA (containing a defective 3' fragment) and PTM1 (contain normal 3' *lacZ* sequence). 48 hours post-transfection cells were assayed for  $\beta$ -galactosidase enzyme activity. Efficient trans-splicing of PTM1 into the *lacZ* target 2 pre-mRNA will

result in the production of functional  $\beta$ -galactosidase activity. As demonstrated in Figure 11B-E, trans-splicing of PTM 1 into lacZ target 2 results in restoration of  $\beta$ -galactosidase enzyme activity up to 5% to 10% compared to control.

#### 7.2.2. TARGETED TRANS-SPLICING BETWEEN THE *lacZ* TARGET PRE-mRNA and PTM2

To assay for *trans*-splicing, *lacZ* target pre-mRNA and PTM2 were transfected into 293 T cells. Following transfection, total RNA was analyzed using RT-PCR. The following primers were used in the PCR reactions: *lacZ*-TR1 (*lacZ* 5' exon specific) and HCGR2 ( $\beta$ HCGR exon 2 specific). The RT PCR reaction produced the expected 195 bp *trans*-spliced product (Fig. 11, lanes 2 and 3) demonstrating efficient *trans*-splicing between the *lacZ* target pre-mRNA and PTM 2. Lane 1 represents the control, which does not contain PTM 2.

The efficiency of the *trans*-splicing was also measured by staining for  $\beta$ -galactosidase enzyme activity. To assay for *trans*-splicing, 293T cells were co-transfected with *lacZ* target pre-mRNA and PTM 2. 24 hours post-transfection, cells were assayed for  $\beta$ -galactosidase activity. If there is efficient *trans*-splicing between the target pre-mRNA and the PTM, a chimeric mRNA is produced consisting of the 5' fragment of the *lacZ* target pre-mRNA and  $\beta$ HCGR6 exon 2 is formed which is incapable of coding for an active  $\beta$ -galactosidase. Results from the co-transfection experiments demonstrated that *trans*-splicing of PTM2 into *lacZ* target 1 resulted in the reduction of  $\beta$ -galactosidase activity by compared to the control.

To further confirm that *trans*-splicing between the *lacZ* target pre-mRNA and PTM2 is accurate, RT-PCR was performed using 5' biotinylated *lacZ*-TR1 and non-biotinylated HCGR2 primers. Single stranded DNA was isolated and sequenced directly using HCGR2 primer (HCG exon 2 specific primer). As evidenced by the sequence of the splice junction, *trans*-splicing occurred exactly as predicted between the splice sites (Fig. 12A and 12B), confirming that a conventional pre-mRNA can be invaded by an engineered PTM during splicing, and moreover, that this reaction is precise.

2002246959 18 Feb 2008

## 8. EXAMPLE: CORRECTION OF THE CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR GENE

Cystic fibrosis (CF) is one of the most common genetic diseases in the world. The gene associated with CF has been isolated and its protein product deduced (Kerem, B.S. et al., 1989, Science 245:1073-1080; Riordan et al., 1989, Science 245:1066-1073; Rommans, et al., 1989, Science 245:1059-1065). The protein product of the CF associated gene is referred to as the cystic fibrosis transmembrane conductance regulator (CFTR). The most common disease-causing mutation which accounts for ~70% of all mutant alleles is a deletion of three nucleotides in exon 10 that encode for a phenylalanine at position 508 (ΔF508). The following section describes the successful repair of the cystic fibrosis gene using spliceosome mediated *trans*-splicing and demonstrates the feasibility of repairing CFTR in a model system.

### 8.1 MATERIALS AND METHODS

#### 8.1.1. PRE-TRANS-SPICING MOLECULE

The CFTR pre-trans-splicing molecule (PTM) consists of a 23 nucleotide binding domain complementary to CFTR intron 9 (3' end, -13 to -31), a 30 nucleotide spacer region (to allow efficient binding of spliceosomal components), branch point (BP) sequence, polypyrimidine tract (PPT) and an AG dinucleotide at the 3' splice site immediately upstream of the sequence encoding CFTR exon 10 (wild type sequence containing F508). This initial PTM was designed for maximal activity in order to demonstrate *trans*-splicing; therefore the PTM included a UACUAAC yeast consensus BP sequence and an extensive PPT. An 18 nucleotide HIS tag (6 histamine codons) was included after wild type exon 10 coding sequence to allow specific amplification and isolation of the *trans*-spliced products and not the endogenous CFTR. The oligonucleotides used to generate the two fragments included unique restriction sites. (ApaI and PstI, and PstI and NotI, respectively) to facilitate directed cloning of amplified DNA into the mammalian expression vector pcDNA3.1.

2002246959 18 Feb 2008

### 8.1.2. THE TARGET CFTR PRE-mRNA MINI-GENE

The CFTR mini-gene target is shown in Figure 13 and consists of CFTR exon 9; the functional 5' and 3' regions of intron 9 (260 and 265 nucleotides from each end, respectively); exon 10 [ΔF508]; and the 5' region of intron 10 (96 nucleotides). In addition, as depicted in Figure 16, a mini-target gene comprising CFTR exons 1-9 and 10-24 can be used to test the use of spliceosome mediated *trans*-splicing for correction of the cystic fibrosis mutation. Figure 17, shows a double splicing PTM that may also be used for correction of the cystic fibrosis mutation. As shown, the double splicing PTM contains CFTR BD intron 9, a spacer, a branch point, a polypyrimidine tract, a 3' splice site, CFTR exon 10, a spacer, a branch point, a polypyrimidine tract, a 5' splice site and CFTR BD exon 10.

### 8.1.3. OLIGONUCLEOTIDES

The following oligonucleotides were used to create CFTR PTM:

#### Forward CF3

15 ACCT GGGCCC ACC CAT TAT TAG GTC ATT AT CCGCGG AAC ATT ATA  
ApaI site. Intron 9 CFTR, -12 to -34.

#### Reverse CF4

ACCT CTGCAGGTGACC CTG CAG GAA AAA AAA GAA G  
PstI. BstEI. PPT.

#### Forward CF5

ACCT CTGCAG ACT TCA CTT CTA ATG ATG AT  
PstI. Exon 10 CFTR, +1 to +24

#### Reverse CF6

25 ACCT GCGGCCGC CTA ATG ATG ATG ATG ATG ATG CTC TTC TAG TTG GCA  
TGC Not I Stop Polyhistamine tag Exon 10 CFTR, +15 to +132

The following nucleotides were used to create the CFTR TARGET pre-mRNA mini gene (Exon 9 + mini-Intron 9 + Exon 10 + 5' end Intron 10):

59

2002246959 18 Feb 2008

Forward CF18

GACCT CTCGAG GGA TTT GGG GAA TTA TTT GAG  
 XhoI Exon 9 CFTR, 1 to 21.

5

Reverse CF19

CTGACCT GCGGCCGC TAC AGT GTT GAA TGT GGT GC  
 NotI Intron 9 5' end.

Forward CF20

CTGACCT GCGGCCGC CCA ACT ATC TGA ATC ATG TG  
 NotI Intron 9 3' end.

10

Reverse CF21

GACCT CTTAAG TAG ACT AAC CGA TTG AAT ATG  
 ARII Intron 10 5' end.

15

The following oligonucleotides were used for detection of trans-spliced

products:

Reverse Bio-His

CTA ATG ATG ATG ATG ATG ATG  
 Stop. Polyhistidine tag (5' biotin label).

20

Reverse Bio-His(2)

CGC CTA ATG ATG ATG ATG ATG  
 3' UT Stop. Polyhistidine tag (5' biotin label).

Forward CF8

CTT CTT GGT ACT CCT GTC CTG  
 Exon 9 CFTR.

25

Forward CF18

GACCT CTCGAG GGA TTT GGG GAA TTA TTT GAG  
 XhoI Exon 9 CFTR.

Reverse CF28

AAC TAG AAG GCA CAG TCG AGG  
 Pc3.1 vector sequence (present in PTM 3' UT but not target).

30

## 8.2. RESULTS

The PTM and target pre-mRNA were co-transfected in 293 embryonic kidney cells using lipofectamine (Life Technologies, Gaithersburg, MD). Cells were harvested 24 h post transfection and RNA was isolated. Using PTM and target-specific primers in RT-PCR reactions, a *trans*-spliced product was detected in which mutant exon 10 of the target pre-mRNA was replaced by the wild type exon 10 of the PTM (Figure 14). Sequence analysis of the *trans*-spliced product confirmed the restoration of the three nucleotide deletion and that splicing was accurate, occurring at the predicted splice sites (Figure 15), demonstrating for the first time RNA repair of the cystic fibrosis gene, CFTR (Mansfield et al., 2000, Gene Therapy 7:1885-1895).

## 9. EXAMPLE: DOUBLE-TRANS-SPlicing

The following example demonstrates accurate replacement of an internal exon by a double-*trans*-splicing between a target pre-mRNA and a PTM RNA containing both 3' and 5' splice sites leading to production of full length functionally active protein.

As described herein, any pre-mRNA can be reprogrammed by providing a *trans*-reactive RNA molecule containing either a 3'-splice site, a 5'-splice site or both. The following example describes successful targeting and replacement of a single internal exon utilizing pre-*trans*-splicing molecules (PTMs) containing both the 5' and 3' splice sites. Such PTMs can promote two *trans*-splicing reactions with the intended target gene mediated by the spliceosome(s). To test this mechanism, a splicing lacZ model target gene consisting of lacZ 5' "exon" - CFTR mini-intron 9 - CFTR exon 10 (ΔF508) - CFTR mini-intron 10 followed by lacZ 3' "exon" was created. In this target transcript, a 124 bp central portion of the β-galactosidase ORF was substituted by exon 10 (ΔF508) of CFTR, thus it produces non-functional protein. A PTM consisting of the missing 124 bp lacZ "mini-exon" and a 5' and 3' *trans*-splicing domain containing binding domains (BDs) complementary to the target introns and exons was created. Transfection of HEK 293T cells with either target alone or PTM alone showed no detectable levels of β-gal activity. In contrast, 293T cells transfected with target plus PTM produced substantial levels of β-gal activity

2002246959 18 Feb 2008

indicating the restoration of protein function. The accuracy of *trans*-splicing between the target and PTM was confirmed by sequencing the appropriate RT-PCR product, which revealed the predicted internal exon substitution. The feasibility of this approach in a disease model was tested by replacing the CFTR  $\Delta$ F508 exon 10 with normal exon 10 containing F508 in cystic fibrosis. These results demonstrate that a *trans*-splicing technology can be easily adapted to correct many of the genetic defects whether they are associated with the 5' exon or 3' exon or any internal exon of the gene.

Figure 18 is a schematic of a model lacZ target consisting of lacZ 5' exon - CFTR mini-intron 9 - CFTR exon 10 (delta 508) - CFTR min-intron 10 followed by the lacZ 3' exon. In this target, a 124 bp central portion of the lacZ gene is substituted with CFTR exon 10 which has a mutation at position 508 (delta 508). The pre-mRNA target undergoes normal *cis*-splicing to produce an mRNA consisting of lacZ 5' exon - CFTR exon 10 (delta 508) followed by the lacZ 3' exon. Because of the disruption in  $\beta$ -galactosidase ORF it produces truncated proteins which are non-functional.

To restore  $\beta$ -gal function by double-*trans*-splicing, three PTMs were created consisting of the missing 124 bp lacZ "mini-exon" and a 5' and 3' *trans*-splicing domain containing binding domains complementary to the target introns and exons as shown in Figure 19. These PTMs have an 120 bp 3' binding domain (complementary to intron 9) from PTM24 (see below) used in 3' exon replacement, spacer sequence, yeast branch point, polypyrimidine tract, 3' acceptor AG dinucleotide, lacZ "mini-exon", 5' splice site, spacer sequence followed by the 5' binding domain. These PTMs differ only in their 5' binding domain sequences. DSPTM5 has a 27 bp BD which is complementary to intron 10 and blocks just the 5' splice site of the target. DSPTM6 has 120 bp 5' BD and covers both 5' and 3' splice sites of the target, while, DSPTM7 has 260 bp BD which masks both the splice sites (5' and 3') and also covers the entire exon of the target.

A schematic representation of a double-*trans*-splicing reaction showing the binding of DSPTM7 with DSCFT1.6 target pre-mRNA is shown in Figure 20. 3' BD: 120 bp binding domain complementary to mini-intron 9; 5' BD

2002246959 18 Feb 2008

(260 bp); second binding domain complementary to mini-intron 10 and exon 10. ss: splice sites; BP: branch point, and PPT: polypyrimidine tract.

The important structural elements of DSPIM7 (Figure 21) are as follows:

- 5 (1) 3' BD (120 BP):  
 GATTCACCTTGCTCCAATTATCATCCTAAGCAGAAGTGTATATTCTTA  
 TTTGTAAAGATTCTATTAACCTATTGATTCAAAATATTTAAATACCTCCT  
 GTTTCATACTCTGCTATGCAC
- 10 (2) Spacer sequences (24 bp): AACATTATTATAACGTTGCTCGAA
- (3) Branch point, pyrimidine tract and acceptor splice site:
- 15 BP Kpn I PPT EcoRV 3' ss  
 TACTAAC T GGTACC TCTTCTTTT TTTT TATATC CTGCAG |GGC GGC|  
 ↓ lacZ mini-exon
- (4) 5' donor site and 2<sup>nd</sup> spacer sequence:
- 20 5' ss  
 lacZ mini-exon ↓  
 |TGA ACG| GTAAGT  
 GTTATCACCGATATGTGTCTAACCTGATTGGGGCCTTC  
 GATACGCTAAGATCCACCGG
- 25 (5) 5' BD (260 BP):  
 TCAAAAAGTTTTACATAATTCTTACCTCTTCT  
 TGAATTCATGCTTTGATGACGCTTCTGTATCTATATTC  
 ATCATTGGAAACACCAATGATTTTTCTTTAATGGTGCC  
 TGGCATAATCCTGGAAAACTGATAACACAATGAAATT  
 30 CTTCCACTGTGCITAAAAAACCCCTCTGAATTCTCCA  
 TTTCTCCATAATCATCATTACAACTGAACCTCTGGAAA  
 TAAAACCCATCATTATTAATCATTATCAAATCACGC

- 35 To determine whether the restoration of  $\beta$ -gal function is RNA *trans*-  
 splicing mediated, the mutants are depicted in Figure 22. DSPIM8 is a 3' splice  
 mutant in which the 3' splice elements such as BP, polypyrimidine tract and the 3'  
 acceptor AG dinucleotides were deleted and replaced with random sequences. This  
 PTM still has 3' and 5' binding domains and the functional 5' splice site. PTM29 lacks  
 the 2<sup>nd</sup> binding domain + 5' ss but still has the 3' binding domain 3' splice site, while



2002246959 18 Feb 2008

PTM30 lacks the 1<sup>st</sup> binding domain + 3' splice site but has the functional 5' splice site and 2<sup>nd</sup> binding domain.

To examine the double-*trans*-splicing mediated restoration of  $\beta$ -gal function, 293T cells were either transfected with 2  $\mu$ g of target or PTM alone or co-transfected with 2  $\mu$ g of target + 1.5  $\mu$ g of PTM using Lipofectamine Plus reagent. 48 hrs. after transfection, total RNA was isolated and analyzed by RT-PCR using K1-1F and Lac-6R primers. These primers amplify both *cis*- and *trans*-spliced products in a single reaction which were identified based on the size. The *cis*-spliced product is 295 bp in size while the *trans*-spliced product is 230 bp in size. To confirm that *trans*-splicing between DSPTM7 and DSCFT1.6 pre-mRNA is precise, RT-PCR amplified products were excised, re-amplified using K1-2F and Lac-6R primers and sequenced directly using K1-2F or Lac-6R primers. As shown in Figure 23 *trans*-splicing occurred exactly at the predicted splice sites, confirming the precise internal exon substitution by two *trans*-splicing events.

The repair of defective lacZ pre-mRNA by double *trans*-splicing events and subsequent production of full-length  $\beta$ -gal protein was investigated in co-transfection assays. 293T cells were co-transfected with DSCFT1.6 target and DSPTM7 expression plasmids, as well as with DSCFT1.6 target or DSPTM7 alone as controls. Western blot analysis of total cell lysates using polyclonal anti- $\beta$ -galactosidase antiserum specifically recognized a ~ 120 kDa protein only in cells co-transfected with DSCFT1.6 target + DSPTM7 plasmids (Fig. 24, lanes 3 and 4) but not in cells transfected with either DSCFT1.6 target (Lane 1) or DSPTM7 plasmid alone (Lane 2). Similarly, no full-length protein was detected in cells co-transfected with DSCFT1.6 target + 3' splice mutant (Lane 5 and 6) or PTM29 or 30 in which either 3' *trans*-splicing domain or 5' *trans*-splicing domains has been deleted (Lane 7). In addition, the 120 kDa protein band co-migrated with the full-length functional  $\beta$ -gal produced using lacZ-T1 plasmid (positive control, data not shown). These results not only confirmed the production of full-length protein by double-*trans*-splicing between the target and PTM but also demonstrated that both the 3' splice site and 5' splice sites are essential for this process.

2002246959 18 Feb 2008

To determine whether the full-length protein produced by double-*trans*-splicing between the target pre-mRNA and DSPTM7 RNA is functionally active, 293T cells were co-transfected with DSCFT1.6 targeted + one of the double splicing PTMs 5, 6 or 7 expression plasmids, or transfected with DSCFT1.6 target or DSPTM7 alone. Total cell extracts were prepared and assayed for  $\beta$ -gal activity using ONPG assay (Invitrogen).  $\beta$ -gal activity in extracts prepared from cells transfected with either DSCFT1.6 target or DSPTM7 alone was almost identical to the background levels detected in mock transfection (Fig. 25). In contrast, 293T cells co-transfected with DSCFT1.6 target and DSPTM7 produced ~21 fold higher levels of  $\beta$ -gal activity over the background (Fig. 25). These results confirmed the accurate double-*trans*-splicing between the target pre-mRNA and PTM RNA and production of the full-length functional protein.

To confirm that restoration of  $\beta$ -gal activity by double-*trans*-splicing reaction is absolutely depended on the presence of both 3' and 5' splice sites of the PTM, we constructed several mutants: (a) DSPTM8, is identical to DSPTM7 except the functional 3' splice elements (branch point, polypyrimidine tract and the 3' acceptor AG dinucleotides) were deleted and substituted with random sequences (see Fig. 22 for details); (b) PTM29 lacks 5' splice site as well as the 5' binding domain but has the 3' binding domain and 3' splice site, and (c) PTM30 lacks 3' binding domain and 3' splice site but has the 5' splice site and 5' binding domain.  $\beta$ -gal activity in extracts prepared from cells transfected with either DSCFT1.6 target or DSPTM7 alone was almost identical to the background levels detected in mock transfection (Fig. 26). Similarly, no significant increase in  $\beta$ -gal activity was detected in cells transfected with either DSPTM8 alone (3' splice site mutant) or co-transfection of DSCFT1.6 target + one of the above mutant PTMs. On the other hand, cells co-transfected with DSCFT1.6 target and DSPTM7 with functional 3' and 5' splice sites produced substantial levels of  $\beta$ -gal activity over the background (Fig. 26). These results confirmed the requirement of both splice sites in the double-splicing PTM and also eliminated the possibility that restoration of  $\beta$ -gal activity was due to complementation between the truncated proteins (Fig. 26).

2002246959 18 Feb 2008

Different concentrations of the target and PTM were co-transfected and analyzed for  $\beta$ -gal activity restoration. As expected, 293T cells co-transfected with DSCFT1.6 target + DSPTM7 showed substantial levels of  $\beta$ -gal activity (~ 30 fold) over the controls. Increasing the concentrations of the PTM by 2 and 3 fold did increase the level of  $\beta$ -gal activity, but not significantly (Fig. 27). These results further confirmed the double-*trans*-splicing mediated restoration of  $\beta$ -gal enzyme function.

The specificity of double-*trans*-splicing reaction was examined by constructing a non-specific target (DSHCGT1.1) which is similar to that of specific target (DSCFT1.6) but has  $\beta$ HCG intron 1 -  $\beta$ HCG exon 2 and  $\beta$ HCG intron 2 instead of CFTR mini-intron 9 - CFTR exon 10 (delta 508) and CFTR mini-intron 10 (Fig. 28). RT-PCR analysis of the total RNA isolated from cells transfected with either DSHCGT1.1 (non-specific target) alone or in combination DSPTM7 (targeted to DSCFT1.6 target) failed to produce the expected 314 bp double-*trans*-spliced product. On the other hand, RT-PCR analysis of the total RNA prepared from cells co-transfected with specific target + PTM produced the expected 314 pb product. This was further confirmed by  $\beta$ -gal activity assay of the total cellular extract. The level  $\beta$ -gal activity detected in cells transfected with non-specific target alone or in combination with DSPTM7 targeted to DSCFT1.6 target was almost identical to the background level. In contrast substantial levels of  $\beta$ -gal activity was detected in cells co-transfected with specific target (DSCFT1.6) + DSPTM7 (Fig. 27). These results confirmed that the double-*trans*-splicing is highly specific.

The repair model in Fig. 30 shows a portion of a target CFTR pre-mRNA consisting of exons 1-9, mini-intron 9, exon 10 containing the delta 508 mutation, mini-intron 10 and exons 11-24 (Fig. 30). The PTM shown in the figure consists of exon 10 coding sequences (containing codon 508) and two *trans*-splicing domains each with its own splicing elements (acceptor and donor sites, branchpoint and pyrimidine tract) and a binding domain complementary to intron 9 splice site, part of exon 10 (5' and 3' ends) and intron 10 5' splice site (Fig. 31 (DS-CF1)). Exon 10 of the PTM also has modified codon usage throughout to reduce antisense effects between exon 10 of the PTM and it's own binding domains and for PTMs that have

2002246959 18 Feb 2008

binding domains which are complementary to exon sequences (Fig. 31). A double-*trans*-splicing event between the PTM and target should produce a repaired full-length mRNA.

Fig. 32 shows the sequence of a single PCR product showing target exon 9 correctly spliced to PTM 20 exon 10 (with modified codons) (upper panel), codon 508 in exon 10 of the PTM (middle panel) and PTM exon 10 correctly spliced to target exon 11 (lower panel). The sequence of a repaired target was generated by RT-PCR followed by PCR.

#### 10. EXAMPLE: TRANS-SPICING REPAIR OF THE CYSTIC FIBROSIS GENE USING A PTM THAT CAN PERFORM 5' EXON REPLACEMENT

The key advantage of using 5' exon replacement for gene repair are

- (a) it permits replacement of the 5' portion of a gene
- (b) the construct requires less sequence and space than a full-length gene construct,
- (c) PTMs can be produced that lack a polyA signal which should prevent PTM translation, and (d) the 5' end can be modified to increase translation.

### 10.1 MATERIALS AND METHODS

#### 10.1.1 PLASMID CONSTRUCTION

The CFTR coding sequences (exons 1-10) for PTM30 were generated by PCR using a partial cDNA plasmid template (61160; American Type Culture Collection, Manassas, VA). The *trans*-splicing domain (TSD) [including the binding domain, spacer sequence, polypyrimidine tract (PPT), branchpoint (BP) and 3' splice site] was generated from a PCR product (using an existing plasmid template) and by annealing oligonucleotides. The different fragments (the TSD and coding sequences) were then cloned into pcDNA3.1(-) using appropriate restriction sites. Oligodeoxynucleotide primers were procured from Sigma Genosys (The Woodlands, TX). All PCR products were generated with either RBD7aq (Sigma, St. Louis, MO), or cloned *Pfu* (Stratagene, La Jolla, CA) DNA Polymerase. PCR primers for

2002246959 18 Feb 2008

amplification contained restriction sites for directed cloning. PCR products were digested with the appropriate restriction enzymes and cloned into the mammalian expression plasmid pc3.1DNA(-) (Invitrogen, Carlsbad, CA).

## 10.2 CELL CULTURE AND TRANSFECTIONS

- 5 Constructs were cotransfected in human embryonic kidney (HEK) 293T or 293 cells ( $1.25 \times 10^6$  cells per 60 mm poly-d-lysine coated dish) using LipofectaminePlus (Life Technologies, Gaithersburg, MD) and the cells were harvested 48 h after the start of transfection. Total RNA was isolated as described in the manufacturers instructions (Epicenter Technologies, Inc.). HEK 293T cells were  
10 grown in Dulbecco's Modified Eagle's Medium (Life Technologies) supplemented with 10% v/v fetal bovine serum (Hyclone, Inc., Logan, UT). All cells were kept in a humidified incubator at 37°C and 5% CO<sub>2</sub>.

### 10.1.3 REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)

- 15 RT-PCR was performed using an EZ-RT-PCR kit (Perkin-Elmer, Foster, CA). Each reaction contained 0.03 to 1.0 µg of total RNA and 80 ng of a 5' and 3' specific primer in a 40 µl reaction volume. RT-PCR products were electrophoresed on 2% Seaken agarose gels. The PTM- and target-specific oligonucleotides used to generate *trans*-spliced products are  
20 5'-CGCTGGAAAAACGAGCTTGTG-3' (primer CF93) and 5'-ACTCAGTGTGATTCCACCTTCTC-3' (primer CF111), respectively. The PTM- and target-specific oligonucleotides used to generate *cis*-spliced products were CF1 and CF93. The sequence of oligonucleotide CF1 is 5'-GACCTCTGCAGACTTCACTTCTAATGATGATTATGG-3'.  
25 The repair model in Fig. 33 shows a portion of a target CFTR pre-mRNA consisting of exons 1-9, mini-intron 9, exon 10 containing the delta 508 mutation, mini-intron 10 and exons 11-24 (Fig. 33). The PTM shown in the figure consists of exon 1-10 coding sequences (containing codon 508) and a *trans*-splicing domain with its own splicing elements (donor site, branchpoint and pyrimidine tract)  
30 and a binding domain. Several PTMs have been constructed with different binding

2002246959 18 Feb 2008

domains. Three examples are shown in Figure 34. In Fig. 34A the binding domain is complementary to the splice site of intron 9 and part of exon 10 (3' end; CF-PTM 11). In Fig. 34B the PTM has an extended binding domain which also covers the 5' end of exon 10 and the 3' splice site of intron 9 (CF-PTM 20). In the last example (Fig. 34C) the binding domain is the same as that shown in panel B except the binding domain extends the full-length of exon 10 (CF-PTM 30). In the latter case the PTM exon 10 has modified codon usage to reduce antisense effects with its own binding domain (Fig. 34). Further examples of binding domains are shown in Figure 35.

Figure 36 shows the sequence of *cis*- and *trans*-spliced products. The top panel of Fig. 36A shows target exon 10 with its three missing nucleotides (CTT), whilst the lower panel shows exon 10 and 11 of the target correctly spliced together. Figure 36B is a partial sequence of a single PCR product showing the modified codons in exon 10 of the PTM (upper panel), codon 508 in exon 10 of the PTM (middle panel), and PTM exon 10 correctly spliced to target exon 11 (lower panel), indicating that *trans*-splicing is accurate. The sequence of the repaired target was generated by RT-PCR followed by PCR.

11. EXAMPLE: PTMs WITH A LONG BINDING DOMAIN, WHICH MAY BE DISCONTINUOUS, HAVE INCREASED *TRANS*-SPLICING EFFICIENCY AND SPECIFICITY

#### 11.1. MATERIALS AND METHODS

##### 11.1.1. CELL CULTURE

Human embryonic kidney cells (293 or 293T) were from the University of North Carolina tissue culture facility at Chapel Hill (Chapel Hill, NC). Cells were maintained at 37°C in a humidified incubator with 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (Life Technologies, Bethesda, MD) supplemented with 10% v/v fetal bovine serum (Hyclone, Logan, UT). Cells were passaged every 2-3 days using 0.5% trypsin and re-plated at the desired density. Stable cells, expressing an endogenous mutant *lacZ* pre-mRNA (*lacZCF9*) were maintained in the presence of 0.5 mg/ml G418 (Calbiochem, San Diego, CA).

2002246959 18 Feb 2008

## 11.1.2. RECOMBINANT PLASMIDS

Targets: pc3.1lacZCF9, pc3.1lacZCF9m, and pc3.1lacZHCG1m.

pc3.1lacZCF9 encodes for a normal *lacZ* pre-mRNA was constructed using *lacZ* coding sequences nucleotides 1-1788 as 5' exon, CFTR mini-intron 9 followed by

- 5 *lacZ* coding sequences nucleotides 1789-3174 as 3' exon. This is similar to pc3.1lacZ-T2 construct but without stop codons in the *lacZ* 3' exon and has CFTR mini-intron 9 instead of  $\beta$ HCG6 intron 1 (Fig. 37A). CFTR mini-intron 9 was PCR amplified using plasmid T5 as template and primers CFIN-9F (5'-CTAGGATCCCGTTCTTTTGTCTTCACT ATTA) and CFIN-9R (5'-CTAGGGTTACCGAAGTAAACCATACTTATTAG, restriction sites underlined),
- 10 digested with *Bam*HI and *Bst*E II and cloned in place of  $\beta$ HCG6 intron 1 of pc3.1lacZ-T2 plasmid. pc3.1lacZCF9m expresses a defective *lacZ* pre-mRNA and is identical to pc3.1lacZCF9 but contains two in-frame non-sense codons in the 3' exon (Fig. 37A). pc3.1lacZHCG1m is a chimeric target, which includes the *lacZ* 5' exon
- 15 followed by intron 1 and exon 2 of  $\beta$ HCG6. This is similar to pc3.1lacZCF9m except that it contains exon 2 of  $\beta$ HCG6 in place of mutant *lacZ* 3' exon.  $\beta$ HCG6 exon 2 was PCR amplified using  $\beta$ HCG6 plasmid (accession # X00266) as template DNA and primers HCGEx-2F (5'-GCATGGTTACCTGCAGGGGCTGCTGCTGTGCTG) and HCGEx-2R (5'-CTGAAGCTTGTTAACCAGCTCACCATGGTGGGGCAG, restriction sites
- 20 underlined) digested with *Bst*E II and *Hind* III and cloned in place of the *lacZ* 3' exon of pc3.1lacZCF9m. Plasmid pcDNA3.1/HisB/*lacZ* (Invitrogen, Carlsbad, CA) was used as DNA template to produce 5' and 3' *lacZ* exons. The *lacZ* 5' exon is 1788 bp long, has an ATG initiation codon, *lacZ* 3' exon (without stop codons) is 1385 bp long
- 25 and has a transcription termination signal at the end of the 3' exon. CFTR mini-intron 9 and  $\beta$ HCG6 intron 1 are 548 bp and 352 bp in size, respectively, and both have 5' and 3' splice signals. Exon 2 of  $\beta$ HCG6 is 162 bp long and has a transcription termination signal at the end of the exon.

Pre-trans-splicing Molecules (PTMs): PTM-CF14 is an identical

- 30 version of pcPTM1 with minor modifications in the *trans*-splicing domain (Fig. 37B). PTM-CF14 is a linear version and contains a 23 bp antisense binding domain (BD)

2002246959 18 Feb 2008

70

(5'-ACCCATCATTATTAGGTCATTAT) complementary to CFTR mini-intron 9, 18 bp spacer, a canonical branch point sequence (UACUAAC; BP) and an extended polypyrimidine tract (PPT) followed by normal *lacZ* 3' exon. PTM-CF22, PTM-CF24, PTM-CF26 and PTM-CF27 are identical to PTM-CF14 except they differ in length of the BD (Fig. 37B). sPTM-CF18 has a 32 bp BD, sPTM-CF22 and sPTM-CF24 contain the same BD as PTM-CF22 and PTM-CF24, respectively. In these PTMs, the binding domains were modified to create intra-molecular stem-loop structure ("safety") to mask the 3' splice-site of the PTM. Different binding domains were produced by PCR amplification using specific primers (with unique *Nhe* I and *Sac* II sites) and a plasmid containing CFTR mini-intron 9 as template. PCR products were digested with *Nhe* I and *Sac* II and cloned into a PTM plasmid consisting of spacer sequences, 3' splice elements (BP, PPT and acceptor AG dinucleotide) followed by a normal *lacZ* 3' exon.

#### 11.1.3. TRANSFECTION OF PLASMID DNAs INTO 293T CELLS

The day before transfection,  $1 \times 10^6$  293T cells were plated on 60 mm plates coated with Poly-D-lysine (Sigma, St. Louis, MO) to enhance the adherence of cells and grown for 24 hr at 37°C. Cells were transfected with expression plasmids using LipofectaminePlus reagent according to standard protocols (Life Technologies, Bethesda, MD). In a typical co-transfection, 2 µg of pc3.1lacZCF9m target and 1.5 µg of PTM expression plasmids were transfected into cells and for controls (target and PTM alone transfections) total DNA concentration was normalized to 3.5 µg with pcDNA3.1 vector.

Forty-eight hours after transfection the plates were rinsed with PBS, cells harvested and total RNA or DNA was isolated using MasterPure RNA/DNA purification kit (Epicenter Technologies, Madison, WI). Contaminating DNA in the RNA preparation was removed by treating with DNase I, while, contaminating RNA in the DNA preparation was removed by digesting with RNase A at 37°C for 30-45 min.



2002246959 18 Feb 2008

#### 11.1.4. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)

RT-PCR was performed as suggested by manufacturer using an EZ *rTth* RNA PCR kit (Perkins-Elmer, Foster City, CA). A typical reaction (50  $\mu$ l) contained 25-500 ng of total RNA, 100 ng of 5' target specific primer (common to *cis*- and *trans*-spliced products) (Lac-9F, 5'-GATCAAATCTGTCGATCCTTCC) and 100 ng of 3' primer (Lac-3R, 5'-CTGATCCACCCAGTCCCATTA, target specific primer for *cis*-splicing, and Lac-5R, 5'-GACTGATCCACCCAGTCCCAGA, PTM specific primer for *trans*-splicing), 1X reverse transcription buffer (100 mM Tris-HCl, pH 8.3, 900 mM KCl with 1 mM  $MnCl_2$ ), 200  $\mu$ M dNTPs and 10 units of *rTth* DNA polymerase. RT reactions were performed at 60°C for 45 min. followed by 30 sec pre-heating at 94°C and 25-35 cycles of PCR amplification at 94°C for 18 sec, annealing and extension at 60°C for 1 min followed by a final extension at 70°C for 7 min. The reaction products were analyzed by agarose gel electrophoresis.

#### 11.1.5. PROTEIN PREPARATION AND $\beta$ -GAL ASSAY

Total cellular protein from cells transfected with expression plasmids was isolated by freeze thaw method and assayed for  $\beta$ -galactosidase activity using a  $\beta$ -gal assay kit (Invitrogen, Carlsbad, CA). Protein concentration was measured by the dye-binding assay using Bio-Rad protein assay reagents (BIO-RAD, Hercules, CA).

#### 11.1.6. WESTERN BLOT

About 5-25  $\mu$ g of total protein was electrophoresed on a 7.5% SDS-PAGE gel and electroblotted onto PVDF-P membrane (Millipore). After blocking for 1 hr at room temperature (blocking buffer: 5% dry milk and 0.1% Tween-20 in 1X PBS), the blot was incubated with a 1:2500 dilution of polyclonal rabbit anti- $\beta$ -galactosidase antibody for 1 hr at room temperature (Research Diagnostics Inc. NJ), washed 3x with blocking buffer and then incubated with a 1:5000 diluted anti-rabbit HRP conjugated secondary antibody. After incubating at room temperature for 1 hr,

it was washed 3x in blocking buffer and developed using ECLPlus Western blotting reagents (Amersham Pharmacia Biotech, Piscataway, NJ).

#### 11.1.7. IN SITU $\beta$ -GAL STAINING

Cells were monitored for the expression of functional  $\beta$ -galactosidase using a  $\beta$ -gal staining kit (Invitrogen, Carlsbad, CA). The percentage of  $\beta$ -gal positive cells were determined by counting stained vs. unstained cells in 5-10 randomly selected fields.

#### 11.1.8. SELECTION OF NEOMYCIN RESISTANT CLONES EXPRESSING AN ENDOGENOUS DEFECTIVE *lacZ* PRE-mRNA TARGET

On day 1,  $1 \times 10^6$  293 cells were plated on 60 mm plates and grown for 24 hr at 37°C. On day 2, the cells were transfected with 2  $\mu$ g of pc3.1lacZCF9m using LipofectaminePlus transfection reagent as described above. 48 hr post-transfection, cells were split (1:20 ratio) and grown in media containing 0.5 mg/ml G418. At the end of 2 weeks, neomycin resistant colonies were selected, pooled, expanded and maintained constantly in the presence of G418.

#### 11.2. RESULTS

A model system was developed that permits facile and versatile analysis of spliceosome mediated RNA *trans*-splicing in cells. The bacterial *lacZ* gene was split with a truncated intron 9 from the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene (Figure 37A). This split *lacZ* gene, when introduced into human 293T cells, directed the synthesis of a *lacZ* pre-mRNA that could splice properly. The open reading frame of the *lacZ* gene was mutated by insertion of two in-frame nonsense codons near the 5' end of the second exon (Figure 37A). This *lacZ* gene is referred to as lacZCF9m. In 293T cells, lacZCF9m directs the synthesis of lacZCF9m pre-mRNA, which encodes a truncated  $\beta$ -galactosidase ( $\beta$ -gal) protein that does not have enzymatic activity. Cells bearing the lacZCF9m gene are a model system for genetic disorders caused by loss of function mutations.

2002246959 18 Feb 2008

Pre-*trans*-splicing molecules (PTMs) were designed to *trans*-splice with lacZCF9m pre-mRNA and repair the mutation caused by the two nonsense codons. PTMs were constructed with binding domains spanning 23, 91 and 153 nucleotides (nt), which we named PTM-CF14, PTM-CF22 and PTM-CF24 (Figure 37B). The PTM-CF24 binding domain does not bind 153 contiguous nt in the targeted CFTR gene intron 9, but rather creates a loop of 47 nt in the target in between two regions of complementarity of 27 and 126 nt (Figure 37B). These PTMs were predicted to repair the deficiency created by lacZCF9m (Figure 37C).

Semi-quantitative RT-PCR analysis was used to tests the efficiency of *trans*-splicing mediated by PTMs with long target binding domains. Repair of lacZCF9m transcripts by *trans*-splicing was tested in two different ways: co-transfection of PTM and target (lacZCF9m) plasmids or transfection of cells that had been modified to express the target as an endogenous pre-mRNA. Co-transfecting plasmids encoding PTMs with the lacZCF9m plasmid provided a facile method for screening the former for efficiency. PTM-CF22 and PTM-CF24 were approximately 3-fold and 10-fold more efficient than PTM-CF14 in a semi-quantitative RT-PCR assay suggesting a significant improvement in mRNA repair (Figure 38). Sequencing of the RT-PCR products showed that *trans*-splicing was accurate, resulting in proper ligation of the exons from the target and the PTM. Moreover, mutation of key *cis*-acting elements in the 3' splice site of the PTMs resulted in an abrogation of *trans*-splicing. In these and all other assays described herein controls were carried out to rule out recombination at the DNA level. Thus, repair of the lacZCF9m transcripts was a result of targeted RNA *trans*-splicing.

Transfection of PTM-CF14, -CF22 or -CF24 into 293 cells bearing an endogenous lacZCF9m gene confirmed that the longer target binding domains provided the PTMs with higher efficiency (Figure 38B). It should be noted that similar levels of RT-PCR *trans*-splicing specific product were obtained after 30 PCR cycles and 35 cycles for PTM-CF24 and PTM-CF14, respectively. The data therefore suggests that PTMs with long binding domains repaired lacZCF9m transcripts at least an order of magnitude better than previously described PTMs.

2002246959 18 Feb 2008

More than one in ten transcripts of lacZCF9m can be repaired by *trans*-splicing. Quantitative, real-time PCR was used to measure the fraction of lacZCF9m transcripts repaired by PTMs with long binding domains. The co-transfection assay described above was used in these experiments. PTM-CF14, which contains a

5 binding domain of 23 nt, was shown to repair between 1.2 and 1.6% of lacZCF9m RNAs in 293T cells and 2.1% of lacZCF9m RNAs in the H1299 human lung cancer cells. PTM-CF24, which has a 153 nt long binding domain, was significantly more efficient, correcting between 12.1 and 15.2% of lacZCF9m RNAs in 293T cells and 19.7% in H1299 cells. This in effect resulted in a measurable reduction in the levels

10 of lacZCF9m mRNA. These data also confirmed the remarkable capability of this RT-PCR assay to distinguish between the products of *cis*-splicing, the lacZCF9m and mRNA, and the products of *trans*-splicing, repaired lacZCF9m mRNA. This is the first true quantification of the efficacy of *trans*-splicing mediated mRNA repair at the RNA level. These data confirm the suggestions of the semi-quantitative RT-PCR

15 analysis shown above. Similar experiments were carried out using 293 cells that express an endogenous lacZCF9m pre-mRNA target. Consistent with the data shown above, PTM-CF24 was ten times more efficient than PTM-CF14, with the former correcting between 1.3 and 4.1% of endogenous lacZCF9m transcripts. These data confirmed that increasing the length of the PTMs provided a remarkable enhancement

20 in *trans*-splicing efficiency.

*Trans*-splicing mediated mRNA repair results in the synthesis of active  $\beta$ -galactosidase. At the cellular level, the ultimate criterion for the success of mRNA repair is the production of an active protein. Using a western assay it was determined that full-length  $\beta$ -gal was produced as a result of *trans*-splicing. Full-length  $\beta$ -gal

25 was not observed following transfection of 293T cells with plasmids encoding lacZCF9m or PTM-CF24. Co-transfection of both plasmids, however, resulted in robust production of full-length  $\beta$ -gal protein, which was readily detectable using anti- $\beta$ -gal antiserum (Figure 39). This result complements enzymatic activity data suggests that the latter was not due to a complementation by truncated  $\beta$ -gal proteins.

30 The Western blot analysis revealed that full-length  $\beta$ -gal protein was made in 293T

2002246959 18 Feb 2008

cells by *trans*-splicing and furthermore confirmed that the PTMs with long binding domains were efficiently spliced.

Appropriate repair of  $\beta$ -gal mRNA and synthesis of full-length  $\beta$ -gal protein should lead to the production of active enzyme. Indeed, 293T cells co-transfected with lacZCF9m and PTM-CF24 were shown to have  $\beta$ -gal activity measured either *in situ* (Figure 40A) or in extracts (Figure 40B). This activity was shown to depend on the *trans*-splicing between the target pre-mRNA and the PTM. The quantitative in solution assay further confirmed the data presented above; PTM-CF22 and PTM-CF24 were 2.9 and 9.3 fold more efficient respectively than PTM-CF14. Most impressive, however, were results using 293 cells that harbor lacZCF9m as a stable endogenous gene. When these cells were transfected with PTM-CF14 the levels of  $\beta$ -gal activity obtained were barely above background. Transfection with PTM-CF24, however, resulted in a considerable level of  $\beta$ -gal activity (Figure 40C). This was paralleled by the appearance of full-length  $\beta$ -gal protein. These data demonstrate a sizeable increase in the efficiency of *trans*-splicing to repair a mutated pre-mRNA. In fact all prior reports of repair of endogenous RNA in mammalian cells by either group I ribozymes or *trans*-splicing have been only documented using RT-PCR, an indication of the low level of repair.

PTMs with very long binding domains are highly specific. It was shown that a secondary structure within the binding domain could enhance specificity of PTMs in HeLa nuclear extracts. In order to ascertain the specificity of the *trans*-splicing reactions *in vivo* a second target gene was prepared, which could serve as reporter of non-specific reactions. This gene, which is referred to as lacZHCG1m, shares the first exon with lacZCF9m. The intron in lacZHCG1m is intron 1 of the  $\beta$ -subunit of the human chorionic gonadotropin gene 6 ( $\beta$ hCG6) and the second exon is exon 2 of the same gene. lacZHCG1m drives the synthesis of a pre-mRNA that is spliced correctly to yield a chimeric mRNA that does not encode a full-length  $\beta$ -gal (see below). PTM-CF14, -CF22 and -CF24 are not targeted to lacZHCG1m pre-mRNA since there is no complementarity between the binding domains in these PTMs and the target gene. Any *trans*-splicing between these PTMs and lacZHCG1m pre-mRNA is therefore non-specific (Figure 41A).

2002246959 18 Feb 2008

293T cells were transfected with PTM-CF14, -CF22 or -CF24 and the level of non-specific *trans*-splicing was determined by RT-PCR and by in solution  $\beta$ -gal assays. Semi-quantitative RT-PCR suggested that PTM-CF24 was significantly less likely than PTM-CF14 to *trans*-splice with lacZHCG1m pre-mRNA.

- 5 Measurement of  $\beta$ -gal activity confirmed this; cells co-transfected with lacZHCG1m and PTM-CF24 produced 3.7 fold less  $\beta$ -gal than those co-transfected with lacZHCG1m and PTM-CF14 (Figure 41C). Based on these data it was estimated that PTM-CF24 is 50 times more likely to *trans*-splice to its target than to a non-specific target. A "safety" version of PTM-CF24, sPTM-CF24, did not confer further
- 10 specificity (Figure 41C). Nonetheless, for PTMs with shorter binding domains a "safety" stem involving the binding domain was seen to improve specificity *in vivo* (Figure 41C). It was concluded from these data that the longer binding domains resulted in PTMs that were not only more efficient but also more specific.

- The observation that long binding domains increased the specificity of
- 15 PTMs suggested that very long binding domains (>200 nt) could further enhance discrimination. Plasmids encoding PTM-CF26 and -CF27, which have binding domains that span 200 nt and 411 nt respectively, were constructed and co-transfected with lacZHCG1m plasmid. Non-specific *trans*-splicing of these two PTMs was barely detectable with RT-PCR (Figure 41B). As measured by the  $\beta$ -gal assay PTM-
- 20 CF26 and -CF27 had minimal non-specific *trans*-splicing activity (Figure 41C). In a specific *trans*-splicing reaction with lacZCF9m as measured by the solution  $\beta$ -gal assay PTM-CF26 was as active as PTM-CF14 (Figure 41B). It was estimated that PTM-CF26 is 80 times more likely to *trans*-splice to the specific target (lacZCF9m) than to a non-specific target (lacZHCG1m). Therefore, inclusion of very long binding
- 25 domains confers to these PTMs very high specificity.

#### 12. EXAMPLE: CORRECTION OF THE FACTOR VIII GENE USING 3' EXON REPLACEMENT

- Hemophilia is a bleeding disorder caused by a deficiency in one of the blood clotting factors. Hemophilia A, which accounts for about 80 percent of all
- 30 cases is a deficiency in clotting factor VIII. The following section describes the

2002246959 18 Feb 2008

successful repair of the clotting factor VIII gene using spliceosome mediated *trans*-splicing and demonstrates the feasibility of repairing the factor VIII using gene therapy.

- The coding region for mouse factor VIII PTM (exons 16-24) was PCR
- 5 amplified from a cDNA plasmid template using primers that included unique restriction sites for directed cloning. All PCR products were generated with cloned Pfu DNA Polymerase (Stratagene, La Jolla, CA). The coding sequence was cloned into pc3.1DNA(-) using EcoRV and PmeI restriction sites. The binding domain (BD) was created by PCR using genomic DNA as a template. Primers included unique
  - 10 restriction sites for directed cloning. The PCR product was cloned into an existing PTM plasmid (PTM-CF24, pc3.1DNA) using NheI and SacII restriction sites. This plasmid already contained the remaining elements of the TSD including a spacer sequence, polypyrimidine tract (PPT), branchpoint (BP) and 3' acceptor site. The whole of the TSD was then subcloned into the vector (described above) containing the
  - 15 factor VIII PTM coding sequences. Finally, bovine growth hormone 3' untranslated sequences from a separate plasmid clone were subcloned into the above PTM using PmeI and BamHI restriction sites.

- The whole construct was sequenced and then analyzed by RT-PCR for possible cryptic splicing, and then subcloned into the AAV plasmid pDLZ20-M2
- 20 using XhoI and BamHI restriction sites (Chao et al., 2000, *Gene Therapy* 95:1594-1599; Flotte and Carter, 1998, *Methods Enzymol.*, 292:717-32). For some viral (and non-viral) delivery systems, the size of the therapeutic is essential. Viral vectors such as adeno-associated virus are preferred because they are a (i) non-pathogenic virus with a broad host range (ii) it induces a low inflammatory response when compared to
  - 25 adenovirus vectors and (iii) it has the ability to infect both dividing and non-dividing cells. However, the packaging capacity of the rAAV is limited to approximately 110% of the size of the wild type genome, or ~4.9 kB, thus, leaving little room for large regulatory elements such as promoters and enhancers. The B-domain deleted human factor VIII is close to the packaging size of AAV, thus, *trans*-splicing offers
  - 30 the possibility of delivering a smaller transgene while permitting the addition of regulatory elements.

2002246959 18 Feb 2008

To eliminate cryptic donor sites in the pre-mRNA upstream of the *XhoI* PTM cloning site approximately 170 bp of sequence was eliminated from the original AAV construct that includes part of exon 1 and all of the intron 1 sequence (see Fig. 44C).

5 The repair model in Fig. 44D shows a simplified model of the mouse factor VIII pre-mRNA target (endogenous gene) consisting of exons 1-14, intron 14, exon 15, intron 16, and exon 16-24 containing a neomycin gene insertion. The PTM shown in the figure consists of exon 16-24 coding sequences and a trans-splicing domain with its own splicing elements (donor site, branchpoint and pyrimidine tract) and a binding domain. Details of the binding domain are shown in Fig. 44A and 44B. 10 The binding domain is complementary to the splice site of intron 15 and part of exon 16 (5' end).

The key advantages of using 3' exon replacement for gene repair are (i) the construct requires less sequence and space than a full length gene construct, 15 thereby leaving more space for regulatory elements, (ii) SMaRT repair should only occur in those cells that express the target gene, therefore eliminating any potential problems associated with ectopic expression of repaired RNA.

Factor VIII deficient mice were maintained at the animal facilities at the University of North Carolina at Chapel Hill. For plasmid injections each mouse 20 was sedated and placed under a dissecting microscope and a 1 cm vertical midline abdomen incision was made. Approximately 100 micrograms of PTM plasmid DNA in phosphate buffered saline was injected to liver portal vein. Blood was collected from the retro-orbital plexus at intervals of 1, 2, 3 and 20 days after injection and assayed for factor VIII activity using the Coatest assay.

25 Factor VIII activity in blood samples collected from mice were assayed using a standard test called the Coatest assay. The assay was performed according to manufacturer's instructions (Chromgenix AB, Milan, Italy). Data indicating repair of factor VIII in factor VIII knock out mice is demonstrated in Figure 46.

30 Hemophilia A defects in humans are broadly split into several categories that include gross DNA rearrangements, single DNA base substitutions, deletions and insertions. It has been determined that a rearrangement of DNA



2002246959 18 Feb 2008

involving an inversion and translocation of exons 1-22 (together with introns) away from exons 23-26 is responsible for ~40% of all cases of severe hemophilia A. The canine hemophilia A model also has a very similar gross rearrangement. This mutation will be used as the basis for our human and canine factor VIII PTM designs.

- 5               Methods for building the human factor VIII PTM will be very similar to that described above for the mouse PTM except that different coding regions (exons 23-26) will be amplified from a human cDNA, the binding domain will be amplified from human genomic sequence templates (whole genomic DNA or a genomic clone), and a C-terminal FLAG tag will be engineered in the PTM to be used
- 10 to detect repaired factor VIII protein. The remaining elements of the trans-splicing domain including a spacer sequence, polypyrimidine tract (PPT), branchpoint (BP) and 3' acceptor site will be obtained from an existing plasmid. Where necessary changes will be made to the binding domain sequence to eliminate any cryptic splicing within the PTM. The final PTM will be subcloned into the same mouse AAV
- 15 plasmid vector, pDLZ20-M2 and virus preparation made from this plasmid. The canine factor VIII PTM will be made in an identical fashion but using canine cDNA and genomic plasmid.

### 13. EXAMPLE: TARGETED TRANS-SPLICING OF PAPILLOMAVIRAL RNA

- 20               The vast majority of cervical cancers are associated with oncogenic human papilloma viruses (HPVs) and express viral mRNAs encoding the E6 and E7 oncoproteins. As described below, PTMs targeted against the E6 region of HPV-16 and splice the TM exon to the 5' end of the E6 ORF using the 5' splice site at the nucleotide 226.

#### 25               13.1 MATERIALS AND METHODS

- The target DNA (p1059) was used to test PTM efficiency and contains the entire HPV-16 early region (nt 79-4468) cloned behind the SV40 early promoter and origin of replication. Specificity was assessed using the heterologous expression vector lacZCF9m as target (Puttaraju *et al.* 2001. Mol Ther 4:105-14). Plasmids were
- 30 prepared using Qiagen maxi prep kits.

2002246959 18 Feb 2008

Nearly confluent 6 cm plates of 293 cells were transfected with 2 µg target DNA and 2 µg PTM DNA using LipofectAmine 2000 (Life Technologies). At two days post-transfection, cells were washed on the plate with PBS and lysed on the plate using 300 µl lysis buffer. Total cell RNA was prepared using Ambion

- 5 RNAqueous kit. Transfected DNA was removed from the RNA by LiCl precipitation followed by DNase I treatment using the Ambion DNA-free™ DNase treatment and removal reagents.

- RNA was converted to cDNA using RT from the High Capacity cDNA Archive Kit (PE Applied Biosystems) as directed by the manufacturer with the  
10 following modifications: the amount of random primer was cut in half and 5 µl of a 50 µM stock of oligo(dT16) and 5 µl of a 20 units/µl stock of RNase inhibitor were added per 100 µl reaction. RT reactions were diluted to 50 ng/µl and 5 ng/µl (based on original RNA content) for real time Quantitative PCR (QPCR) analysis. Amounts of specific cis and trans spliced mRNAs were quantitated using Real Time  
15 Quantitative PCR. These assays are referred to as Real Time QRT-PCR. These reactions were carried out on the Bio-Rad iCycler iQ Real Time PCR instrument using the SYBR Green kit from PE Applied Biosystems essentially as described previously (Puttaraju *et al.* 2001 Mol Ther 4:105-14.).

- Total HPV-16 RNA levels (cis and trans-spliced) were assessed using  
20 a common amplicon in E6 exon 1 (HPV-16 nt 152-204; 53 bp). This assay uses the HPV-16 primers oJMD-15 (ACAGAGCTGCAAACAACACTAT) and oJMD-16 (TTGCAGTACACATTCTAA). The amount of RT reaction used for each PCR reaction was 5 ng. Trans-splicing from the HPV-16 nt 226 5' splice site to the PTM lacZ exon was assessed using a 53 bp chimeric amplicon. This assay uses the HPV-  
25 16 senser primer oCCB-348 (GCAAGCAACAGTTACTGCGA; HPV-16 nt 201-220) and the lacZ antisense primer oCCB-322 (ATCCACCCAGTCCCAGA). The amount of RT reaction used for each PCR reaction was 50 ng. Both assays used the same plasmid (p3671) to generate standard curves for quantitation. Trans-splicing from the HPV-16 nt 880 5' splice site to the PTM lacZ exon was assessed using a 50 bp  
30 chimeric amplicon. This assay uses the HPV-16 sense primer oCCB-366 (ATCTACCATGGCTGATCCTG; HPV-16 nt 858-877) and the lacZ antisense

2002246959 18 Feb 2008

primer oCCB-322. The amount of RT reaction used for each PCR reaction was 50 ng. The plasmid p3672 was used to generate the standard curve for this assay.

Plasmids used as standards for real time QPCR were cloned as follows.

- 5 An RT reaction from cotransfections of p1059 and HPV-PTM1 in 293T cells was used as template for PCR reactions. Primers oCCB-257 (HPV-16 nt 127-147; ACCCAGAAAGTTACCACAGTT) and oCCB-322 gave a 127 bp band which was TOPO-cloned into pCRII-TOPO (Invitrogen) to give p3671. Sequencing showed that this DNA corresponds to trans-splicing from HPV-16 nt 226 into the 3' splice site of the PTM. Primers oJMD-17 (HPV-16 nt 689-708; GACAAGCAGAACCGGACAGA) and oCCB-322 gave a 219 bp band which was TOPO-cloned into pCRII-TOPO to give p3672. Sequencing showed that this DNA corresponds to trans-splicing from HPV-16 nt 880 into the 3' splice site of the PTM. Plasmids stocks (1 ng/ $\mu$ l) were quantitated using PicoGreen (Molecular Probes) prior to use for standard curves.

- 15 Quantitation of *cis*- and *trans*-splicing for the cotransfections with PTMs and the target lacZCF9m were done exactly as described previously (Puttaraju *et al.* 2001, Mol. Ther. 4:105-14). The amount of RT reaction used for each PCR reaction was 5 ng.

### 13.2 RESULTS

- 20 HPV and CF PTMs were cotransfected into 293 cells with either the HPV-16 expression vector p1059 to assess *trans*-splicing efficiency or with lacZCF9m (containing a CF intron) to assess *trans*-splicing specificity. Real Time QRT-PCR assays were done as described above to assess levels of *trans*-splicing relative to *cis*-splicing of each target. The results are shown in Table 1. All RNA levels are expressed as fg of the DNA standard. The standards p3671 and p3672 are close to the same size so these values can be used to represent relative RNA levels for each assays. HPV-PTM1, 2, 5, and 6 efficiently trans-spliced to the HPV-16 nt 226 5' splice site. Up to 70% trans-splicing was seen for the HPV-PTM1. As expected, HPV-PTM5 *trans*-splicing was abolished by mutations in the branch point and polypyrimidine tracts of the PTM. These PTMs showed less than 1% trans-splicing to
- 30

2002246959 18 Feb 2008

the nt 880 5' splice site. This data is consistent with the design of these PTMs which have binding domains complementary to the nucleotide 409 and 526 3' splice sites. HPV-PTM-8 and HPV-PTM-9 *trans* binding domains downstream of the nt 880 5' splice site and show efficient *trans*-splicing to this 5' splice site (37% for HPV-PTM8 and 22% for HPV-PTM9) and somewhat less efficient *trans*-splicing to the nt 226 5' splice site. HPV-PTM9 may interfere sterically with binding of splicing factors to the nt 880 5' splice site. The specificity of HPV-PTM1, 2, 5 and 6 was also assessed by their ability to *trans*-splice to a target pre-mRNA with a CF intron. Specificity ranged from 274 to 606 fold.

83

## MSP Co-transfection 8/201

283 cells

Target: p3514 (LacZCFRm) (all cells have target)

6 cm plates; Lipofectamine 2000; 2 ug target and 2 ug PTM

p3517 for cis splicing standard curve

p3519 for trans-splicing standard curve

## Specificity Assay

Sample#	Transfection #/PTM	Std curve:		p3519	%Trans
		fa.cts	fu.cts		
1 #1A HPV-PTM1		1,200.00	1.44	327/322	0.1%
2 #1B HPV-PTM1		1,380.00	3.60		0.3%
3 #2A HPV-PTM2		2,840.00	4.10		0.1%
4 #2B HPV-PTM2		2,060.00	3.17		0.2%
5 #3A HPV-PTM5		1,820.00	1.85		0.1%
6 #3B HPV-PTM5		1,750.00	1.82		0.1%
7 #4A HPV-PTM6		772.00	0.69		0.1%
8 #4B HPV-PTM6		1,720.00	2.05		0.1%
9 #5A HPV-PTM8		2,570.00	5.06		0.2%
10 #5B HPV-PTM8		1,800.00	3.46		0.2%
11 #6A HPV-PTM9		2,300.00	2.29		0.1%
12 #6B HPV-PTM9		2,880.00	2.74		0.1%
13 #7A CF14		1,350.00	22.20		1.6%
14 #7B CF14		1,320.00	21.50		1.0%
15 #8A CF24		1,520.00	59.90		5.6%
16 #8B CF24		1,500.00	72.00		4.6%
17 #8A CF27 (OK by PCR)		1,410.00	3.83		0.3%
18 #8B CF27 (OK by PCR)		1,370.00	4.53		0.3%
21 #11A pCDNA3.1		1,520.00	0.04		0.0%
22 #11B pCDNA3.1		1,370.00	0.07		0.0%
23 p3517 (10 pg)		0.00	0.17		
24 p3518 (10 pg)		0.00	0.17		

Note: the identity of the CF PTMs was rechecked by PCR of both the plasmids and the RNA samples (before DNase treatment) and are OK.

18 Feb 2008 6569472002

2002246959 18 Feb 2008

#### 14. EXAMPLE: DESIGN OF TARGETED PAPILLOMA VIRUS PTMs

Initial pre-therapeutic RNA molecules ("PTMs") are developed based on the abundance and splicing patterns of HPV mRNA. The transcription map of HPV-16 in benign infections is shown in Figure 48. *Cis* and *trans* splicing assays are performed on the initial PTMs and the data obtained from the assays is used to create specific PTMs with optimized efficacy in spliceosome-mediated RNA *trans*-splicing reactions.

The most effective PTM is one that *trans*-splices an HPV target transcript with a PTM encoding a toxic product which will kill the infected cell. In targeting the most frequently used HPV splice sites, two viable 5' splice site targets and two viable 3' splice site targets can be used. Less frequently used splice sites can also make good targets if the PTM is designed to block the more frequently used site. Choice of target splice sites is further restricted if the intention is to treat cancers, since integration of HPV-16 in many cervical cancers leads to expression of only the E6 and E7 regions in these cancers.

The following target splice sites are used in the development of the initial PTMs which leads to the expression of a toxic product:

##### i) 5' splice site targets:

– nt 226: This splice site is used in the synthesis of all E6\* species. In most tumors and cell lines, the vast majority of P97 promoter transcripts will be spliced using this 5' splice site.

– nt 880: This splice site is used in the synthesis of all E6US (unspliced) and E6\* species except E6\*III, both splice sites are good targets in both productive infections and cancers; and

##### ii) 3' splice site targets:

– nt 409: This 3' splice site is used in the splicing of E6\*I species which are generally more abundant than E6\*II species. This splice site is used in cancers and productive HPV infection.

2002246959 18 Feb 2008

-- nt 3358: This target is used for splicing of most mRNAs, but only if the viral DNA is extrachromosomal. This splice site is not a good target for the treatment of most cancers.

In addition, a double *trans*-splicing PTM is developed to replace the internal exons nt 409-880 or nt 526-880 in productively infected tissue and in cancers.

Alternatively, initial PTMs are designed in which *trans*-splicing produces an mRNA encoding a fusion protein that is part viral and part exogenous peptide encoded by the PTM. The fusion protein will change the function of the viral protein so that it inhibits an essential viral function. The splice sites listed above are targeted to produce three viral fusion proteins:

- (i) The E6 N terminus, using the nt 226 5' splice site as the target;
- (ii) The E6 C terminus, using the nt 409 (best) or nt 526 3' splice sites as the targets; and

(iii) The E2 C terminus, using the nt 3358 3' splice site as target.

This fusion protein is produced in productive infections and cancers containing extrachromosomal viral DNA. The C terminal domain of E2 is the DNA binding and dimerization domain, and can be used to target a fusion protein to the P97 promoter and block transcription. At high concentrations, the E2 viral protein binds just upstream of the P97 promoter and inhibits transcription by competing with the transcription factors, SP1 and TFIID, for binding. However, these E2 binding sites are weaker than those upstream in the Long Control Region (LCR) and are only saturated at high concentrations of the viral E2 protein. At low concentrations of E2, the protein binds to the E2 binding sites in the upstream LCR and activates transcription. Thus, a "repressor" domain can be added to the fusion protein resulting in a block of transcription through binding to any E2 binding site. This fusion protein is also useful to block viral DNA replication, since an E1/E2 complex binds the origin of replication. It has been demonstrated, however, that a complex of the E2 DNA binding domain and E1 does not bind to the origin. Since E2 is a dimer, heterodimerization of the E2 fusion protein with full length E2 protein would probably eliminate E2 function in DNA replication.

2002246959 18 Feb 2008

PTM(s) based on their ability to target and *trans*-splice to the HPV target splice sites depicted in Figure 48 listed above are constructed and screened such that splicing results in the expression of diphtheria toxin sub unit A (DT-A) product, which will kill the infected cells or express a marker gene which can be easily detected. Other peptide or protein toxins may also be encoded. A typical prototype PTM (3' *trans*-splicing) consists of an antisense target binding domain (25 or more) complementary to HPV sequences, spacer sequence, canonical branchpoint sequence (UACUAAC), an extensive polypyrimidine tract (12-15 U's), AG dinucleotide of the 3' splice site followed by the delivered gene. PTMs are also constructed to carry out PTM-mediated trans-splicing with HPV 3' splice sites (Fig. 66B). The *trans*-splicing domain (TSD) of the PTMs are constructed in modular fashion. Unique restriction sites are incorporated between each of the PTM elements, facilitating the replacement of individual elements. Schematic diagrams of 3' exon replacement and 5' exon replacement models are shown (Figure 66A-B), respectively. It has previously been demonstrated that both efficiency and specificity of *trans*-splicing can be modulated substantially by altering several sequences in the TSD, including, the length of the binding domain, spacer sequences, strength of the PPT etc.

"Linear" PTMs are designed initially to maximize the *trans*-splicing efficiency, thereby identifying the PTM sequences that provide highest *trans*-splicing efficiency. Linear PTMs refer to the binding domain in the PTM as single stranded in configuration. To achieve a higher degree of targeting specificity, another form of TSD referred to as a "safety stem" can be constructed. In these PTMs, the splice site of the PTM is protected from reacting with other pre-mRNA targets by binding to itself in a folded structure. Contact with the specific target promotes unwinding of the safety stem exposing and activating the PTM's 3' splice site for spliceosome formation.

To further enhance the *trans*-splicing specificity, a PTM that requires two *trans*-splicing events to produce the expected therapeutic effect is also constructed (Fig. 65). This PTM will have an upstream 3' splice site that will *trans*-splice into an HPV 5' splice site, producing a singularly *trans*-spliced product. This product does not contain the required polyadenylation signals and would be inactive



2002246959 18 Feb 2008

due to failure in nucleocytoplasmic transport and translation of the mRNA. A second *trans*-splicing event with a HPV 3' splice site is necessary to provide the PTM with the signals required for polyadenylation (Fig. 65). Polyadenylation is necessary for PTMs with linear binding domains in which both 3' and 5' binding domains are linear, or with 3' safety + 5' linear binding domains, are also designed for inhibition of viral expression. In addition, PTMs are designed as "double safety" PTMs with both 3' and 5' safety splice sites or 3' linear or 5' safety sites.

Testing of the PTMs is performed using *in vitro* splicing assays and cell culture-based assays. HPV-16-containing cell lines are used for testing the ability of PTMs to *trans*-splice. W12 cells (80263 cells) contain extrachromosomal HPV-16 DNA and express the full HPV-16 early region and can be used to test PTMs targeting. SiHa and CaSki cell lines contain integrated HPV-16 and express only the viral E6/E7/5'E1 regions. These cell lines are useful because they express viral pre-mRNAs characteristic of those expressed in cervical cancers. However, they may not be useful cell lines for testing a PTM targeting the nt 3358 3' splice site. CaSki cells express considerably higher levels of HPV-16 mRNAs than any of the other cell lines tested and therefore may be the best cells for assaying other PTMs.

Cell culture-based cotransfection experiments with a PTM expression vector and an HPV-16 early region expression vector are assayed for expression of the PTM. Several plasmids driving the expression of HPV-16 have been constructed. For example, two plasmids that can be used in co-transfection experiments include ones that express HPV-16 under the direction of either the SV40 early promoter (p1059) or the K14 promoter (p2571; pK14-1203).

Combined isoform-specific (i.e. splice-specific) primers with quantitative real time reverse transcription polymerase chain reaction (QRT/PCR) are used to assay for alternative splicing. This assay is very isoform specific, relatively insensitive to RNA degradation, sensitive to one molecule of cDNA, has a wide dynamic range (at least seven orders of magnitude), and gives absolute quantitation of each isoform. Primer pairs specific for each PTM/target pre-mRNA combination are used. The sequence specificity of the assay permits the monitoring of the specificity of the *trans*-splicing reactions. The sensitivity and quantitative nature of the assay as

2002246959 18 Feb 2008

well as the rapidity with which assays can be developed and performed is useful for the optimization of PTMs targeted against papillomaviral pre-mRNAs.

The specificity of PTM induced *trans*-splicing (i.e. to determine the specificity of targeted *trans*-splicing to HPV target pre-mRNA) is also evaluated by 5' and/or 3' rapid amplification of cDNA ends (RACE) according to standard procedures. This method is relatively fast compared to the conventional cDNA library construction, and gives complete sequences of 5' and/or 3' cDNA ends, so that the number of specific and non-specific splicing events can be determined. Initially, two cDNA libraries are constructed comprised of RNA isolated from cells co-transfected with a (i) linear PTM + HPV mini-gene target and (ii) safety PTM + HPV mini-gene target. For example, in order to identify the 5' ends of the *trans*-spliced RNAs (3' exon replacement), a 5' RACE assay is performed with a PTM antisense primer. Similarly, to identify the 3' ends of the *trans*-spliced RNAs (5' exon replacement), a 3' RACE assay is performed using a PTM sense primer. The cDNA is amplified by PCR, digested with restriction enzymes and cloned into a plasmid vector. The cDNA clones are initially screened by colony hybridization using a PTM specific probe. From each cDNA library, positive clones are selected and sequenced, and the sequence information is used to compare the specificity of linear vs. safety PTM. This permits identification of non-specific targets that *trans*-splice at high frequencies. Analysis of these targets provides useful information about the sequences that are responsible for non-specific *trans*-splicing and helps in the construction of specific PTMs.

The *trans*-splicing efficiency and specificity data obtained from the analysis of the initial candidate PTMs in *trans*-splicing assays is used to formulate and develop PTMs with optimal *trans*-splicing capabilities. The optimal PTMs are analyzed using the *trans*-splicing assays described above.

A mouse model for papillomavirus infections using an organotypic "raft/xenograft" technique. Papillomaviruses are generally species and cell type specific. Productive infections have been established in nude mice using bovine keratinocytes and bovine papillomaviruses. In this system, keratinocytes are initially plated onto a collagen "raft" containing fibroblasts and allowed to grow to confluence

2002246959 18 Feb 2008

in tissue culture. The keratinocytes are then infected or transfected with papillomavirus or viral genomic DNA, respectively, and allowed to grow in culture for a few days. These rafts are then grafted onto the backs of nude mice where they develop into productively infected bovine tissue. Human papillomavirus infections

5 can be established using the same techniques combined with human papillomaviruses and keratinocytes. This system is useful for testing the *in vivo* efficacy of anti-papillomavirus PTMs. In addition, grafting of cervical carcinoma tissue or cervical cancer cell lines onto nude mice is used. In addition, testing can be done using

10 several animal models including bovine papillomavirus (BPV-1), Canine oral papillomavirus (COPV), and Cottontail rabbit papillomavirus (CRPV). COPV, in particular, has served as a good model for vaccine development.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art

15 from the foregoing description and accompanying Figures. Such modifications are intended to fall within the scope of the appended claims. Various references are cited herein, the disclosure of which are incorporated by reference in their entireties.

2002246959 18 Feb 2008

90

## THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A nucleic acid molecule recognized by nuclear splicing components within a cell comprising:
  - a) one or more target-binding domains, at least one said target-binding domain being between 10 and 600 nucleotides long, wherein said one or more target binding domains binds the nucleic acid molecule to a target pre-mRNA expressed within the cell;
  - b) (1) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site and/or (2) a 5' splice site;
  - c) a spacer region that separates the 3' splice region or the 5' splice site from the target-binding domain; and
  - d) nucleotide sequence trans-spliced to the target pre-mRNA to correct a genetic defect in a human Factor VIII gene, wherein a functional clotting factor is produced.
2. The nucleic acid molecule according to Claim 1, wherein the nucleic acid has the 3' splice region and further comprises a 5' donor site.
3. The nucleic acid molecule according to Claim 1 or 2, wherein the nucleic acid further comprises sequence encoding a translatable protein product.
4. The nucleic acid molecule according to Claims 1, 2 or 3, wherein the target pre-mRNA is a Factor VIII encoding pre-mRNA.
5. The nucleic acid molecule according to any preceding Claim, wherein the nucleic acid further comprises nucleotide sequence containing a translational stop codon.
6. The nucleic acid molecule according to Claim 1, wherein the sequence to be trans-spliced replaces exons 23 to 26 of the human Factor VIII gene.
7. The nucleic acid molecule according to any preceding Claim, wherein the nucleic

2002246959 18 Feb 2008

91

acid further comprises a safety sequence, wherein said safety sequence comprises one or more complementary sequences that bind to one or both sides of any one of the 3' splice region or 5' splice site.

8. A cell comprising a recombinant vector recognized by nuclear splicing components within the cell and which expresses a nucleic acid molecule comprising:
  - a) one or more target-binding domains, at least one said target binding domain being between 10 and 600 nucleotides long wherein said one or more target binding domains binds the nucleic acid molecule to a target pre-mRNA expressed within the cell;
  - b) (1) a 3' splice region comprising a branchpoint, a pyrimidine tract and a 3' splice acceptor site or (2) a 5' splice site;
  - c) a spacer region that separates the 3' splice region or the 5' splice site from the target-binding domain; and
  - d) nucleotide sequence to be trans-spliced to the target pre-mRNA to correct a genetic defect in a human Factor VIII gene, wherein a functional clotting factor is produced.
9. The cell according to Claim 8, wherein the nucleic acid molecule is as defined in any one of Claims 2 to 7.
10. A method of producing a chimeric RNA molecule in a cell, comprising contacting a target pre-mRNA expressed within the cell with a nucleic acid molecule recognized by nuclear splicing components within the cell and comprising:
  - a) one or more target-binding domains, at least one said target-binding domain being between 10 and 600 nucleotides long wherein said one or more target binding domains binds the nucleic acid molecule to a target pre-mRNA expressed within the cell;
  - b) (1) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site and/or (2) a 5' splice site;

2002246959 18 Feb 2008

92

- c) a spacer region that separates the 3' splice region or the 5' splice site from the target-binding domain; and
  - d) nucleotide sequence trans-spliced to the target pre-mRNA to correct a genetic defect in a human Factor VIII gene, wherein a functional clotting factor is produced.
- 11. The method according to Claim 10, wherein the nucleic acid molecule is as defined in any one of Claims 2 to 6.
- 12. An expression vector which expresses in a cell a nucleic acid molecule claimed in Claim 1, 2 or 3, which is recognized by nuclear splicing components within the cell and comprises:
  - a) one or more target-binding domains, at least one said target-binding domain being between 10 and 600 nucleotides long wherein said one or more target binding domains binds the nucleic acid molecule to a target pre-mRNA expressed within the cell;
  - b) (1) a 3' splice region comprising a branch point, a pyrimidine tract and a Y splice acceptor site and/or (2) a 5' splice site;
  - c) a spacer region that separates the 3' splice region or the 5' splice site from the target-binding domain; and
  - d) nucleotide sequence trans-spliced to the target pre-mRNA to correct a genetic defect in a human Factor VIII gene, wherein a functional clotting factor is produced.
- 13. The expression vector according to Claim 12, wherein the nucleic acid molecule is as defined in any one of Claims 2 to 7.
- 14. The expression vector according to Claim 12 or 13, wherein the cell is a eukaryotic cell.
- 15. A vector for use in gene therapy, which is recognized by nuclear splicing

2002246959 18 Feb 2008

93

components within a host cell *in vivo*, or *ex vivo*, within an autologous host cell for introduction *in vivo*, wherein the nucleic acid comprises

- a) one or more target-binding domains, at least one said target-binding domain being between 10 and 600 nucleotides long, and binds the nucleic acid molecule to a target pre-mRNA expressed within the cell;
  - b) (1) a 3' splice region comprising a branch point, a pyrimidine tract and a 3' splice acceptor site and/or (2) a 5' splice site;
  - c) a spacer region that separates the 3' splice region or the 5' splice site from the target-binding domain; and
  - d) nucleotide sequence trans-spliced to the target pre-mRNA to correct a genetic defect in a human Factor VIII gene,
- wherein a functional clotting factor is produced.

- 16. A vector according to Claim 15, for use in gene therapy, wherein the cell is a host cell *in vivo* or is *ex vivo* an autologous host cell for introduction *in vivo*.
- 17. A vector according to Claim 15 in the form of a viral vector.
- 18. A vector according to Claim 16 which is an adeno-associated virus (AAV), adenovirus or a defective or attenuated retrovirus vector.
- 19. A composition comprising a pharmaceutically acceptable carrier and a nucleic acid molecule claimed in Claim 1, 2 or 3.
- 20. A nucleic acid molecule according to Claim 1, 2 or 3 for introducing into target cells of a human subject expressing a human Factor VIII target pre-mRNA to correct a genetic defect in factor VIII and thereby produce a functional clotting factor.
- 21. A nucleic acid molecule or vector according to Claim 8 wherein the introduction is indirect, in which host cells are first transformed with the nucleic acid *in vitro* and

2002246959 18 Feb 2008

94

then transplanted into the target cells of the subject.

22. A nucleic acid molecule or vector according to Claim 8 wherein the introduction is direct, *in vivo*, in which the target cells of the subject are directly exposed to the nucleic acid.
23. A vector according to claims 13, 14 or 15 for introducing into target cells of a human subject expressing human Factor VIII target pre-mRNA to correct a genetic defect in factor VIII and thereby produce a functional clotting factor.
24. A nucleic acid molecule according to any one of Claims 1 to 7 or 20 to 22, or a cell according to any one of Claims 8 to 9 or a method according to any one of Claims 10 to 11 or an expression vector according to any one of Claims 12 to 14 or a vector according to any one of Claims 15 to 18 or 23 or a composition according to Claim 19 substantially as hereinbefore described with reference to the Figures and/or Examples.






FIG.1A

1 / 91

2002246959 20 Feb 2008

2002246959 20 Feb 2008

2 / 91




FIG.1B




FIG.1C

2002246959 20 Feb 2008

3 / 91




FIG.2A




FIG.2B

2002246959 20 Feb 2008




FIG.3

2002246959 20 Feb 2008

6/91



FIG.4A




FIG.4B

2002246959 20 Feb 2008

7/91






FIG.4C



**Fig. 5**





9/91

2002246959 20 Feb 2008




FIG. 7A

10/91

EXON 1 OF  $\beta$ HC36 ↓  
5'-CAGGGACGACCAAGGATGGAGATGTTCCAG-GGGCTGATGATGTTGTT  
↓ 1ST CODING NUCLEOTIDE OF DT-A  
GATCTCTTAAATCTTTTGTGATGSAAACTTTTCTTCTGATACACGGGACTA  
AACCTGGTTATGTAGATTCCATTCAAAA-3'

FIG.7B

11/91

2002246959 20 Feb 2008




FIG.8A

12 / 91

2002246959 20 Feb 2008

2002246959 20 Feb 2008

13 / 91




FIG.8B

14 / 91





FIG.9

pc3.1Lac-T1

**Target 1:**



**FIG. 10A**

16/91




FIG.10B



2002246959 20 Feb 2008




FIG.11A

17/91

2002246959 20 Feb 2008

18 / 91




FIG.11B

20-02-'08 14:19 FROM-Davies Collision Cave +61392542770 T-407 P022/095 F-395

2002246959 20 Feb 2008

19 / 91




FIG.11C

20-02-'08 14:19 FROM-Davies Collision Cave +61392542770 T-407 P023/095 F-395

2002246959 20 Feb 2008

20 / 91




FIG.12A

**Biolac-TR1**

GGGCTTTGGCTACCTGGAGACGCGCGCGCTGATCCTTTGGCAATACGCCACGCGATGGGTAAACAGTCTTG

## Splice junction

GGGGGTTTGGCTAAATACTGGCAGCGTTTGGTCAGTATCCCGTTTACAG/GGGGCTTGGTCTAATAATG

CGGACTGGGTGGATCAGTCGCTGATTAAATAATGATGAACGGCAACCGTGGTGGCTTACGGGGTGATTT

**Lac-TR2**

TGGCGATACGGCAACGATGCCAGTTCIGTATGAACGGTCTGGCGAGCGCAGCGGCATCCAG  
CUC-TINZ

## 2. NUCLEOTIDE SEQUENCES OF THE *trans*-SPLICED PRODUCT (195 bp)

**Biolac-TR1**

GGGCTTTGGCTAOCITGGAGAGACGCGCCGCTGATCTTTGGCAATACGCCCAACGGATGGGTAAACAGTCTTGG

## Splice junction

CGGGTTTCGCTAAATACTGGCAGCGTTTGGTCAGTATCCCGGTTACAG/GGGCTGCTGCTGTTGCTGCTGCT

**HCGR2**


GAGCA TGGCGGACA TGGCATCCAAGGAGCCACTTGGCCACGGTGCGG

**FIG. 12B**


2002246959 20 Feb 2008

22 / 91

CFTR Pre-therapeutic molecule (PTM or "bullet")



CFTR mini-gene target-construction



Trans-splicing Repair




FIG.13

2002246959 20 Feb 2008

23 / 91






FIG.14

2002246959 20 Feb 2008







2002246959 20 Feb 2008

26 / 91




FIG.16

2002246959 20 Feb 2008

Double Splicing  
PTM





FIG.17

27/91

DOUBLE TRANS-SPICING SPECIFIC TARGET




FIG.18

DOUBLE TRANS-SPICING PTMS





FIG.19



Repaired LacZ mRNA


**FIG.20**




- (1) 3' BD (120 BP): GATTCAGCTGCTGCGAATATCATGCTAAGCAGAGGTATATCTATTATTTGTAAGCATTCTATTAACCTCATTCATTC  
 AATAATATTAATAATACTTCCTGTTTCATACTCTGCTATGACAC
- (2) Spacer sequences (24 bp): AACATYATTATAAGGTGCTCGAA
- (3) Branch point, pyrimidine tract and acceptor splice site: TACTAAC I GGTACC TCCTCTCTTTTTT GATATCTCTGAC GGC GGC
- 3' ss    LocZ mini  
           exon  
           EcoRV  
           PPT  
           Kpn I  
           BP
- (4) 5' donor site and 2nd spacer sequence: TGA AGGCTGAAGT GTTATCAGCGATATGTCTAACTGATCGGGGCTTCGATAGC  
 LocZ mini 5' ss  
 exon  
 CTAGATCCAGCGC
- (5) 5' BD (260 BP): TCGAAAGTTTCACAAATTTCTAGCTCTCTCTGAATTCATGCTTTGATGAGCTCTGTATCTATATTCATCATCGGAA  
 ACACCATGATTTTTTCTTTAATGCTGCTTGGCATATCTCGGAAAGCTGATTAACACATCAAAATCTCTCCACTGCTGTTAA  
 AAAAGCCCTCAGATTCCTCATTTCTGCCATATCATCATATCAGATGACCTCGSAAATAAAGCCCATCATTTATTAAGTCA  
 TTATCAAAATCAAGC

**FIG. 21**

DSP148: (A 3' ss: 3' splice elements i.e. BP, PPT & AG dinucleotide has been deleted and replaced with random sequences, but still has the functional 5' splice site)



PTM29 (lacks 2nd BD and 5' ss)



PTM30 (lacks 1st BD and 3' ss)



FIG.22

Mutants



2002246959 20 Feb 2008

# ACCURACY OF DOUBLE TRANS-SPICING REACTION




FIG.23A

33 / 91

T-407 P037/095 F-395

20-02-'08 14:20 FROM-Davies Collision Cave +61392542770

COMS ID No: ARCS-180003 Received by IP Australia: Time (h:m) 14:29 Date (Y-M-d) 2008-02-20

ACCURACY OF DOUBLE TRANS-SPICING REACTION




FIG.23B

2002246959 20 Feb 2008




FIG.24

35 / 91

2002246959 20 Feb 2008




FIG.25

RESTORATION OF  $\beta$ -GAL ACTIVITY IS DUE TO DOUBLE RNA  
TRANS-SPLICING EVENTS




FIG.26

37/91




FIG.27





FIG.28

2002246959 20 Feb 2008

40 / 91



**FIG.29**

20-02-'08 14:21 FROM-Davies Collision Cave +61392542770 T-407 P044/095 F-395



2002246959 20 Feb 2008

41 / 91





FIG.30

T-407 P045/095 F-395

20-02-'08 14:21 FROM-Davies Collision Cave +61392542770

PTM with a long binding domain masking  
two splice sites and part of exon 10  
in a mini-gene target



AGAGCTTGCTCATGATGATGATGCGGAGTTAGAACAGTCAAGCGAGATCAACAATTCCG  
GCGGATCAAGCTTTTCAGGCAATTGAGTTGATGATGCGGCTACCAITGAGGAGACATTAAT  
CATTGCGGCTCAGTTAGAGAGTACGCTATGCTGCGTGAATTAAGGCTGTCAGTTGAGAGAG  
 MCU in exon 10 of PTM  
 88 of 192 (46%) bases in PTM exon 10 are not complementary to  
 its binding domain (bold and underlined).

FIG.31

42 / 91

2002246959 20 Feb 2008

43 / 91

Sequence of a double  
Trans-spliced product




FIG.32

CF-TR Repair: 5' Exon-Replacement schematic diagram of a PTM binding to the splice site of intron 10 of a mini-gene target




FIG.33

2002246959 20 Feb 2008

45 / 91

PTM with a short binding domain masking a single splice site in a mini-gene target.




FIG.34A

PTM with a long binding domain masking two splice sites in a mini-gene target.




FIG.34B

PTM with a long binding domain masking two splice sites and the whole of exon 10 in a mini-gene target.





FIG.34C



MCU in exon 10 of PTM  
88 of 192 (46%) bases in PTM exon 10 are not complementary to its binding domain.

ACGAGCTTGGTCATGATGATCATGGCCGAGTTAGAACCAAGTGAGCGCAAGATCAAAACATTGGG  
GGCGCATCAGCTTTTGGAGCCAAATTGATTGATCATGCCGGGTACCATTCAGAGGAACAATAT  
CTTGGCGGTCAGTTACGAGCGAGTADGGCTATGGCTGGTGATTAAAGCGGCTGCAGTTGGAGGAG

FIG. 35

2002246959 20 Feb 2008

47 / 91




FIG.36A

2002246959 20 Feb 2008

48 / 91

*Cis*-spliced product  
[Primers CF1+CF111]




FIG.36A-1



2002246959 20 Feb 2008

49 / 91

Trans-spliced product  
[Primers CF93+CF111]




FIG.36B




FIG.37A

2002246959 20 Feb 2008

51 / 91




FIG.37B





FIG.37C

2002246959 20 Feb 2008



2002246959 20 Feb 2008

54 / 91




FIG.38B

2002246959 20 Feb 2008

55 / 91




FIG.39

2002246959 20 Feb 2008

56/91



FIG.40A(a)



FIG.40A(b)

20-02-'08 14:22 FROM-Davies Collision Cave +61392542770 T-407 P060/095 F-395



2002246959 20 Feb 2008

57/91




FIG.40B




FIG.40C

T-407 P061/095 F-395

20-02-'08 14:22 FROM-Davies Collision Cave +61392542770

2002246959 20 Feb 2008

58 / 91





FIG.41A



16 / 65

2002246959 20 Feb 2008




FIG.41C

60/91

2002246959 20 Feb 2008

2002246959 20 Feb 2008

61 / 91

Exons

1-10

ATGCAGAGGTGGCTCTGGAAGGGCCAGCGTGTCTCCAACTTTTTCAGCTGGACCAGACCAATTTTGAGGAAAG  
GATACAGACAGCGCTGGAAATGTGACAGATATACCAATCCCTTCTGTGATCTGCTGACAATCTATCTGAAAAAT  
GGAAGACAATGGATAGAGAGCTGGCTTCAAGAAAAATCCTAACTCATTATGCCCTTCGGCGATGTTTTCTGG  
AGATTTATGTTCTATGGAATCTTTTATATTTAGGGGAAGTCACCAAGCAGTACAGCCTCTCTTACTGGGAAGATCA  
TAGCTTCTATGACCCGGATAACAAGGAGGAGCGCTATCGCGATTATCTAGGCATAGCCTTATGCCCTCTCTTTAT  
TGTGAGGACACTGCTCTACACCCAGCCATTTTGGCCTTCATCACAATTGGAATGCAGATGAGAATAGCTATGTTAGT  
TTGATTATAAGAGACTTTAAAGCTGTCAAGCGGTGTCTAGATAAAATAGTATTGGACAATGTTAGTCTCCTTT  
CCAACAACCTGAACAAATTTGATGAAGGACTTGCATTGGCACATTCGTGTGGATGCTCCTTTGCAAGTGGCACTCCT  
CATGGGCTAATCTGGGAGTGTGTACAGGCTCTGCCCTTCTGTGGACTTGGTTTCTGATAGTCTTGGCTTTTTCAG  
GCTGGGCTAGGAGCAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGTGAAGACTTGTGATTACCTCAG  
AAATGATCGAGAACATCCAATCTGTTAAGGCATAGCTGTGGGAAGCAATGAAAAAATGATTGAAAACTTAAGACA  
AACAGAACTGAACTGACTCCGAAGGAGCCTATGTCAGATACTTCAATAGCTCAGCCTCTCTTCTCAGGGTCTTT  
GTGGTGTTTTATCTGTGCTTCCCTATGCACTAATCAAGGAATCATCCTCGGAAAAATTCACCACCATCTCATTCT  
GCATTGTTCTGGCATGGCGTCACTCGGCAATTTCCCTGGGCTGTACAAACATGATGACTCTCTTGGAGCAATAAA  
CAAAATACAGGATTTCTTACAAAAGCAAGATATAAGACATTGGAATATAACTTAAGGACTACAGAGTAGTGATGGAG  
AATGTAACAGCCTTCTGGGAGGAGGATTGGGGAATTATTTGAGAAACCAAAACAAATAACAATAGAAAACTT  
CTAATGGTGATGACAGCCTCTTCTTCAATAATTTCTCACTTCTTGGTACTCCTGTCTGAAAGATATTAATTTCAAGAT  
AGAAGAGGACAGTTGTGGCGGTGTGGATCCACTGGAGCAGGCAAGCAGCTTGTCTATGATGATCATGGGCGAG  
TTAGAACCAAGTCAAGGCAAGATCAACATTTGGCGGCGCATCAGCTTTTGCAGCCAACTTCACTTGGATCATGCCCGTA  
CCATCAAGGAGACATAATCTTGGCGCTCAGTTACGAGGATACCGCTATCGCTGGTGATTAGGCGCTGTCACTTGA  
GGAG

Trans-splicing domain

GTAAATATACCGATATGTGTCTAAGCTGATTGGCGCTTCGATAGGCTAAGATCCACCG  
TCAAAAAGTTTTACATAATTTCTTACCTCTCTTGAATTCATGCTTTGATGACCTTCTGTATCTATTCATCATIG  
GAAACACCAATGATATTTCTTTAATGGTGGCTGGCATAATCTGGAAAAGTGAACACAATGAAATTTCTCCACTGT  
GCTTAATTTTACCTCTGAATTTCTCCATTTCTCCATAATCATCATTACAAGTGAACCTCTGGAAAAAACCACATCAT  
ATTAACCTATTATCAATCAGCT

FIG.42

2002246959 20 Feb 2008

153 bp PTM24 Binding Domain:

Nhe I

153 bp BD underlined

GCTAGC-AATAATGACGAAGCGCGCCCTCACGCTCAGGATTCACCTTGCTCCCAATTATCATCCTAAGCAGAAGTGATATA  
TTCCTATTGTAAAGATTCTATTAACTCATTTTGATTCAAAATATTTAAATACTTCCTGTTTCACCTACTCTGCTATGC

Sac II

AC-CGGCGG

FIG.43A

62/91

2002246959 20 Feb 2008

63 / 91

Trans-splicing domain

AATAATCAGGAAGCGCCCTCAGGCTCAGGATCACTTGCCTCCAATTATCATCTAAGCAGAAGTGATATCTTA  
TTTGTAAGATCTATTAACCTATTTCATTCAAAATATTAAAATACTTCCTGTTTCACCTACTCTGCTATGCACCCGC  
CGAACATTATTATAACCTTCTCBAATACTAAGTGTACCTCTCTTTTTTTTGATATCTGCAG

Exons 10-24

ACTTCACTTCTAATGATGATTATGGGAGAACTGGACCTTCAGAGGGTAAAATTAAGCAGAGTGAAGAATTTCACTCT  
 CTTCTCAGTTTTCTGGATTATGCTGGCACCATTAAAGAAAATATCATCTTTGGTGTTCCTATGATGAATATAGATA  
 CAGAAGCGTCATCAAGCATGCCAAGTAGAAGAGGACATCTCCAAGTTGCAGAGAAAGACAATATAGTTCTGGAGAA  
 GGTGAATCAGCTGAGTGGAGGTCAAGCAGCAAGAAATTTCTTTAGCAAGAGCAGTATACAAAGATGCTGATTGTATT  
 TATTAGACTCTCTTTTGGATACCTAGATGTTTAAACAGAAAAGAAATATTTGAAAGCTGTGTCTGTAAGCTGATGCC  
 TAACAAAATAGGATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTGACAAAATATTAATTTTCATGANGGT  
 AGCAGCTATTTTATCGGACATTTTCAGAACTCCAAAATCTACAGCCAGACTTTAGCTCAAACTCATGGATGTGATT  
 CTTTCCACCAATTTAGTGCAGAAAGAAATCAATCTAAGTACCTTACACCTTTCTCATTAGAAGGAGATGC  
 TCCTGTCTCCCTGCAGCAAAACAAAACAAATCTTTTAAACAGACTGGAGCTTTGGGAAAAAGGAATTTCTATT  
 CTCATCCAACTCACTCTATAGCAAAATTTTCCATTGTCCAAAAGACTCCCTTACAAATGAATGCCATCGAAGAGGATT  
 CTGATGAGCTTTTAGAGAGAGGCTGTCTTAGTACCAGATTCTGACGAGGAGAGGGGACTGCTGCTCCATCAGCT  
 GATCAGCACTGGCCCCACGCTTCAGGCAGAGGAGGAGCTGTCTGAACTGATGACACTCAGTTAACCAAGGT  
 CAGAAGCTTACCGAAAGACAACAGCATCCACAGCAAAAGTGTCACTGGCCCTCAGGCAAACTTGACTGAAGTGGATA  
 TATATTCAAGAGGTTATCTCAAGAACTGGCTTGGAAATAGTGAAGAAATTAAGGAAGAGACTTAAAGGAGTCTT  
 TTTTGTGATATGAGAGCATACAGCAGTACTACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTA  
 ATTTTGTGCTAATTTGGTCTTAGTAATTTTCTGGCAGAGGTGGCTGCTCTTTGGTTGTGCTGTGGCTCTCTGGAA  
 ACACCTCTCTCAAGCAAAAGGAATAGTACTCATAGTAAATTAACCTATGACAGTATTATCAGCAGCAGCTTC  
 GTATTATGTGTTTACATTTAGCTGGGAGTAGCCAGACTTTGCTGTCTATGGGATCTTCAGAGGTCTACCACTGGT  
 CATACTCTAATCAGAGTGTGAAAATTTACACCAAAAATGTTACATTTCTGTTCTTCAAGCACTATGTCACCTCA  
 ACAGCTTGAAAGCAGGTGGGATTCTTAATAGATTCTCAAGATATAGCAATTTGGATGACCTTCTGCTCTTACCAT  
 ATTTCACTTCATCCAGTTGTTAATTTGTGATTGGAGCTATAGCAGTTGTGCGAGTTTACAACCTACATCTTTGTT  
 GCAACAGTGGCAGTGATAGTGGCTTTTATTATGTGAGAGCATATTTCTTCAAACTCAGCAAACTCAAAACACTGC  
 AATCTGAAGGAGGAGTCCAATTTCACTCATCTTGTACAGCTTAAAGGACTATGGACACTTGTGCTTGGAGG  
 CGAGCTTACTTTGAACTCTGTTCCACAAAGCTCTGAATTTACATAGTCCAACTGCTTCTGTACCTGTCAACACTG  
 CGCTGGTTCCAAATGAGAAATAGAAATGATTTTGTCTCTTCTCATTGTCTTACCTTCAATTTCAATTTAAACAG  
 GAGAAGGAGAGGAGTGTGATTATCTGACTTTAGCCATGAATATCATGATACATTGCAAGTGGGCTGTAAACTC  
 CAGCATAGATGTGGATAGCTTGATGGATCTGTGAGCCGAGTCTTTAAGTTCAATGACATGCCAACAGAGGTAAACCT  
 ACCAAGTCAACCAAAACATACAGAATGGCCACTCTGAAAGTTATGATTATGAGAATTCACAGTGAAGAAAGATG  
 ACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCAGCAAAATACAGAGGTGGAAATGCCATATTAGA  
 GAACATTTCTCTCAATAAGTCTGGCCAGAGGTGGCCCTCTTGGAGAACTGATCAGGGAAGAGTACTTTGTTA  
 TCAGCTTTTTTGAGACTACTGAACACTGAAGGAGAAATCCAGATGATGGTGTGCTTTGGGATTCAATAACTTTGCAAC  
 AGTGGAGGAAGCCCTTTGGAGTATACACAGAAAGTATTTATTTTCTGGAACATTTAGAAAAAATTTGGATCCCTA  
 TGAACAGTGGAGTGATCAAGAAATATGGAAGTTCCAGATGAGGTTGGGCTCAGATCTGTGATAGAAGTCTTCTGGG  
 AAGCTTGACTTTGCTTGTGGATGGGGCTGTGTCTTAAGCCATGGCCACAGCAGTTGATGTCTTGGCTAGATCTG  
 TTCTCAGTAAGCGAGATCTTGTCTGTTGATGAACCCAGTCTCATTGGATCCAGTAACATACCAATAATTAGAAG  
 AACTCTAAACAGCATTTCTGATTCCACAGTAATTTCTGTGAACACAGGATAGAAGCAATGCTGGAATGCCAACAA  
 TTTTGGTCTAGAGAGAGAAAGTCCGGCAGTACGATTCCATCCAGAACTGCTGAAGCAGAGGAGCTCTTCCGGC  
 AAGCCATCAGCCCTCCGACAGGTGAAGCTCTTCCCAAGGAACTCAAGCAAGTGAAGTCTAAGCCCAAGATTGC

Histidine tag Stop

TGCTCTGAAGAGGAGACAGAAGAAGGTCCAAGATACAAGGCTTCATCATCATCATCATTAG

FIG.43B

T-487 P067/095 F-395

20-02-08 14:23 FROM-Davies Collision Cave +61392542770




FIG.44A



2002246959 20 Feb 2008




FIG.44B

65 / 91

T-407 P069/095 F-395

20-02-'08 14:23 FROM-Davies Collision Cave +61392542770

66 / 91

Sequence not included in construct

Extent of promoter in above construct

Extent of promoter in original construct

CMV enhancer 525

CBA promoter 277

Exon 1 (partial) 94


Intron 1 (partial) 117


F13+F2=235+106=341 bp

F13+F4=235+315=550 bp

Chicken Beto Actin Promoter (including exon 1 and part of intron 1)

FIG. 44C





Method:  
Excise TSD and part of exon 16 with  
XhoI and PstI and ligate in a PCR product that:  
1) eliminates the TSD and splice acceptor site  
2) inserts EcoRV adjacent to exon 16  
3) restores the coding for exon 16

FIG.45

2002246959 20 Feb 2008

69/91

# Repair of Factor VIII Preliminary results from one experiment

FVIII activity in Exon 16 FVII-KO mice  
after IV PTM-FVII intraportal infusion  
(100µgDNA)(n=3)




FIG.46

T-407 P073/095 F-395

20-02-'08 14:24 FROM-Davies Collision Cave +61392542770

Detailed structure of a mouse factor VIII PTM containing normal sequences for exons 16-26 and a C-terminal FLAG tag. BGH=bovine growth hormone 3' UTR; Binding domain= 125 bp.




FIG.47A

T-407 P074/095 F-395

-61392542770

20-02-'08 14:24 FROM-Davies Collision Cave



T-487 P076/095 F-395

20-02-'08 14:24 FROM-Davies Collision Cave +61392542770




FIG.48










2002246959 20 Feb 2008


76/91



Binding domain sequence: CAGTTAATAC ACCTAATTAA CAAATCACAC AACGCTTTGT TGTATTGCTG TTCTAATGTT GTTCCATAC CACTATAACA

FIG.52A

HPV-PTM2 with 149 bp binding domain targeted to 3'ss at 409:




Binding domain sequence: CAGTTAATAC ACCTAATTAA CAAATCACAC AACGCTTTGT TGTATTGCTG TTCTAATGTT GTTCCATAC CACTATAACA ATAATGCTA TACTACTAA TTTTGAATA AACCTTAAA CATTATAC ATACACATA TCGATTCCC

FIG.52B

Binding Domains of HPV-PTM3 and 4

HPV-PTM3 Binding domain (covers both 3'ss at 409 and 526; has 53 bp bubble)  
 GATGATCTGCACACAGACATACATCGACGGTCCA(53 nt bubble)CTTCAGGACACAGTGGCTTTTGAC  
 AGTTAATACACCTAATTACAAATCACACACGTTTGTGATTGCAGTTCTAATGTTGCCATACACACTA  
 TAACAAAT



HPV-PTM4 Binding domain (covers both 3'ss at 409 and 526; has 76 bp bubble)  
 GATGATCTGCACACAGAC(76 nt bubble)GACACAGTGGCTTTTGACAGTTAATACACCTAATTACAAATC  
 ACACACGTTTGTGATTGCAGTTCTAATGTTGCCATACACACTATAACAAAT






FIG.53

### HPV-PTM5 and 6

**HPV-PTM5**, Binding domain (140 nt, has 53 nt bubble, covers 3'ss at position 409 and 526)




**HPV-PTM6**, Binding domain (117 nt, has 76 nt bubble, covers 3'ss at position 409 and 526)



Note: Nucleotides in bold are modified to prevent PTMs cryptic splicing


FIG.54



PTM	Region	Size (nt)
HPV-PTM1	A	80
HPV-PTM2	A	149
HPV-PTM5	A+B	140
HPV-PTM6	A+B	117
HPV-PTM8	C	104
HPV-PTM9	C	174

**FIG. 55**

Trans-splicing Efficiency of HPV-PTMs in 293T Cells



RT-PCR Analysis of total RNA

FIG.56



Trans-splicing between target pre-mRNA and  
PTM is accurate (293T cells)






FIG.57

2002246959 20 Feb 2008



PTM	Binding Domain		% trans-spliced	
	Region	Size (nt)	226 sd	880 sd
HPV-PTM1	A	80	69	0.6
HPV-PTM2	A	149	45	0.9
HPV-PTM5	A+B	140	55	0.8
HPV-PTM5ΔBP/PPT	A+B	140	0.5	0.2
HPV-PTM6	A+B	117	59	1
HPV-PTM8	C	104	7	37
HPV-PTM9	C	174	14	22
CF-PTM27	CF intron	411	0	0

Quantification of Trans-splicing efficiency using real-time QRT-PCR

FIG.58

Trans-splicing into Endogenous HPV Pre-mRNA Target in SiHa & CaSki Cells






FIG.59

Accurate Trans-splicing of HPV-PTM1  
in Si Ha Cells (Endogenous target pre-mRNA)



Quantification of trans-splicing efficiency using real-time QRT-PCR

FIG.60

2002246959 20 Feb 2008

85 / 91

**Trans-splicing in SiHa Transfections  
(Endogenous target)**

<u>PTM</u>	<u>% trans-spliced</u>
pcDNA3.1	0
HPV-PTM1	0.16
HPV-PTM5	0.12
HPV-PTM6	0.11
CF-PTM27	0

Quantification of *trans*-splicing efficiency using real-time QRT-PCR

**FIG.61**

Trans-splicing Efficiency of HPV-PTM1, 5, & 6 in SiHa Cells




FIG.62

86 / 91

# Deletion of polypyrimidine tract abolishes trans-splicing

HPV-PTM5 (has all the elements)



HPV-APPT (PPT has been deleted)




FIG.63


## Methods:

- > SIHa cells transfected with 1.5 µg of plasmid DNA
- > Total RNA isolated after 48 hr and analyzed by RT-PCR (30 cycles)

Primers: oJMD15+Lac6R  
Expected product: 269 bp

Lanes 1 & 2: RNA from cells transfected with HPV-APPT (mutant); No trans-splicing detected


Lanes 3 & 4: RNA from cells transfected with HPV-PTM5 plasmid; trans-splicing Detected (269 bp product)



Schematic diagram of a PTM binding to the 5' splice site of the HPV mini-gene target

FIG.64





Schematic diagram of a double Trans-splicing PTM binding to the 3' and 5' splice sites of the HPV mini-gene target

FIG.65

2002246959 20 Feb 2008

90 / 91

SMaRT Strategy by 3' Exon Replacement: Schematic diagram of a PTM binding to the 3' splice site of the HPV mini-gene target




FIG.66A

SMaRT Strategy by 5' Exon Replacement: Schematic diagram of a PTM binding to the 5' splice site of the HPV mini-gene target





FIG.66B

**HPV-PTM3 (For Internal exon replacement)**



**FIG.67**